oseltamivir has been researched along with zanamivir in 646 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (2.63) | 18.2507 |
| 2000's | 237 (36.69) | 29.6817 |
| 2010's | 344 (53.25) | 24.3611 |
| 2020's | 48 (7.43) | 2.80 |
| Authors | Studies |
|---|---|
| Babu, YS; Bantia, S; Chand, P; Dehghani, A; El-Kattan, Y; Elliott, AJ; Hutchison, TL; Kotian, PL; Lin, TH; Montgomery, JA | 1 |
| Bailey, KW; Barnard, DL; Day, CW; Furuta, Y; Morrey, JD; Sidwell, RW; Smee, DF; Wong, MH | 1 |
| Kati, WM; Kempf, DJ; Kohlbrenner, WE; Krueger, AC; Maring, CJ; McDaniel, KF; Molla, A; Montgomery, D; Xu, Y | 1 |
| Chen, XG; Chen, YL; Hu, ZD; Liu, MC; Lü, WJ; Luan, F; Ma, WP; Zhang, XY | 1 |
| Hata, K; Hirai, G; Koseki, K; Miyagi, T; Moriya, S; Sodeoka, M; Suzuki, Y; von Itzstein, M; Yamaguchi, K; Yingsakmongkon, S | 1 |
| Kakuta, M; Kubo, S; Nasu, H; Tokumitsu, A; Tomozawa, T; Yamashita, M | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Douangngeun, B; Govorkova, EA; Ilyushina, NA; McClaren, JL; Naipospos, TS; Webster, RG | 1 |
| Barr, IG; Holien, JK; Hurt, AC | 1 |
| Mercader, AG; Pomilio, AB | 1 |
| Demmler-Harrison, GJ; Deyde, VM; Gubareva, LV; Klimov, AI; Okomo-Adhiambo, M; Sheu, TG; Xu, X | 1 |
| Chavas, LM; Dyason, JC; Fusi, P; Kato, R; Mann, MC; McKimm-Breschkin, J; Monti, E; Suzuki, N; Tettamanti, G; Thomson, RJ; Tringali, C; Venerando, B; von Itzstein, M; Wakatsuki, S | 1 |
| Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Sheu, TG | 1 |
| Barrett, S; McKimm-Breschkin, JL; Newman, J; Oakley, AJ; Peat, TS; Saito, T; Streltsov, VA; Tashiro, M; Waddington, L | 1 |
| Albohy, A; Cairo, CW; Sandbhor, M; Zou, Y | 1 |
| Cheng, YS; Fang, JM; Lee, PS; Liu, KC; Wang, SY; Wong, CH | 1 |
| Boulanger, MJ; Brant, MG; Bromba, CM; Chan, T; Lunke, MD; Mason, JW; Petric, M; Wulff, JE | 1 |
| Chen, CA; Chen, CL; Cheng, TJ; Cheng, YS; Fang, JM; Hsieh, WC; Hu, OY; Huang, PW; Jan, JT; Lin, WH; Shie, JJ; Tarbet, EB; Wang, SY; Weinheimer, S; Wong, CH | 1 |
| Dinh, H; He, Y; Iyer, SS; Li, X; Yang, Y | 1 |
| Clement, B; Koch, O; Kotthaus, J; Müller-Fielitz, H; Raasch, W; Riebling, L; Schade, D; Schmidtke, M; Seidel, N | 1 |
| Chen, CL; Cheng, YS; Fang, JM; Jan, JT; Lin, CJ; Lin, TC; Shie, JJ; Tsai, KC; Wang, SY; Wong, CH | 1 |
| Fernández, R; Font-Bardia, M; Miquet, S; Naesens, L; Torres, E; Vanderlinden, E; Vázquez, S | 1 |
| Arns, S; Bourque, E; Dercho, S; Galey, A; Gusti, V; Liggins, R; Paquette, J; Ross, F; Sun, S; Tan, J; Udechukwu, J; Webb, M; Withers, SG; Zisman, N | 1 |
| Hao, C; Jiang, T; Wang, W; Yin, R; Yu, R; Zhang, L; Zhang, M | 1 |
| Cheng, TJ; Cheng, YE; Chiu, DC; Fang, JM; Hsu, PH; Jan, JT; Lee, PS; Tsai, KC; Wu, KL | 1 |
| Cairo, CW; Guo, T; Hunter, CD; Richards, MR | 1 |
| Cui, M; Hu, A; Li, S; Lian, W; Lin, D; Liu, A; Xiao, M; Xu, L; Yan, X; Ye, J; Zhang, M; Zhao, J | 1 |
| Bourguet, E; Figurska, S; Fra Czek, MM | 1 |
| Aljohani, MA; Keil, JM; Rafn, GR; Sahebjam-Atabaki, R; Sun, XL; Turan, IM | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Wade, RC | 1 |
| Bethell, RC; Blick, TJ; Colman, PM; Hart, GJ; McDonald, M; McKimm-Breschkin, JL; Sahasrabudhe, A; Varghese, JN | 1 |
| Bischofberger, N; Chen, MS; Escarpe, PA; Huffman, JH; Jakeman, KJ; Kim, CU; Lacy, SA; Lew, W; Li, W; Mendel, DB; Merson, J; Sidwell, RW; Sweet, C; Tai, CY; Williams, MA; Zhang, L | 1 |
| Bailey, KW; Barnard, DL; Huffman, JH; Kim, CU; Morrison, A; Sidwell, RW; Syndergaard, T; Wong, MH | 1 |
| Hughes, J; Ostroff, S | 1 |
| Calfee, DP; Hayden, FG | 1 |
| Stephenson, J | 1 |
| Bischofberger, N; Laver, WG; Webster, RG | 1 |
| Hayden, FG | 3 |
| Keating, MR | 1 |
| Kelly, GD; Laver, WG | 1 |
| Couch, RB | 1 |
| Barza, M | 1 |
| Koopmans, PP; Simonian, S; van Loon, FP; Voordouw, AC | 1 |
| Goldman, MP; Long, JK; Mossad, SB | 1 |
| Vallée, JP | 1 |
| Gubareva, LV; Hayden, FG; Kaiser, L | 1 |
| Lemon, M; Meade, F | 1 |
| Vogel, GE | 3 |
| Macdonald, L | 1 |
| Vogel, G; Wutzler, P | 1 |
| Caserta, MT; Hall, CB | 1 |
| Hiramoto, Y; Nerome, K; Nishimura, Y; Shitara, E; Takeuchi, T | 1 |
| Ashley, JV; Gum, KD; Montalto, NJ | 1 |
| Rosen, DS | 1 |
| Snell, J | 1 |
| Briganti, E; Calza, L; Chiodo, F; Manfredi, R | 1 |
| McNicholl, IR; McNicholl, JJ | 1 |
| Mossad, SB | 2 |
| Matsumoto, K | 1 |
| Kaji, M | 2 |
| Ananth, SL; Andries, K; Babu, YS; Bantia, S; Chand, P; Dehghani, A; El-Kattan, Y; Horn, LL; Hutchison, TL; Kellog, DL; Kotian, PL; Lin, T; Montgomery, JA; Parker, CD | 1 |
| Brocavich, J; Dreitlein, WB; Maratos, J | 1 |
| Hayden, FG; Zambon, M | 1 |
| Cross, J; Wedekind, CA | 1 |
| Tooley, P | 1 |
| Bush, K; Goloubeva, OG; Govorkova, EA; Leneva, IA; Webster, RG | 1 |
| Preboth, M | 1 |
| Holdiness, MR | 1 |
| Gross, PA | 1 |
| Gubareva, LV; Hayden, FG; Webster, RG | 2 |
| Roberts, NA | 1 |
| McKimm-Breschkin, JL | 2 |
| Senior, K | 1 |
| Farr, BM; Hall, KK; Hayden, FG; Salgado, CD | 1 |
| Pitts, SR | 1 |
| Carrick, R; Gusick, N; Kati, W; Kempf, DJ; Kohlbrenner, W; Maring, C; Molla, A; Montgomery, D; Ng, TI; Shi, Y; Steffy, K; Stewart, KD; Stoll, VS | 1 |
| Bridges, CB; Cox, NJ; Fukuda, K; Singleton, JA; Uyeki, TM | 1 |
| Colman, PM; Fernley, RT; McDonald, M; McKimm-Breshkin, JL; Smith, BJ; Varghese, JN | 1 |
| Boivin, G; Goyette, N | 1 |
| Prober, CG | 1 |
| Englund, JA | 1 |
| Fleming, DM | 1 |
| Clements, DA; Hamilton, JD; Huber, J; Lee, PY; Matchar, DB; Peterson, ED | 1 |
| Davidson, HE; Gravenstein, S | 1 |
| Sugaya, N | 5 |
| Uyeki, T; Winquist, A | 1 |
| Roberts, MS; Smith, KJ | 1 |
| Dumyati, G; Falsey, AR | 1 |
| Mendel, DB; Tai, CY; Wang, MZ | 1 |
| Noyola, DE | 1 |
| Wutzler, P | 1 |
| Da Silva, PR; Hayward, AC; Nguyen, VT | 1 |
| Uyeki, TM | 2 |
| Lange, W; Vogel, GE | 1 |
| Balasingam, S; Bossuyt, S; Lambkin, R; Mann, A; Novelli, P; Oxford, JS | 1 |
| Mitamura, K | 2 |
| Abrams, KR; Cooper, NJ; Nicholson, KG; Sutton, AJ; Turner, D; Wailoo, A | 1 |
| Hansen, L | 3 |
| Hampson, A; Hay, A; Hayden, F; Klimov, A; McKimm-Breschkin, J; Tashiro, M; Trivedi, T; Zambon, M | 1 |
| Kirkbride, HA; Watson, J | 1 |
| Harnden, A; Matheson, NJ; Sheikh, A; Shepperd, S; Symmonds-Abrahams, M | 1 |
| Blanco, J; Curtis, S; Ottolini, M; Peterson, L; Porter, D; Prince, G | 1 |
| Bellantonio, S; Rose, DN; Rothberg, MB | 1 |
| Myers, JW | 1 |
| Phillips, TG | 1 |
| Kashiwagi, S | 3 |
| Drusano, GL; McDonough, AC; McSharry, JJ; Olson, BA | 1 |
| Liedholm, H | 1 |
| Pegram, PS; Williamson, JC | 1 |
| Beyer, WE; de Jong, JC; Fouchier, RA; Osterhaus, AD; Rimmelzwaan, GF | 1 |
| Barr, IG; Hampson, AW; Hartel, G; Hurt, AC | 1 |
| Lin, JT | 1 |
| Barr, IG; Hampson, AW; Hurt, AC; Komadina, N | 1 |
| Klimov, A; Mungall, BA; Xu, X | 1 |
| Barr, IG; Hampson, AW; Hurt, AC; Komadina, N; McDonald, M; McKimm-Breschkin, JL | 1 |
| Di Natale, R; Guy, RJ; Hampson, AW; Kelly, HA; Lambert, SB; Robinson, PM; Tallis, G; Tobin, S | 1 |
| Ebell, MH | 2 |
| Kossow, KD; Lode, H; Ruf, BR; Scholz, H; Vogel, GE; Wutzler, P | 1 |
| Abed, Y; Boivin, G; Goyette, N | 1 |
| Barr, IG; Durrant, CJ; Hampson, AW; Hurt, AC; Shaw, RP; Sjogren, HM | 1 |
| Fagan, HB; Moeller, AH | 1 |
| Faughnan, ME; Langley, JM | 1 |
| Fang, HB; Govorkova, EA; Tan, M; Webster, RG | 1 |
| Suzuki, H | 1 |
| Aizawa, H; Fukuda, T; Kaji, M; Tanaka, M | 1 |
| Bergemann, R; Gyldmark, M; Hayden, FG; Morris, J; Mueller, E; Sander, B | 1 |
| Babu, YS; Bantia, S; Chand, P; El-Kattan, Y; Kotian, PL; Lin, TH | 1 |
| Abbott, A | 1 |
| Govorkova, EA; Monto, AS; Webster, RG; Yen, HL | 1 |
| Brandstaedt, A; Haertl, A; Sauerbrei, A; Schmidtke, M; Wutzler, P | 1 |
| Ferraris, O; Kessler, N; Lina, B | 1 |
| Cyranoski, D | 1 |
| Gubareva, LV; Hayden, FG; Mishin, VP; Novikov, D | 1 |
| Govorkova, EA; Herlocher, LM; Hoffmann, E; Matrosovich, MN; Monto, AS; Webster, RG; Yen, HL | 1 |
| Moscona, A | 2 |
| Hosoya, M; Kato, K; Sato, M; Suzuki, H | 1 |
| Goto, H; Horimoto, T; Kawaoka, Y; Kiso, M; Le, QM; Muramoto, Y; Nguyen, KH; Nguyen, TH; Ngyen, HH; Pham, ND; Sakai, YT; Someya, K; Suzuki, T; Suzuki, Y; Takada, A; Yamada, S | 1 |
| Groeneveld, K; van der Noordaa, J | 1 |
| Altschuler, EL; Bhatia, A; Kast, RE | 1 |
| Buchholz, U | 1 |
| Bradley, D | 1 |
| Amyard, M; Hampson, A; Hay, A; Hayden, F; Klimov, A; Macken, C; McKimm-Breschkin, J; Monto, A; Tashiro, M; Webster, RG; Zambon, M | 1 |
| Mayor, S | 1 |
| Alymova, IV; Portner, A; Taylor, G | 1 |
| Gupta, RK; Nguyen-Van-Tam, JS | 1 |
| Barr, IG; Hampson, AW; Hurt, AC; Iannello, P; Jachno, K; Komadina, N; McKimm-Breschkin, JL | 1 |
| Chou, KC; Du, QS; Sun, H; Wei, DQ | 1 |
| Kondo, T; Matsumura, T; Tsujimura, K; Yamanaka, T | 1 |
| Asaoka, N; Ohuchi, M; Ohuchi, R; Sakai, T | 1 |
| Davies, T | 1 |
| Suzuki, T; Suzuki, Y; Takahashi, T | 1 |
| Ferraris, O; Kessler, N; Lina, B; Valette, M | 1 |
| Deray, G; Izzedine, H; Janus, N; Karie, S; Launay-Vacher, V | 1 |
| Demicheli, V; Di Pietrantonj, C; Jefferson, TO; Jones, M; Rivetti, D | 1 |
| Monto, AS; Ohmit, SE | 1 |
| Del Mar, C; Jones, M | 1 |
| Eng, P; Lam, WK; Liam, CK; Seto, WH; Shim, YS; Tsang, KW; Wong, TK | 1 |
| Barr, IG; Deed, N; Hurt, AC; Iannello, P; Komadina, N; Tomasov, C | 1 |
| Nau, JY | 1 |
| Halloran, ME; Hayden, FG; Longini, IM; Monto, AS; Yang, Y | 1 |
| Abed, Y; Baz, M; Boivin, G; McDonald, J | 1 |
| Barr, IG; Brown, L; Hurt, AC; Komadina, N; Selleck, P; Shaw, R | 1 |
| Dwyer, DE; Emery, S; Harrod, ME | 1 |
| Abed, Y; Baz, M; Boivin, G | 2 |
| Hayden, FG; Pavia, AT | 1 |
| Monto, AS; Whitley, RJ | 1 |
| Harnden, AR; Matheson, NJ; Perera, R; Sheikh, A; Symmonds-Abrahams, M | 1 |
| Chou, KC; Du, QS; Wang, SQ | 1 |
| Brydak, LB; Gawryluk, D; Machała, M; Wiatr, E | 1 |
| Gras-Masse, H; Willand, N | 1 |
| Bauer, K; Schmidtke, M; Schrader, C; Suess, J; Wutzler, P | 1 |
| Lynch, JP; Walsh, EE | 1 |
| Hayden, FG; Ong, AK | 1 |
| Wiwanitkit, V | 1 |
| Reece, PA | 2 |
| Azzi, A; Bandini, G; Campitelli, L; Donatelli, I; Giannecchini, S | 1 |
| Carrat, F; El Sawi, A; Gaillat, J; Grandmottet, G; Schlemmer, C | 1 |
| Hirotsu, N; Horii, S; Ikematsu, H; Iwaki, N; Kanazawa, H; Kashiwagi, S; Kawai, N; Kawamura, K; Kawashima, T; Maeda, T; Nagai, T; Tanaka, O; Yamauchi, S | 1 |
| Crusat, M; de Jong, MD | 1 |
| Chen, J; Gubareva, LV; Haldar, J; Klibanov, AM; Tumpey, TM | 1 |
| Wesseling, G | 1 |
| von Itzstein, M | 1 |
| Bouscambert-Duchamp, M; Escuret, V; Ferraris, O; Frobert, E; Grog, I; Lina, B; Morfin, F; Sabatier, M; Valette, M | 1 |
| Aruksakunwong, O; Decha, P; Hannongbua, S; Intharathep, P; Malaisree, M; Rungrotmongkol, T | 1 |
| Johnson, MA; McKimm-Breschkin, JL; Selleck, PW; Usman, TB | 1 |
| Choe, H; Farzan, M; Huang, IC; Li, W; Marasco, W; Sui, J | 1 |
| Worrall, G | 1 |
| Matsunami, N; Nagano, Y; Ono, H; Sugiyama, S; Tanabe, M; Yamamoto, S | 1 |
| Panknin, HT; Trautmann, M | 1 |
| Bovin, NV; Govorkova, EA; Gray, TE; Ilyushina, NA; Webster, RG | 1 |
| Cheng, YS; Fang, JM; Jeng, KS; Shie, JJ; Su, CY; Temperton, NJ; Wang, SY; Wong, CH | 1 |
| Collins, PJ; Gamblin, SJ; Haire, LF; Hay, AJ; Lin, YP; Liu, J; Martin, SR; Russell, RJ; Skehel, JJ; Walker, PA | 1 |
| Moyad, MA; Robinson, LE | 1 |
| Chidiac, C | 1 |
| Nüesch, R | 1 |
| Ichikawa, M; Kawakami, C; Kawaoka, Y; Mitamura, K; Sugaya, N; Tamura, D; Yamazaki, M | 1 |
| Monto, AS | 2 |
| Glezen, WP | 1 |
| Bresee, JS; Broder, K; Cox, NS; Fiore, AE; Iskander, JK; Mootrey, G; Shay, DK; Uyeki, TM | 1 |
| Brydak, LB; Nitsch-Osuch, A; Wardyn, AK | 1 |
| Traynor, K | 1 |
| Balish, A; Bright, RA; Deyde, VM; Gubareva, LV; Klimov, AI; Lindstrom, S; Nguyen, T; Shu, B | 1 |
| Falahee, ML; Vallerand, AH; Vantine, M | 1 |
| Cooper, K; Jackson, R; Nicholson, K; Read, R; Rees, A; Simpson, E; Tappenden, P | 1 |
| Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawashima, T; Maeda, T | 1 |
| Couzin-Frankel, J | 1 |
| Butler, D | 2 |
| Bauer, K; Richter, M; Schmidtke, M; Wutzler, P | 1 |
| Jefferson, T | 2 |
| Oxford, JS | 1 |
| Barr, IG; Besselaar, TG; Birch, C; Buchy, P; Chittaganpitch, M; Chiu, SC; D'Souza, H; Deng, YM; Dwyer, D; Ernest, J; Guigon, A; Harrower, B; Hurt, AC; Iannello, P; Kei, IP; Kelso, A; Kok, T; Komadina, N; Lin, C; McPhie, K; Mohd, A; Olveda, R; Panayotou, T; Rawlinson, W; Scott, L; Shaw, R; Smith, D | 1 |
| Temte, JL | 2 |
| Garcia-Bournissen, F; Ito, S; Koren, G; Murashima, A; Nakajima, K; Tanaka, T | 1 |
| Magano, J | 1 |
| Agarwal, N; Arya, SC | 1 |
| Agarwal, SK; Gupta, A; Ignatius, A; Khaira, A | 1 |
| Barr, IG; Holien, JK; Hurt, AC; Kelso, A; Parker, M | 1 |
| Gu, Y; Kamiya, H; Komiya, N; Matsui, T; Okabe, N; Yahata, Y; Yasui, Y | 1 |
| Buttery, JP; Cheng, AC; Dwyer, DE; Jenkins, CR; Johnson, PD; Korman, TM; Kotsimbos, AT; Krause, VL; Starr, M | 1 |
| Bravata, DM; Gould, MK; Holty, JE; Khazeni, N; Stave, CD; Uyeki, TM | 1 |
| Burch, J; Corbett, M; Duffy, S; Elliot, AJ; Nicholson, K; Palmer, S; Stewart, L; Stock, C; Westwood, M | 1 |
| Harnden, A; Heneghan, C; Mant, D; Perera, R; Shun-Shin, M; Thompson, M | 1 |
| Brown, LE; Doherty, PC; Kelso, A; Turner, SJ | 1 |
| Jiang, H; Li, N; Liu, H; Luo, C; Ma, J; Qin, G; Shen, X; Wang, Q; Xu, Z; Yang, C; Yu, K; Zhu, W | 1 |
| Bren, U; Frecer, V; Rungrotmongkol, T; Stanislav, M; Udommaneethanakit, T | 1 |
| Hacker, J | 1 |
| Koopmans, MP; van den Wijngaard, CC; van der Sande, MA; van Steenbergen, JE | 1 |
| Ami, O; Donnadieu, AC; Dupont-Bernabé, C; Fernandez, H; Frydman, R; Guillet, M; Martinez, V; Picone, O; Senat, MV; Trichot, C; Vauloup-Fellous, C | 1 |
| Deyde, VM; Garten, RJ; Gubareva, LV; Klimov, AI; Sheu, TG | 1 |
| Belshe, RB; Fang, F; Gubareva, LV; Hedlund, M; Klimov, AI; Larson, JL; Moss, RB; Triana-Baltzer, GB; Wurtman, DF | 1 |
| Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawamura, K; Kawashima, T; Maeda, T; Matsuura, S; Nishimura, M; Tanaka, O; Yamauchi, S | 1 |
| Deyde, VM; Garten, RJ; Gubareva, LV; Klimov, AI; Nguyen, HT; Okomo-Adhiambo, M; Shaw, MW; Sheu, TG; Sleeman, K; Xu, X | 1 |
| Ariano, RE; Smith, JR; Toovey, S | 1 |
| Barr, IG; Holien, JK; Hurt, AC; Parker, MW | 1 |
| Nayak, JL; Treanor, JJ | 1 |
| Clardy, BH; Payne, EM; Spradlin, TL; Vinson, J | 1 |
| Bagga, B; Barman, S; Bhojwani, D; Flynn, PM; Gaur, AH; Hayden, R; Hoffman, JM; Lamptey, A; Tuomanen, E; Webby, R | 1 |
| Chan, CH; Chen, CL; Su, ZY; Wang, YT | 1 |
| Kakuta, M; Kubo, S; Tokumitsu, A; Tomozawa, T; Yamashita, M | 2 |
| Du, GH; Liu, AL; Wang, HD; Yang, F | 1 |
| Caram, LB; Cunningham, CK; Cunningham, HM; Hendershot, EF; Lopez-Marti, MG; Purdy, WK; Sangvai, DG; Tsalik, EL; Woods, CW | 1 |
| Eagel, BA | 1 |
| Nakamura-Uchiyama, F; Ohnishi, K | 1 |
| Bozzo, P; Djokanovic, N; Koren, G | 1 |
| Chee, JJ; Chong, CY; Lim, ML; Lim, WY; Tee, WS | 1 |
| Del Mar, C; Dooley, L; Doshi, P; Foxlee, R; Jefferson, T; Jones, M | 1 |
| Kawaoka, Y; Kiso, M; Kubo, S; Le, QM; Nidom, CA; Ozawa, M; Yamashita, M | 1 |
| Abiko, C; Aoki, Y; Itagaki, T; Katsushima, Y; Matsuzaki, Y; Mizuta, K; Obuchi, M; Odagiri, T; Sanjoh, K; Sugawara, K; Suto, A; Takashita, E; Tashiro, M; Ujike, M | 1 |
| Bouscambert-Duchamp, M; Escuret, V; Ferraris, O; Lina, B; Morfin, F | 1 |
| Haas, W | 1 |
| Colombo, C; Daccò, V; Daleno, C; Esposito, S; Lackenby, A; Molteni, CG; Principi, N | 1 |
| Ohashi, Y; Sugaya, N | 1 |
| Davey, RT; Fang, F; Moss, RB; Steigbigel, RT | 1 |
| Chappell, JD; Creech, CB; Denison, MR; Domm, J; Dulek, DE; Frangoul, HA; Schulert, AK; Williams, JV | 1 |
| Lecumberri, J; Montané, E; Pedro-Botet, ML | 1 |
| Han, J; Liu, H; Wang, C; Yao, X | 1 |
| Baranovich, T; Dapat, C; Dapat, IC; Ishitani, N; Matsuda, R; Oguma, T; Saito, R; Sato, I; Suzuki, H; Suzuki, Y; Zaraket, H | 1 |
| Aardema, H; Boucher, CA; de Jager, CM; Riezebos-Brilman, A; Tulleken, JE; van den Biggelaar, RJ; Wolters, BA | 1 |
| Fujita, N; Horikawa, H; Kageyama, T; Kato, Y; Kishida, N; Mochizuki, K; Obuchi, M; Odagiri, T; Shimabukuro, K; Shirakura, M; Tashiro, M; Ujike, M; Yamashita, K | 1 |
| Baranovich, T; Caperig-Dapat, I; Dapat, C; Dbaibo, GS; Medlej, F; Reda, M; Saito, R; Suzuki, H; Suzuki, Y; Tabet, C; Wakim, R; Zaraket, H | 1 |
| Prosenc, K; Socan, M; Tevz-Cizej, N | 1 |
| Govorkova, EA; Ilyushina, NA; Rehg, JE; Seiler, JP; Webster, RG | 1 |
| Amidon, GL; Dahan, A; Gupta, D; Miller, JM; Varghese, S | 1 |
| Bilgin, H; Odabas, D; Sert, A; Yazar, A | 1 |
| Barr, IG; Hurt, AC; Lowther, S; Middleton, D | 1 |
| Hatakeyama, S; Kawaoka, Y; Ozawa, M | 1 |
| Moura, FE | 1 |
| DeLiberto, T; DuBois, RM; Govorkova, EA; Gramer, MR; Krauss, S; Negovetich, NJ; Senne, DA; Stallknecht, DE; Stoner, TD; Swafford, S; Webster, RG | 1 |
| Cayley, WE | 1 |
| Lundgren, J; Madsen, L; Nielsen, A | 1 |
| Sinha, M | 1 |
| Boyko, Y; Jensen, R; Nielsen, LP; Severinsen, IK; Storgaard, M; Terp, K | 1 |
| Beekmann, SE; Dharan, NJ; Finelli, L; Fiore, A; Fry, AM; Polgreen, PM; Uyeki, TM | 1 |
| Albrecht, RA; García-Sastre, A; Kaminski, M; Kochs, G; Medina, RA; Palese, P; Philipp, J; Rubbenstroth, D; Schwalm, F; Seibert, CW; Staeheli, P; Stertz, S | 1 |
| Alvarez de Cienfuegos, L; Chen, J; Gubareva, LV; Haldar, J; Klibanov, AM; Tumpey, TM; Weight, AK | 1 |
| Tsukahara, Y | 1 |
| Ishii, H; Kadota, J; Tokimatsu, I; Yoshioka, D | 1 |
| Watanabe, A | 2 |
| Allenet, B; Bussières, JF; Ferreira, E; Skalli, S | 1 |
| Boucher, CA; Stelma, FF; van der Vries, E | 1 |
| Chang, SC; Chu, DW; Kim, MJ; Ohashi, Y; Watanabe, A | 1 |
| Cooper, KL; Jackson, RJ; Nicholson, KG; Read, RC; Rees, A; Simpson, EL; Tappenden, P | 1 |
| Chen, Z; Collins, PJ; Hay, AJ; Lin, Y; Zheng, YH | 1 |
| Heikkinen, T; Heinonen, S; Lehtinen, P; Silvennoinen, H; Vainionpää, R | 1 |
| Calistri, A; Chillemi, C; Cusinato, R; Da Dalt, L; Franchin, E; Gambino, A; Palù, G; Salata, C; Sgarabotto, D; Toscano, G | 1 |
| Birkner, P; Duwe, SC; Schweiger, B; Wedde, M | 1 |
| Andreoletti, L; Blanchon, T; Bouscambert-Duchamp, M; Charlois-Ou, C; Duval, X; Enouf, V; Leport, C; Lina, B; Mentré, F; Mosnier, A; Tibi, A; Tubach, F; van der Werf, S; Vincent, C | 1 |
| Alonso, M; Bouza, E; Catalán, P; García de Viedma, D; Gayoso, J; Giannella, M; López Bernaldo de Quirós, JC; Rodríguez-Sánchez, B | 1 |
| Anraku, M; Husain, S; Mazulli, T; Pierre, AF | 1 |
| Yamashita, M | 1 |
| Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Maeda, T; Matsuura, S; Nishimura, M; Tanaka, O; Yamauchi, S | 1 |
| Abed, Y; Boivin, G; Bouhy, X; Pizzorno, A | 1 |
| Deyde, VM; Fry, AM; Garten, RJ; Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Okomo-Adhiambo, M; Shaw, MW; Sheu, TG; Sleeman, K; Trujillo, AA | 1 |
| Das, RR | 1 |
| Bornhäuser, M; Duwe, S; Ehninger, G; Pöhlmann, C; Schetelig, J; Schweiger, B; Shayegi, N | 1 |
| Dolin, R | 1 |
| Ichikawa, M; Kawakami, C; Kawakami, E; Kawaoka, Y; Kiso, M; Mitamura, K; Ozawa, M; Shimizu, H; Sugaya, N; Takano, R; Tamura, D; Uehara, R; Yamazaki, M | 1 |
| Lennerstrand, J; Olsen, B; Orozovic, G; Orozovic, K | 1 |
| Adams, JR; Brown, AN; Drusano, GL; Kulawy, R; McSharry, JJ; Weng, Q | 1 |
| Alcantara-Perez, P; Alpuche-Aranda, C; Barrera-Badillo, G; Cordova Villalobos, JA; Cortez-Ortiz, I; Díaz-Quiñonez, JA; Gatell-Ramírez, HL; Gonzalez-Duran, E; Gubareva, L; Hernández-Avila, M; Lezana-Fernández, MA; Lopez-Martinez, I; Nguyen, H; Olivera-Diaz, H; Ramirez-Gonzalez, JE; Wong-Arambula, C | 1 |
| Ellermann-Eriksen, S; Gubbels, S; Ilkjær, S; Jensen-Fangel, S; Keld, DB; Lindskov, C; Petersen, E | 1 |
| Chambers, CD; Jones, KL; Louik, C; Mitchell, AA; Schatz, M | 1 |
| Li, JF; Shen, JS; Xiong, RS; Zhang, Q; Zhao, QJ | 1 |
| Al-Hegelan, MS; Cheifetz, IM; Noble, PW; Ozment, CP; Peters, MA; Peterson-Carmichael, SL; Rehder, KJ; Turner, DA; Williford, WL | 1 |
| Hankins, RW; Hattori, H; Iida, H; Miyachi, K; Takano, T; Ukai, H; Watanabe, A | 1 |
| Bailey, AL; Bennink, JR; Das, SR; Gibbs, JS; Hensley, SE; Schmidt, LM; Yewdell, JW | 1 |
| Horimoto, T; Imai, H; Kakugawa, S; Kawaoka, Y; Kiso, M; Le, MT; Noda, T; Ozawa, M; Takahashi, K | 1 |
| Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K | 1 |
| Gut, H; Taylor, GL; Walsh, MA; Xu, G | 1 |
| Geyer, H; McKimm-Breschkin, JL; Mohr, PG | 1 |
| Ejima, M; Kageyama, T; Konomi, N; Nakauchi, M; Oba, K; Obuchi, M; Odagiri, T; Takashita, E; Takayama, I; Tashiro, M; Ujike, M | 1 |
| Devroey, D; Semaille, P; Van De Vijver, E; Vandevoorde, J; Vansintejan, J | 1 |
| Barr, IG; Caldwell, N; Cui, L; Deng, YM; Freeman, K; Hurt, AC; Kelso, A; Komadina, N; Leang, SK; Lee, RT; Lin, RT; Maurer-Stroh, S; Phuah, SP; Smith, D; Speers, D | 1 |
| Bauer, K; Dahse, HM; Dürrwald, R; Pfarr, K; Schlegel, M; Schmidtke, M; Topf, D; Wiesener, N; Wutzler, P | 1 |
| Chueasuwanchai, S; Day, NP; Fukuda, C; Hanpithakpong, W; Jittamala, P; Leowattana, W; Lindegardh, N; Pan-Ngum, W; Panapipat, S; Permpunpanich, S; Phakdeeraj, A; Pukrittayakamee, S; Singhasivanon, P; Stepniewska, K; White, NJ | 1 |
| Barman, S; Boltz, DA; Duan, S; Govorkova, EA; Li, J; Marjuki, H; Oshansky, CM; Webby, RJ; Webster, RG | 1 |
| Bowkalow, S; Brauer, M; Gross, W; Schleussner, E | 1 |
| Dwyer, DE | 1 |
| Granath, F; Kieler, H; Stephansson, O; Svensson, T | 1 |
| Al'khovskiĭ, SV; Aristova, VA; Bazarova, MV; Burtseva, EI; Chuchalin, AG; Fediakina, IT; Kolobukhina, LV; Malyshev, NA; Maslov, AM; Merkulova, LN; Morozova, TN; Ponomarenko, RA; Prilipov, AG; Proshina, ES; Samokhvalov, EI; Shchelkanov, MIu; Sutochnikova, OA | 1 |
| Angeles-Garay, U; Arias-Flores, R; Gayosso Rivera, JA; Rechy-Luna, M; Terrazas Estrada, JJ; Zacate-Palacios, Y | 1 |
| Alexander, DC; Bastien, N; Eshaghi, A; Gubbay, JB; Higgins, RR; Li, Y; Low, DE; Patel, SN; Sarabia, A; Savchenko, A; Stojios, PJ | 1 |
| Chan, K; Chua, YY; Cui, L; Tan, BH; Wijaya, L | 1 |
| Chiang, VW; Chung, EY | 1 |
| Beersma, MF; Boucher, CA; de Jong, MD; Fouchier, RA; Fraaij, PL; Horrevorts, AM; Houmes, RJ; Koopmans, MP; Kroes, AC; Niesters, HG; Osterhaus, AD; Reis Miranda, D; Ridwan, BU; Riezebos-Brilman, A; van der Eijk, AA; van der Vries, E; van Dissel, JT; Wolfhagen, MJ | 1 |
| Ohuchi, M; Ushirogawa, H | 1 |
| Barrett, S; McKimm-Breschkin, JL; Mohr, PG; Schmidt, PM | 1 |
| Razonable, RR | 1 |
| Ikematsu, H; Kawai, N | 1 |
| Arnold, K; Baumbach, J; Bennett, NM; Doshi, S; Finelli, L; Fry, AM; Gershman, K; Hancock, EB; Kamimoto, L; Lynfield, R; Morin, C; Perez, A; Reingold, A; Ryan, P; Schaffner, W; Thomas, A; Yousey-Hindes, K; Zansky, S | 1 |
| Feng, E; Gao, F; Gao, GF; He, J; Jiang, H; Li, Q; Liu, H; Liu, J; Liu, Y; Qi, J; Vavricka, CJ; Wang, J; Wang, M; Wu, Y | 1 |
| Hama, R; Hayashi, K; Jones, M; Kitao, M; Noda, N; Okushima, H; Sakaguchi, K | 1 |
| Palmer, R | 1 |
| Abed, Y; Beaulieu, E; Boivin, G; Bouhy, X; Mallett, C; Pizzorno, A; Russell, R | 1 |
| Gill, P; Harnden, A; Perera, R; Shun-Shin, M; Wang, K | 2 |
| Del Mar, CB; Doshi, P; Hama, R; Heneghan, CJ; Jefferson, T; Jones, MA; Thompson, MJ | 1 |
| Blanchon, T; Bouscambert, M; Carrat, F; Charlois-Ou, C; Dornic, Q; Duval, X; Enouf, V; Leport, C; Mentré, F; Mosnier, A | 1 |
| Fang, X; Han, W; Tian, L; Wang, Y; Wang, Z; Wu, D; Yu, D | 1 |
| Ajisaka, K; Ikematsu, H; Kashiwagi, K; Kashiwagi, S; Masui, S; Nabeshima, S; Takeoka, H | 1 |
| Baumeister, E; Campos, AM; Pontoriero, A; Savy, VL | 1 |
| Ikematsu, H; Kashiwagi, S; Kawai, N | 1 |
| Akl, EA; Alonso-Coello, P; Brozek, J; Chen, YL; Cheung, A; Flottorp, SA; Hopkins, JP; Hovhannisyan, G; Hsu, J; Ivanova, L; Mustafa, R; Saeterdal, I; Santesso, N; Schünemann, HJ; Smaill, F; Tian, J; Uyeki, TM; Wong, AD | 2 |
| Dzhibladze, KM; Nakashidze, IM; Potskhishvili, ShN; Tsintsadze, NG | 1 |
| Gubareva, LV; Hurt, AC; Okomo-Adhiambo, M | 2 |
| Bastien, N; Beniprashad, M; Chong-King, E; Gubbay, JB; Higgins, RR; Li, Y; Low, DE | 1 |
| Barrett, S; McKimm-Breschkin, JL; Mohr, PG; Rootes, C; Streltsov, VA | 1 |
| Hannongbua, S; Malaisree, M; Mulholland, AJ; Pattarapongdilok, N; Sompornpisut, P; Woods, CJ | 1 |
| Hasegawa, N; Iwata, S; Shinjoh, M; Sugaya, N; Takahashi, T; Takano, Y | 1 |
| Dapat, C; Dapat, IC; Kawashima, T; Kondo, H; Saito, K; Saito, R; Sato, I; Shobugawa, Y; Suzuki, H; Suzuki, Y | 1 |
| Borders-Hemphill, V; Mosholder, A | 1 |
| Feng, E; Hilgenfeld, R; Jiang, H; Li, J; Liu, H; Wang, J; Ye, D; Zhang, D; Zhao, F; Zheng, M | 1 |
| Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Kawashima, T; Maeda, T; Ukai, H | 1 |
| Blanchon, T; Bouscambert-Duchamp, M; Boutitie, F; Cornu, C; Duval, X; Enouf, V; Escuret, V; Gaillard, S; Gueyffier, F; Leport, C; Lina, B; Mosnier, A; Van Der Werf, S | 1 |
| Blanchon, T; Carrat, F; Duval, X; Flahault, A; Leport, C; Mentré, F; Mosnier, A; Tibi, A; Tubach, F; Van der Werf, S | 1 |
| Abou-Jaoudé, G; Caro, V; Enouf, V; LeGoff, J; Mercier-Delarue, S; Molina, JM; Ribaud, P; Rousset, D; Scemla, A; Simon, F; van der Werf, S | 1 |
| Chaudhury, S; Khavrutskii, IV; Kuschner, RA; Liu, J; Reifman, J; Ripoll, DR; Wallqvist, A | 1 |
| Kamei, T; Mazda, O; Murata, K; Suzuki, N; Takahashi, I; Toriumi, Y | 1 |
| Boivin, G; DePasse, JV; Fitch, A; Ghedin, E; Hamelin, ME; Holmes, EC; Papenburg, J; Pinilla, LT | 1 |
| Chipot, C; González-Nilo, F; Lee, EH; Poblete, H; Schulten, K; Vergara-Jaque, A | 1 |
| Hubbard, RJ; Li, J; Meyer, AE; Miller, PE; Mounts, AW; Penn, CR; Rambachan, A; Rolfes, MA; Stephens, P | 2 |
| Boucher, CA; Collins, PJ; Gamblin, SJ; Haire, LF; Hay, AJ; Liu, J; Martin, SR; Osterhaus, AD; Schutten, M; Skehel, JJ; Vachieri, SG; van der Vries, E; Walker, PA; Xiong, X | 1 |
| Gillissen, A | 1 |
| Hurt, AC; Kelso, A | 1 |
| Hannongbua, S; Kamlungsua, K; Khuntawee, W; Meeprasert, A; Nunthaboot, N; Rungrotmongkol, T | 1 |
| Azuma, T; Nakada, N; Tanaka, H; Yamashita, N | 1 |
| Sato, R | 1 |
| Fujisaki, S; Imai, M; Kishida, N; Odagiri, T; Sato, H; Takashita, E; Taniwaki, T; Tashiro, M; Xu, H; Yokoyama, M | 2 |
| Anekthananon, T; Charunwatthana, P; Day, N; Fukuda, C; Jittamala, P; Lawpoolsri, S; Lindegardh, N; Pukritayakamee, S; Pukrittayakamee, S; Puthavathana, P; Ratanasuwan, W; Sapchookul, P; Stepniewska, K; Suwanagool, S; Tarning, J; Taylor, WR; Werarak, P; White, NJ | 1 |
| Cen, S; He, Z; Li, XY; Liu, ZL; Wang, X; Wang, Z; Wei, XL; Yin, X; Zhang, ZZ; Zhou, JM | 1 |
| Cheng, Y; Gubareva, LV; Huang, W; Klimov, AI; Levine, M; Li, X; Nguyen, HT; Shu, Y; Sleeman, K; Tan, M; Wang, D; Xing, X; Xu, X | 1 |
| Cantu, J; Tita, AT | 1 |
| Cordonnier, C; de la Camara, R; Engelhard, D; Ljungman, P; Mohty, B | 1 |
| Chazono, K; Iwajima, Y; Maeda, Y; Nagano, Y; Ohsawa, M; Ono, H; Yamamoto, S | 1 |
| Gao, GF; Kiyota, H; Li, Q; Li, Y; Liu, Y; Qi, J; Sriwilaijaroen, N; Suzuki, Y; Tanaka, K; Vavricka, CJ; Wu, Y; Yan, J | 1 |
| Bance, N; Barrett, S; Buchini, S; Chen, HM; Kim, JH; Liggins, R; McKimm-Breschkin, JL; Niikura, M; Petric, M; Pilling, P; Resende, R; Streltsov, VA; Watts, AG; Wennekes, T; Withers, SG | 1 |
| Abed, Y; Boivin, G; Pizzorno, A; Samson, M | 1 |
| Cabral, E; Carratalá, J; Cordero, E; Cruzado, JM; Delgado, JF; Gavaldá, J; Gómez-Bravo, MÁ; López-Medrano, F; Marcos, MÁ; Pérez-Romero, P; Sabé, N | 2 |
| Coenen, S; Michiels, B; Van Puyenbroeck, K; Verhoeven, V; Vermeire, E | 1 |
| Gubareva, LV; Klimov, AI; Li, Y; Lysén, C; Nguyen, HT; Okomo-Adhiambo, M; Sleeman, K; Xu, X | 1 |
| Kubo, T; Minakami, H; Nakai, A; Saito, S; Unno, N; Yoshimura, Y | 1 |
| Booy, R; Dixit, R; Ilgoutz, S; Khandaker, G; Rashid, H | 1 |
| Ihashi, M; Inoue, Y; Kaneno, H; Kase, T; Mizoguchi, Y; Okabe, N; Shimotsuji, T; Yamamoto, K; Yamamoto, T | 1 |
| Barrett, S; Jachno, K; McDonald, M; McKimm-Breschkin, JL; Mohr, PG; Saito, T; Tashiro, M; Williams, J | 1 |
| Cheung, PP; Choy, KT; Guan, Y; McKimm-Breschkin, JL; Ng, IH; Peiris, JS; Webby, RJ; Webster, RG; Wong, DD; Yen, HL; Zhou, J; Zhu, H | 1 |
| Gubareva, LV; Guo, L; Marjuki, H; Mishin, VP; Okomo-Adhiambo, M; Sheu, TG; Sleeman, K; Xu, X | 1 |
| Hargraves, J; Patel, DM; Pitts, SR | 1 |
| Bröjer, C; Gillman, A; Järhult, JD; Latorre-Margalef, N; Lindberg, RH; Muradrasoli, S; Nordh, J; Olsen, B; Söderström, H; Waldenström, J | 1 |
| Baranovich, T; Burnham, AJ; Govorkova, EA | 1 |
| Hou, T; Li, D; Li, L; Li, Y; Pan, P | 1 |
| Gubareva, LV; Guo, Z; Levine, M; Mishin, VP; Nguyen, HT; Okomo-Adhiambo, M; Sleeman, K; Stevens, J; Tamura, D; Xu, X; Yang, H | 1 |
| Farrukee, R; Hurt, AC; Mosse, J | 1 |
| Cao, B; Hayden, FG | 1 |
| Carney, PJ; Gubareva, LV; Levine, M; Mishin, VP; Sleeman, K; Stevens, J | 1 |
| Louie, JK; Samuel, MC; Schechter, R; Uyeki, TM; Yang, S | 1 |
| Abd Elal, A; Fry, AM; Gubareva, LV; Nguyen, HT; Okomo-Adhiambo, M; Sleeman, K | 1 |
| Chong, M; Henry, B; Kendall, P; Marra, F; Patrick, DM | 1 |
| Long, B; Malaisree, M; McIntosh-Smith, S; Mulholland, AJ; Woods, CJ | 1 |
| Hashimoto, K; Honzumi, K; Hosoya, M; Kawasaki, Y; Miyazaki, K; Sato, M; Sato, T; Watanabe, M | 2 |
| Balish, A; Fry, AM; Garten, RJ; Gubareva, LV; Guo, Z; Mishin, VP; Sleeman, K; Stevens, J; Villanueva, J | 1 |
| Kmietowicz, Z | 2 |
| Herxheimer, A; McGettigan, P; Pollock, A | 1 |
| Järhult, JD; Olsen, B; Orozovic, G; Orozovic, K | 1 |
| Kwoh, CK; Ouyang, X; Tran-To Su, C; Zheng, J | 1 |
| Abed, Y; Boivin, G; Pizzorno, A; Rhéaume, C | 1 |
| Dunstan, HJ; Mill, AC; Stephens, S; Thomas, SH; Yates, LM | 1 |
| Del Mar, CB; Doshi, P; Hama, R; Heneghan, CJ; Howick, J; Jefferson, T; Jones, MA; Mahtani, KR; Nunan, D; Onakpoya, I; Spencer, EA; Thompson, MJ | 2 |
| Torjesen, I | 1 |
| Doshi, P; Jefferson, T | 2 |
| Crawford, S; Hamilton, S; Hurst, BL; Luttick, A; Ng, WC; Pryor, M; Smee, DF; Tarbet, EB; Tucker, SP; Vollmer, AH | 1 |
| Godlee, F | 1 |
| Nguyen-Van-Tam, JS | 1 |
| Leonardi-Bee, J; Myles, PR | 2 |
| Jones, M | 1 |
| Belluz, J | 1 |
| Krumholz, HM | 1 |
| Fry, AM | 1 |
| Al Khuwaitir, TS; Al Mamun, A; Amine, IL; Anovadiya, AP; Azziz-Baumgartner, E; Báez, C; Bassetti, M; Beovic, B; Bertisch, B; Bonmarin, I; Booy, R; Borja-Aburto, VH; Burgmann, H; Cao, B; Carratala, J; Denholm, JT; Dominguez, SR; Duarte, PA; Dubnov-Raz, G; Echavarria, M; Fanella, S; Gao, Z; Gérardin, P; Giannella, M; Gubbels, S; Herberg, J; Hoger, PH; Hu, X; Iglesias, AL; Islam, QT; Jiménez, MF; Kandeel, A; Keijzers, G; Khalili, H; Knight, M; Kudo, K; Kusznierz, G; Kuzman, I; Kwan, AM; Langenegger, E; Lankarani, KB; Leo, YS; Leonardi-Bee, J; Linko, R; Liu, P; Madanat, F; Mayo-Montero, E; McGeer, A; Memish, Z; Metan, G; Mickiene, A; Mikić, D; Mohn, KG; Moradi, A; Muthuri, SG; Myles, PR; Nguyen-Van-Tam, JS; Nymadawa, P; Oliva, ME; Ozkan, M; Parekh, D; Paul, M; Polack, FP; Rath, BA; Rodríguez, AH; Sarrouf, EB; Seale, AC; Sertogullarindan, B; Siqueira, MM; Skręt-Magierło, J; Stephan, F; Talarek, E; Tang, JW; To, KK; Torres, A; Törün, SH; Tran, D; Uyeki, TM; Van Zwol, A; Vaudry, W; Venkatesan, S; Vidmar, T; Yokota, RT; Zarogoulidis, P | 1 |
| Asai, T; Ichikawa, M; Ikezoe, I; Matsumoto, J; Miyagawa, S; Takemoto, Y; Yano, T | 1 |
| Bamba, M; Ichikawa, M; Ide, Y; Kawakami, C; Kawaoka, Y; Mitamura, K; Sakai-Tagawa, Y; Sugaya, N; Yamaguchi, Y; Yamazaki, M; Yasuhara, R | 1 |
| Nguyen-Van-Tam, JS; Nicholson, KG; Openshaw, PJ | 1 |
| Barrett, S; McKimm-Breschkin, JL | 2 |
| Haruyama, T; Kobayashi, N; Matsunaga, A; Rahmasari, R; Watanabe, K | 1 |
| Ak, Ö; Alan, S; Aslan, T; Badur, S; Balkan, II; Benzonana, N; Ceylan, B; Ciblak, M; Dokucu, AI; Engin, D; Eraksoy, H; Ergönül, Ö; Fincancı, M; Gencer, S; Göktaş, P; Gulhan, E; Gündüz, A; Inan, A; Kantürk, A; Midilli, K; Nazlıcan, O; Öncül, O; Özer, S; Özgüneş, N; Ozyurt, M; Saltoğlu, N; Sargın, F; Şimşek, F; Uzun, N; Yazıcı, S; Yıldırmak, T | 1 |
| Adams, O; Gkioule, C; Grund, S; Kobbe, G; Pfeifer, N; Termos, T; Verheyen, J | 1 |
| Antes, G; Meerpohl, JJ | 1 |
| Del Mar, C; Hama, R; Jones, M | 1 |
| Leonardi-Bee, J; Muthuri, SG; Myles, PR; Nguyen-Van-Tam, JS; Venkatesan, S | 1 |
| Schumacher, M; Wolkewitz, M | 1 |
| Dhawane, A; Dinh, H; He, Y; Iyer, SS; Sweeney, J; Yang, Y; Zhang, X | 1 |
| Calderon, A; Cañizares, A; Casas, I; Cuesta, I; Gonzalez, M; Gonzalez-Velasco, C; Lackenby, A; Lopez-Miragaya, I; Molinero, M; Monzon, S; Perez-Sautu, U; Pozo, F; Rey, S; Rodriguez, G | 1 |
| Almeida-Santos, MM; Correia, V; Gíria, M; Rebelo-de-Andrade, H; Santos, LA | 1 |
| Besselaar, T; Correia, V; Daniels, RS; Drager-Dayal, R; Fry, A; Gregory, V; Gubareva, L; Hurt, AC; Kageyama, T; Lackenby, A; Lo, J; Meijer, A; Odagiri, T; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Tashiro, M; Wang, D; Wong, S; Zhang, W | 1 |
| Toniolo Neto, J | 1 |
| Chi, HC; Hsiao, NW; Lin, CY; Shih, KC; Tang, CY; Zhou, J | 1 |
| Król, E; Rychłowska, M; Szewczyk, B | 1 |
| Brydak, LB; Nitsch-Osuch, A | 2 |
| Bastien, N; Eshaghi, A; Gubbay, JB; Higgins, RR; Li, A; Li, Y; Rosenfeld, P; Rotstein, C; Savchenko, A; Shalhoub, S; Stogios, PJ | 1 |
| Chen, Q; Guo, Y; Wei, YN; Zhang, C | 1 |
| Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N | 2 |
| Ali, Z; Dapat, C; Dapat, IC; Dbaibo, G; Ghanem, S; Kayali, G; Kondo, H; Lteif, M; Saito, K; Saito, R; Suzuki, H; Zaraket, H | 1 |
| Baek, YH; Choi, YK; Kim, EH; Kim, MH; Kim, S; Kim, YI; Kwon, HI; Lee, EY; Lim, GJ; Park, KJ; Park, SJ; Pascua, PN; Song, MS; Webby, RJ; Yoon, SW | 1 |
| Millard, PS | 1 |
| Zambon, M | 1 |
| Belardo, G; Cenciarelli, O; La Frazia, S; Rossignol, JF; Santoro, MG | 1 |
| Arastoo, M; Khorshid, HR | 1 |
| Cao, B; Chan, PK; Cheung, CS; Gu, L; Hui, DS; Kyaw, WM; Lee, N; Leo, YS; Li, H; Liu, Y; Liu, Z; Qu, J; Tam, WW; Uyeki, TM; Yung, IM | 1 |
| Birnkrant, DB; Chan-Tack, KM; Kim, C; Moruf, A | 1 |
| Armstrong, J; Burnham, AJ; Govorkova, EA; Lowen, AC; Webster, RG | 1 |
| Ison, MG | 1 |
| Bahl, J; Baranovich, T; Culhane, M; Darnell, D; Govorkova, EA; Kaplan, BS; Lowe, JF; Marathe, BM; Stigger-Rosser, E; Webby, RJ | 1 |
| Besselaar, T; Daniels, RS; Fry, A; Gregory, V; Gubareva, L; Huang, W; Hurt, AC; Lackenby, A; Leang, SK; Lo, J; Mak, GC; Meijer, A; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Tashiro, M; Wang, D; Zhang, W | 1 |
| Li, F; Ma, C; Wang, J | 1 |
| Fairbanks, AJ; Fee, CJ; Fredericks, R; Hall, RJ; Somasundaram, B; Watson, AJ | 1 |
| Dhawane, AN; He, Y; Iyer, SS; Sweeney, J; Vasireddi, M; Zhang, X | 1 |
| Garrison, S; Kolber, MR; Korownyk, C | 1 |
| Campbell, AP; DeBiasi, RL; Fry, AM; Gubareva, LV; Loechelt, B; Mishin, VP; Okomo-Adhiambo, M; Tamura, D; Wiedermann, BL | 1 |
| Azuma, T; Inoyama, T; Ishiuchi, H; Mino, Y; Sato, T; Tanaka, H; Teranishi, Y; Yamaoka, M; Yamashita, N | 1 |
| Batool, S; Kamal, MA; Kamal, W; Mushtaq, G | 1 |
| Boucher, CA; Cowling, BJ; Ip, DK; Schutten, M; Tong, X; van der Vries, E; Wojtowicz, K; Zhang, JD | 1 |
| Fukunishi, Y; Higo, J; Le, L; Nakamura, H; Nguyen, H; Tran, T | 1 |
| Cheong, HJ; Choi, WS; Kim, WJ; Noh, JY; Song, JY | 1 |
| Cheng, Y; Guo, J; Huang, W; Li, X; Shu, Y; Tan, M; Wang, D; Wang, Z; Wei, H; Xiao, N; Zhao, X | 1 |
| Hawkes, N | 1 |
| Buckeridge, DL; Charland, KM; DE Serres, G; Papenburg, J | 1 |
| Kossyvakis, A; Lytras, T; Mentis, A | 1 |
| Damodaran, KV; Janezic, D; Mohamad, S; Mohamed, N; Wahab, HA; Yusuf, M | 1 |
| Bischoff, A | 1 |
| Barr, IG; Chow, MK; Kelso, A; Sullivan, SG | 1 |
| Hussain, M; Jin, R; Li, M; Li, X; Lin, C; Liu, X; Sun, C; Tu, Z; Wan, J; Zhang, J; Zhou, Y | 1 |
| Alame, MM; Ghulmiyyah, LM; Mirza, FG; Nassar, AH; Zaraket, H | 1 |
| Dor, D; Handel, A; Pawelek, KA; Salmeron, C | 1 |
| Haraki, M; Hishiki, H; Inoue, N; Ishiwada, N; Kameoka, Y; Kurosaki, T; Nagasawa, K; Naito, S; Someya, T; Suzuki, K | 1 |
| Azhar, EI; Hashem, AM; Tolah, AM | 1 |
| Bastien, N; Chaudhry, A; Drews, SJ; Li, Y; Pabbaraju, K; Scott, A; Stewart, D; Wong, S | 1 |
| Abed, Y; Boivin, G; Carbonneau, J; Kaiser, L; L'Huillier, AG | 1 |
| Bi, Y; Chen, Y; Fu, L; Gao, F; Gao, GF; Li, X; Mohan, S; Pinto, BM; Qi, J; Tien, P; Vavricka, CJ; Wu, Y | 1 |
| Clement, B; Hoffmann, A; Kirchmair, J; Sauerbrei, A; Schade, D; Schmidtke, M | 1 |
| Kitazawa, T; Koga, I; Ota, Y; Seo, K; Yoshino, Y | 1 |
| Antalis, E; Kalliaropoulos, A; Karakitsos, P; Kossyvakis, A; Lytras, T; Meijer, A; Mentis, AA; Mentis, AF; Pogka, V; Tryfinopoulou, K; Tsiodras, S | 1 |
| Bolon, DN; Finberg, RW; Jensen, JD; Kowalik, TF; Kurt-Yilmaz, N; Özen, A; Prachanronarong, KL; Schiffer, CA; Thayer, KM; Wang, JP; Yilmaz, LS; Zeldovich, KB | 1 |
| Ariza-Heredia, EJ; Chemaly, RF; Shahani, L | 1 |
| Chapman, MJ; Clark, C; Garot, D; Gupta, SK; Husa, P; Jacobs, F; Marty, FM; Merino, E; Peppercorn, AF; Rodriguez-Noriega, E; Shortino, D; Vidal-Puigserver, J; Watson, HA; Yates, PJ | 1 |
| Fischer, TK; Franck, KT; Pedersen, SS; Trebbien, R; Vorborg, K | 1 |
| Boikos, C; Caya, C; Delisle, G; Doll, MK; Dolph, M; Gore, G; Kraicer-Melamed, H; Quach, C; Winters, N | 1 |
| Kolber, MR; Korownyk, C | 1 |
| Koyfman, A; Long, B; Simon, E | 1 |
| Das, S; Mandal, RS; Panda, S | 1 |
| Hurt, AC; Leang, SK | 1 |
| Blanchon, T; Charlois-Ou, C; Chevret, S; Duval, X; Flicoteaux, R; Leport, C; Lina, B; Mosnier, A; Protopopescu, C; Tibi, A; Werf, SV | 1 |
| Asai, N; Furui, T; Hagihara, M; Kato, H; Kato, Y; Koizumi, Y; Kurumiya, A; Mikamo, H; Nishiyama, N; Sakata, M; Takahashi, T; Yamagishi, Y | 1 |
| Besselaar, TG; Daniels, RS; Fry, A; Gregory, V; Gubareva, LV; Huang, W; Hurt, AC; Jorquera, PA; Lackenby, A; Leang, SK; Lo, J; Meijer, A; Odagiri, T; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Wang, D; Zhang, W | 1 |
| Bomblies, R; Luitz, MP; Zacharias, M; Zeller, F | 1 |
| Buettner, I; Chow, MK; Lau, H; Leang, SK; Leung, VK; Spirason, N | 1 |
| Baranovich, T; Davis, CT; Gubareva, LV; Guo, Z; Hodges, E; Sleeman, K; Stevens, J; Yang, H | 1 |
| Boikos, C; Doll, MK; Gore, G; Kraicer-Melamed, H; Quach, C; Winters, N | 1 |
| Cho, J; Jang, EY; Kang, C; Kim, K; Lee, CH; Lee, JY; Lee, MS; Yi, H | 1 |
| Ahn, SJ; Baek, YH; Chae, HB; Choi, WS; Choi, YK; Govorkova, EA; Hwang, J; Jeong, JH; Kim, CJ; Kim, MH; Kwon, HI; Kwon, JJ; Lloren, KKS; Song, MS; Webby, RJ | 1 |
| Adams, JR; Brown, AN; Drusano, GL; Kulawy, R; Pires de Mello, CP; Shudt, M | 1 |
| Kolodziej, H; Quosdorf, S; Schuetz, A | 1 |
| Ishii, H; Ishimoto, H; Kadota, JI; Mukae, H; Nishida, C; Noguchi, S; Sakamoto, N; Umeki, K; Yamasaki, K; Yatera, K | 1 |
| Hasegawa, H; Ito, M; Kawaoka, Y; Kiso, M; Lopes, TJS; Nakajima, N; Neumann, G; Yamashita, M; Yamayoshi, S | 1 |
| Behzadian, F; Kananizadeh, P; Moeini, S; Mozhgani, SH; Pakzad, R; Zarei Ghobadi, M | 1 |
| Hasegawa, T; Hirotsu, N; Saisho, Y; Shishido, T | 1 |
| Christiansen, CB; Fischer, TK; Trebbien, R | 1 |
| Akutsu, Y; Aoyagi, H; Ariga, T; Arioka, H; Azuma, K; Furuyama, H; Hatae, Y; Hazama, K; Inagawa, A; Ishiguro, N; Ishizaka, A; Kaiho, M; Kawamura, N; Kikuta, H; Koike, A; Konno, M; Koseki, N; Kumita, Y; Matsuzono, Y; Morita, K; Murashita, M; Nagano, N; Oba, K; Odagawa, Y; Okamura, A; Sawada, Y; Shibata, M; Shida, S; Tabata, Y; Takada, K; Tobise, C; Togashi, T; Tsubakihara, K; Tsuchida, A; Tsuchiyama, A; Uetsuji, K; Watanabe, T; Yamanaka, T; Yamazaki, S; Yasoshima, K; Yasuda, K; Yoshioka, M | 1 |
| Fushimi, K; Matsui, H; Michihata, N; Miyairi, I; Morisaki, N; Okubo, Y; Shoji, K; Uda, K; Yasunaga, H | 1 |
| Bradbury, N; Lim, WS; Nguyen-Van-Tam, J | 1 |
| Bakulina, AY; Durymanov, AG; Goncharova, NI; Ilyicheva, TN; Kolosova, NP; Maksyutov, RA; Marchenko, VY; Pyankova, OG; Ryzhikov, AB; Sobolev, IA; Susloparov, IM; Svyatchenko, SV | 1 |
| Albati, F; Chilundo, J; Daniels, R; Gudo, E; Machalele, L; Mateonane, E; Mavale, S; McCauley, J; Mussá, T; Muteto, D; Nacoto, A; Nguenha, N; Pale, M; Salência, J; Tivane, A | 1 |
| Cocoros, NM; Haug, N; Maher, C; Panucci, G; Reichman, M; Toh, S | 1 |
| Chen, F; Huang, Q; Liu, M; Liu, S; Liu, T; Tian, Y; Yang, J | 1 |
| Bhatia, S; Chanu, KV; Gupta, CL; Khandia, R; Kumar, N; Mawale, N; Mishra, A; Pateriya, AK; Singh, VP; Sood, R | 1 |
| Liu, GJ; Wang, B; Wang, S; Xing, GW; Yang, X; Zhang, Y | 1 |
| Escuret, V; Gaymard, A; Javouhey, E; Josset, L; Lina, B; Malcus, C; Massenavette, B; Millat, G; Monneret, G; Morfin-Sherpa, F; Picard, C; Pichon, M; Renard, C; Simon, B; Valette, M | 1 |
| Beard, KR; Brendish, NJ; Clark, TW | 1 |
| Ben-Hamouda, N; Jahns, FP; Kirsch, M; Liaudet, L; Roumy, A | 1 |
| Asai, K; Fujioka, M; Hirata, K; Kimura, T; Kureya, Y; Shinataku, H; Tocino, Y; Yoshi, N | 1 |
| Miyazaki, C; Momoi, M; Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K | 1 |
| Araujo-Meléndez, J; Beigel, JH; Galindo-Fraga, A; Gamiño-Arroyo, AE; García-Andrade, LA; Guerrero, ML; Holley, HP; Hunsberger, S; Ibarra-González, V; Kapushoc, H; Llamosas-Gallardo, B; Martínez-López, J; McCarthy, S; Moreno-Espinosa, S; Ramírez-Venegas, A; Roldán-Aragón, Y; Ruiz-Palacios, GM; Smolskis, MC | 1 |
| Bhoye, D; Cherian, SS; Keng, SS; Kode, SS; Mullick, J; Pawar, SD; Tare, DS | 1 |
| Hoshino, K; Kubo, S; Tomozawa, T; Yamashita, M | 1 |
| Calistri, A; Del Vecchio, C; Franchin, E; Marini, G; Nicolè, S; Palù, G; Parolin, C; Salata, C; Sgarabotto, D; Solimbergo, E | 1 |
| Butler, J; Farrukee, R; Hurt, AC; Reading, PC | 1 |
| Bassetti, M; Carnelutti, A; Castaldo, N | 1 |
| Buettner, I; Chow, MK; Iannello, P; Kaye, M; Lau, H; Leung, VK; Roe, M; Tolosa, MX; Zakis, T | 1 |
| Cheng, Y; Huang, W; Li, X; Tang, J; Wang, D; Wei, H; Xin, L; Yang, L; Zhang, J; Zhou, J; Zhu, W; Zou, S | 1 |
| Hurt, AC; Keng, SS; Kode, SS; Mullick, J; Pawar, SD; Tare, DS | 1 |
| Donaldson, EF; Donnelly, RP; Ilyushina, NA; Ince, WL; Komatsu, TE; Lee, N; O'Rear, JJ | 1 |
| Gillman, A; Järhult, JD; Lindberg, RH; Lindström, HS; Lundkvist, Å; Nykvist, M; Skog, E; Tang, C; Tepper, V; Wille, M | 1 |
| Mikurova, AV; Skvortsov, VS | 1 |
| Abed, Y; Boivin, G; Carbonneau, J; Checkmahomed, L; Fage, C; Giannotti, F; Goncalves, AR; Kaiser, L; Schibler, M; Venable, MC | 1 |
| Martin-Loeches, I; O'Sullivan, S; Rodriguez, A; Torres, A | 1 |
| Han, N; Kim, IW; Oh, JM | 1 |
| Miyazaki, C; Momoi, MY; Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K | 1 |
| Gubareva, L; Mohan, T | 1 |
| Deeks, HM; Glowacki, DR; Hare, SR; Mulholland, AJ; O'Connor, MB; Walters, RK | 1 |
| Barr, IG; Brown, SK; Chow, MK; Patel, M; Peck, H; Price, OH; Rynehart, C; Soppe, S; Spirason, N; Todd, A | 1 |
| Cao, R; Dai, Q; Guo, X; Li, W; Li, X; Li, Y; Xia, Q; Xu, K; Yan, Y; Yang, J; Yang, K; Zhao, L; Zhong, W; Zou, G | 1 |
| Bulgakova, VA; Gorodin, VN; Kareva, EN; Pshenichnaya, NY; Selkova, EP; Volchkova, EV | 1 |
| Chung, YS; Kang, C; Kim, HM; Kim, MS; Lee, N | 1 |
| Dong, R; Liu, G; Lu, Q; Peng, L; Tian, G; Wang, J; Yang, J; Zhou, L | 1 |
| Bo, H; Dong, J; Huang, WJ; Li, XY; Liu, J; Tang, J; Wang, DY; Xin, L; Yang, L; Zhang, J; Zhang, SX; Zhou, JF; Zou, SM | 1 |
| Slain, D | 1 |
| Abed, Y; Baz, M; Boivin, G; Checkmahomed, L; Padey, B; Pizzorno, A; Rosa-Calatrava, M; Terrier, O | 1 |
| Chen, Y; Chi, YM; Du, JF; Du, WX; Han, GC; Li, M; Liu, F | 1 |
| Aaron, JG; DiMango, EA; Laplante, JM; Macesic, N; Miko, BA; Pereira, MR; Reshef, R; St George, K | 1 |
| Jansson, M; Rello, J; Solé-Lleonart, C; Tejada, S | 1 |
| Botelho-Nevers, E; Cantais, A; Cizeron, A; Gagneux-Brunon, A; Pillet, S; Saunier, F | 1 |
| Hosohata, K; Iida, T; Inada, A; Iwanaga, K; Kambara, H; Nakatsuji, T; Niinomi, I; Oyama, S; Uchida, M; Ueno, S; Wakabayashi, T | 1 |
| Laghdir, Z; Quach, C; Tadount, F | 1 |
| Govorkova, EA; Gubareva, LV; Hay, AJ; Hayden, FG; Ison, MG; McKimm-Breschkin, JL; Takashita, E | 1 |
| Alencar, EN; Amaral-Machado, L; Araújo, FAC; Costa, MJF; Sette-DE-Souza, PH | 1 |
| Feng, IJ; Hua, YM; Shih, MF; Su, HC; Tang, HJ | 1 |
| Fujiwara, M; Hara, A; Hara, K; Kobayashi, C; Komeda, T; Miyazawa, S; Ogura, E; Urushihara, H; Yoshida, M | 1 |
| Bandera, A; Castelli, V; Gori, A; Lombardi, A; Palomba, E; Renisi, G | 1 |
| Jayabalan, T; Joshi, A; Miller, I; Oliver, A; Peppercorn, A; Wang-Jairaj, J; Zammit-Tabona, P | 1 |
| Ding, P; Guo, Y; Li, Y; Ping, J; Suzuki, Y; Yu, M; Zhang, H; Zhang, Y; Zheng, Y | 1 |
| Chan, KA; Fang, CT; Huang, CT; Su, CP | 1 |
| Aziz, A; Barr, IG; Baz, M; Brown, SK; Tseng, YY | 1 |
| Lai, CC; Wei, JCC | 1 |
| Chang, R; Chen, HY; Hung, YM; Sun, CK | 1 |
| Tian, Y; Wang, K; Zhang, H | 1 |
| Dandekar, T; Sarukhanyan, E; Shanmugam, TA | 1 |
| Aziz, A; Barr, IG; Baz, M; Brown, SK; Deng, YM; Kuba, M; Lau, H; O'Neill, G; Peck, H; Soppe, S; Subbarao, K | 1 |
| Aires, L; Alisson-Silva, F; Amaral, FC; Antônia, J; Báfica, A; Barroso, SPC; Burgel, PR; Chollet-Martin, S; Costa, VV; Cunha, FQ; de Oliveira Formiga, R; de Souza, FRO; Faria, LF; Fonseca, FR; Heck, N; Hurtado-Nedelec, MM; Lorenzini, CB; Macauley, MS; Mansur, DS; Martin, C; Maurici, R; Mendes, DAGB; Morrot, A; Natale, CC; Paula, NM; Queiroz-Junior, CM; Rocha, EL; Santos, AA; Santos, FRS; Silva, PCS; Sordi, R; Souza, CF; Spiller, F; Starick, MR; Van Weyenbergh, J; Wanderley, CWS; Witko-Sarsat, V | 1 |
| Mehta, N; Peppercorn, AF; Watson, HA; Yates, PJ | 1 |
| Adlhoch, C; Bossuyt, N; Brytting, M; Carnahan, A; Delgado-Sanz, C; Domegan, L; Gomes Dias, J; Guiomar, R; Kynčl, J; Larrauri, A; Maistre Melillo, J; Marbus, SD; Melillo, T; O'Donnell, J; Olsen, SJ; Popovici, O; Redlberger-Fritz, M; Slezak, P; Thomas, I; van Gageldonk-Lafeber, AB | 1 |
| Chan, KKP; Hui, DSC | 1 |
| Aoki, S; Chon, I; Kakuya, F; Kawashima, T; Kitano, A; Kodo, N; Li, J; Minato, M; Nagata, N; Ono, Y; Phyu, WW; Saito, R; Saito, T; Sato, I; Shimada, Y; Sun, Y; Suzuki, E; Tanaka, T; Wagatsuma, K; Watanabe, H | 1 |
| Kumar, R; Sagar, R; Tyagi, R; Yadav, Y | 1 |
| Balligand, T; Carpenet, C; Liu, X; Ploegh, HL | 1 |
| Govorkova, EA; Ivachtchenko, AV; Ivanenkov, YA; Ivashchenko, AA; Jones, JC; Karapetian, RN; Pascua, PNQ; Penaflor, MK; Shkil, DO | 1 |
| Barr, IG; Bobbitt, ME; Brown, SK; Chanthalavanh, P; Dapat, C; Deng, YM; Diefenbach-Elstob, TR; Peck, H; Rynehart, C; Spirason, N; Subbarao, K | 1 |
162 review(s) available for oseltamivir and zanamivir
| Article | Year |
|---|---|
Human Neuraminidases: Structures and Stereoselective Inhibitors.
Topics: Amino Acid Sequence; Enzyme Inhibitors; Humans; Models, Molecular; Neuraminidase; Stereoisomerism; Structure-Activity Relationship | 2022 |
Sialidase Inhibitors with Different Mechanisms.
Topics: Antiviral Agents; Biological Products; Enzyme Inhibitors; Humans; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Sialic Acids; Zanamivir | 2022 |
'Flu' and structure-based drug design.
Topics: Amines; Antiviral Agents; Binding Sites; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Influenza, Human; Models, Molecular; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1997 |
New approaches to influenza chemotherapy. Neuraminidase inhibitors.
Topics: Acetamides; Animals; Antiviral Agents; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1998 |
Update on influenza and rhinovirus infections.
Topics: Acetamides; Amines; Antiviral Agents; Common Cold; Guanidines; Humans; Influenza, Human; Intercellular Adhesion Molecule-1; Neuraminidase; Oseltamivir; Oxadiazoles; Oxazoles; Picornaviridae Infections; Pyrans; Recombinant Proteins; Rhinovirus; Sialic Acids; Zanamivir | 1999 |
Antiviral agents for non-human immunodeficiency virus infections.
Topics: 2-Aminopurine; Acetamides; Acyclovir; Amantadine; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance, Microbial; Drugs, Investigational; Enzyme Inhibitors; Famciclovir; Foscarnet; Ganciclovir; Guanidines; Guanine; Humans; Interferons; Lamivudine; Neuraminidase; Organophosphonates; Organophosphorus Compounds; Oseltamivir; Pyrans; Ribavirin; Sialic Acids; Valacyclovir; Valine; Virus Diseases; Zanamivir | 1999 |
Measures for control of influenza.
Topics: Amantadine; Amines; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 1999 |
[Critical review of anti-influenza drugs].
Topics: Acetamides; Adult; Antiviral Agents; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Netherlands; Neuraminidase; Oseltamivir; Public Health; Pyrans; Sialic Acids; Zanamivir | 2000 |
Antiviral agents for treating influenza.
Topics: Acetamides; Amantadine; Antiviral Agents; Drug Administration Schedule; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2000 |
Influenza virus neuraminidase inhibitors.
Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Virus Replication; Zanamivir | 2000 |
Neuraminidase inhibitors in the treatment of influenza A and B--overview and case reports.
Topics: Acetamides; Administration, Inhalation; Adult; Aged; Aged, 80 and over; Antiviral Agents; Bronchitis; Clinical Trials as Topic; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pericarditis; Pyrans; Sialic Acids; Zanamivir | 2000 |
Updated treatment for influenza A and B.
Topics: Acetamides; Amantadine; Antiviral Agents; Clinical Trials as Topic; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Treatment Outcome; Zanamivir | 2000 |
Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention.
Topics: Acetamides; Adult; Anti-Bacterial Agents; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Eustachian Tube; Guanidines; Humans; Infant; Influenza A virus; Influenza B virus; Influenza, Human; Interferon-beta; Oseltamivir; Otitis Media; Otitis Media with Effusion; Picornaviridae Infections; Piperidines; Pressure; Pyrans; Pyridazines; Respiratory Tract Infections; Rhinovirus; Rimantadine; Sialic Acids; Superinfection; Virus Replication; Zanamivir | 2000 |
[Influenza].
Topics: Acetamides; Amantadine; Antiviral Agents; Disease Outbreaks; Guanidines; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Influenza, Human; Italy; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; United States; Zanamivir | 2000 |
Neuraminidase inhibitors: zanamivir and oseltamivir.
Topics: Acetamides; Antiviral Agents; Clinical Trials as Topic; Diarrhea; Enzyme Inhibitors; Guanidines; Headache; Humans; Influenza, Human; Nausea; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2001 |
Prophylactic and symptomatic treatment of influenza. Current and developing options.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Guanidines; Humans; Infant; Influenza Vaccines; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir | 2001 |
[Antiinfluenza-drugs and the standard of the use].
Topics: Acetamides; Amantadine; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2000 |
[Neuraminidase inhibitor].
Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2000 |
Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza.
Topics: Acetamides; Animals; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2001 |
Position statement: global neuraminidase inhibitor susceptibility network.
Topics: Acetamides; Animals; Antiviral Agents; Drug Resistance; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Mutation; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2001 |
Adverse cutaneous reactions to influenza vaccinations and chemotherapy.
Topics: Acetamides; Amantadine; Antiviral Agents; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Orthomyxoviridae; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Skin; Zanamivir | 2001 |
Vaccines for pneumonia and new antiviral therapies.
Topics: Acetamides; Adult; Aged; Amantadine; Antiviral Agents; Centers for Medicare and Medicaid Services, U.S.; Child; Global Health; Guanidines; Health Priorities; Humans; Incidence; Influenza Vaccines; Joint Commission on Accreditation of Healthcare Organizations; Morbidity; Neuraminidase; Oseltamivir; Patient Selection; Pneumococcal Vaccines; Pneumonia; Primary Prevention; Pyrans; Rimantadine; Safety; Sialic Acids; United States; Vaccination; Zanamivir | 2001 |
Perspectives on antiviral use during pandemic influenza.
Topics: Acetamides; Amantadine; Antiviral Agents; Chemoprevention; Disease Outbreaks; Drug Resistance, Multiple, Viral; Drug Tolerance; Guanidines; Humans; Influenza A virus; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2001 |
Treatment of influenza with neuraminidase inhibitors: virological implications.
Topics: Acetamides; Animals; Antiviral Agents; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2001 |
Neuraminidase inhibitors for the treatment and prevention of influenza.
Topics: Acetamides; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Treatment Outcome; Zanamivir | 2002 |
Influenza in the acute hospital setting.
Topics: Acetamides; Amantadine; Antiviral Agents; Cross Infection; Disease Outbreaks; Guanidines; Hospitals; Humans; Influenza Vaccines; Influenza, Human; Nursing Staff, Hospital; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Vaccination; Virginia; Zanamivir | 2002 |
Antiviral therapy for influenza virus infections.
Topics: Acetamides; Age Factors; Amantadine; Antiviral Agents; Child; Clinical Trials as Topic; Global Health; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2002 |
Antiviral therapy of influenza.
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Adult; Amantadine; Antiviral Agents; Child; Drug Resistance, Viral; Guanidines; Humans; Infant; Influenza, Human; Orthomyxoviridae; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2002 |
The management of influenza in people of working age.
Topics: Acetamides; Adolescent; Adult; Amantadine; Antiviral Agents; Cost-Benefit Analysis; Guanidines; Humans; Influenza, Human; Middle Aged; Occupational Health; Oseltamivir; Pyrans; Sialic Acids; United Kingdom; Workplace; Zanamivir | 2002 |
[A revolutionary change in the diagnosis and treatment of influenza].
Topics: Acetamides; Antiviral Agents; Encephalitis, Viral; Enzyme Inhibitors; Guanidines; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Immunologic Tests; Influenza Vaccines; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Vaccines, Attenuated; Zanamivir | 2002 |
Influenza.
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Adult; Amantadine; Antiviral Agents; Child; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Rimantadine; Sialic Acids; Treatment Outcome; Zanamivir | 2002 |
Antivirals for influenza: what is their role in the older patient?
Topics: Acetamides; Aged; Amantadine; Antiviral Agents; Drug Resistance, Viral; Guanidines; Humans; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2002 |
Neuraminidase inhibitors in pediatric patients: potential place in influenza therapy.
Topics: Acetamides; Child; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Otitis Media; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2003 |
Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza.
Topics: Acetamides; Adolescent; Age Distribution; Amantadine; Antiviral Agents; Centers for Disease Control and Prevention, U.S.; Child; Child, Preschool; DNA, Viral; Female; Fluorescent Antibody Technique, Direct; Follow-Up Studies; Guanidines; Humans; Incidence; Infant; Influenza, Human; Male; Orthomyxoviridae; Oseltamivir; Pyrans; Risk Assessment; Severity of Illness Index; Sex Distribution; Sialic Acids; Treatment Outcome; United States; Zanamivir | 2003 |
Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors.
Topics: Acetamides; Amantadine; Antiviral Agents; Clinical Trials as Topic; Disease Outbreaks; Endemic Diseases; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Viral Matrix Proteins; Zanamivir | 2003 |
[Influenza].
Topics: Acetamides; Amantadine; Antiviral Agents; Diagnosis, Differential; Enzyme Inhibitors; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Reagent Kits, Diagnostic; Sialic Acids; Vaccines, Attenuated; Zanamivir | 2003 |
[Antiviral agents for influenza].
Topics: Acetamides; Age Factors; Amantadine; Antiviral Agents; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Viral Matrix Proteins; Zanamivir | 2003 |
Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Guanidines; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza B virus; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2003 |
Review of the use of neuraminidase inhibitors for prophylaxis of influenza.
Topics: Acetamides; Amantadine; Antiviral Agents; Enzyme Inhibitors; Guanidines; Health Planning; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2003 |
Neuraminidase inhibitors for preventing and treating influenza in children.
Topics: Acetamides; Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2003 |
Influenza therapy.
Topics: Acetamides; Adult; Age Factors; Amantadine; Antiviral Agents; Child; Cost-Benefit Analysis; Creatine; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Influenza, Human; Kidney Failure, Chronic; Metabolic Clearance Rate; Oseltamivir; Patient Selection; Primary Prevention; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2003 |
[Influenza virus infection in children].
Topics: Acetamides; Age Factors; Child; Child, Preschool; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza Vaccines; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2003 |
[Criteria for the use of anti-influenza agents].
Topics: Acetamides; Amantadine; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Prodrugs; Pyrans; Sialic Acids; Time Factors; Virus Latency; Zanamivir | 2003 |
[Neuraminidase inhibitor, anti-influenzal agent--mechanism of action, and how to use clinically].
Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir | 2003 |
Neuraminidase inhibitors in patients with underlying airways disease.
Topics: Acetamides; Amantadine; Antiviral Agents; Asthma; Bronchial Spasm; Comorbidity; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive; Pyrans; Rimantadine; Risk Factors; Sialic Acids; Zanamivir | 2002 |
[Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza].
Topics: Acetamides; Antiviral Agents; Cost-Benefit Analysis; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Risk Factors; Seasons; Sialic Acids; Zanamivir | 2004 |
Neuraminidase inhibitors for treatment of influenza.
Topics: Acetamides; Antiviral Agents; Child; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2004 |
What is the best antiviral agent for influenza infection?
Topics: Acetamides; Administration, Oral; Adult; Amantadine; Antiviral Agents; Child; Contraindications; Evidence-Based Medicine; Family Practice; Guanidines; Humans; Influenza A virus; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2004 |
Influenza.
Topics: Acetamides; Adult; Amantadine; Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2003 |
[Super pathogenic avian influenza].
Topics: Acetamides; Amantadine; Animals; Antiviral Agents; Chickens; Disease Outbreaks; Guanidines; Humans; Influenza A virus; Influenza in Birds; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Poultry Diseases; Pyrans; Sialic Acids; Zanamivir; Zoonoses | 2004 |
[Zanamivir, oseltamivir].
Topics: Acetamides; Antiviral Agents; Biological Availability; Clinical Trials as Topic; Drug Monitoring; Enzyme Inhibitors; Guanidines; Half-Life; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2004 |
Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance.
Topics: Acetamides; Animals; Drug Resistance; Enzyme Inhibitors; Guanidines; Hemagglutinins; Humans; Influenza Vaccines; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Product Surveillance, Postmarketing; Pyrans; Sialic Acids; Zanamivir | 2005 |
Influenza.
Topics: Acetamides; Adult; Amantadine; Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2004 |
Neuraminidase inhibitors for influenza.
Topics: Acetamides; Adamantane; Adult; Aged; Antiviral Agents; Child; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2005 |
[Anti-virals for influenza virus infection].
Topics: Acetamides; Amantadine; Animals; Antiviral Agents; Drug Utilization; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Japan; National Health Programs; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2005 |
Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
Topics: Acetamides; Computer Communication Networks; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Matrix Proteins; Zanamivir | 2005 |
Neuraminidase inhibitors as antiviral agents.
Topics: Acetamides; Animals; Antiviral Agents; Azides; Drug Design; Enzyme Inhibitors; Guanidines; Hexuronic Acids; HN Protein; Humans; Molecular Structure; Neuraminidase; Orthomyxoviridae; Oseltamivir; Protein Conformation; Pyrans; Respirovirus; Sialic Acids; Zanamivir | 2005 |
[Role of influenza virus sialidase].
Topics: Acetamides; Antiviral Agents; Apoptosis; Caspase 3; Caspases; Disease Outbreaks; Guanidines; Humans; Hydrogen-Ion Concentration; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Viral Envelope Proteins; Zanamivir | 2006 |
Neuraminidase inhibitors for preventing and treating influenza in healthy adults.
Topics: Acetamides; Amines; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2006 |
Safety of neuraminidase inhibitors for influenza.
Topics: Acetamides; Adult; Aged; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza, Human; Nausea; Neuraminidase; Oseltamivir; Pyrans; Safety; Sialic Acids; Zanamivir | 2006 |
Antiviral drugs prophylaxis and treatment of influenza.
Topics: Acetamides; Animals; Antiviral Agents; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2006 |
Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials.
Topics: Antiviral Agents; Disease Transmission, Infectious; Family Characteristics; Humans; Influenza, Human; Multicenter Studies as Topic; Oseltamivir; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome; Zanamivir | 2007 |
Antivirals in the management of an influenza pandemic.
Topics: Amantadine; Antiviral Agents; Australia; Community-Acquired Infections; Disease Outbreaks; Drug Resistance, Viral; Government Programs; Humans; Infection Control; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; World Health Organization; Zanamivir | 2006 |
Which agents should we use to treat and prevent influenza in 2006-2007?
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Rimantadine; Zanamivir | 2006 |
Neuraminidase inhibitors for preventing and treating influenza in children.
Topics: Acetamides; Antiviral Agents; Child; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2007 |
[Neuraminidase inhibitors and risk of H5N1 influenza].
Topics: Animals; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
Antiviral therapy and prophylaxis for influenza in children.
Topics: Adamantane; Amantadine; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infant; Influenza, Human; Male; Oseltamivir; Primary Prevention; Prospective Studies; Randomized Controlled Trials as Topic; Rimantadine; Risk Assessment; Severity of Illness Index; Treatment Outcome; Zanamivir | 2007 |
[Antiviral agents for influenza].
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Viral Matrix Proteins; Zanamivir | 2007 |
Influenza: evolving strategies in treatment and prevention.
Topics: Aged; Amantadine; Antiviral Agents; Centers for Disease Control and Prevention, U.S.; Child, Preschool; Humans; Infant; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Ribavirin; Rimantadine; United States; Zanamivir | 2007 |
[Threat from newly emerging influenza].
Topics: Animals; Antiviral Agents; Birds; Communicable Diseases, Emerging; Disease Outbreaks; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Oseltamivir; Zanamivir | 2007 |
Current research on drugs and vaccines for fighting bird flu.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Zanamivir | 2007 |
Neuraminidase inhibitor resistance in influenza viruses.
Topics: Acids, Carbocyclic; Adult; Animals; Antiviral Agents; Catalytic Domain; Child; Clinical Trials as Topic; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Seasons; Sentinel Surveillance; Viral Proteins; Virulence; Zanamivir | 2007 |
Neuraminidase inhibitors and their role in avian and pandemic influenza.
Topics: Animals; Antiviral Agents; Birds; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H9N2 Subtype; Influenza in Birds; Influenza, Human; Mice; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
Occasional review: influenza in COPD: pathogenesis, prevention, and treatment.
Topics: Amantadine; Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Pulmonary Disease, Chronic Obstructive; Rimantadine; Zanamivir | 2007 |
The war against influenza: discovery and development of sialidase inhibitors.
Topics: Animals; Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
[Countermeasures for newly-emerging influenza].
Topics: Antiviral Agents; Communicable Diseases, Emerging; Disease Outbreaks; Enzyme Inhibitors; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
Lessons learned from the 2007-2008 cold and flu season: what worked and what was worthless.
Topics: Antiviral Agents; Causality; Common Cold; Diagnosis, Differential; Dietary Supplements; Hand Disinfection; Hospitalization; Humans; Infection Control; Influenza Vaccines; Influenza, Human; Morbidity; Nonprescription Drugs; Oseltamivir; Seasons; United States; Vaccination; Zanamivir | 2008 |
[Influenza].
Topics: Adolescent; Adult; Age Factors; Aged; Amantadine; Anti-Bacterial Agents; Antiviral Agents; Child; Child, Preschool; Diagnosis, Differential; Female; Follow-Up Studies; France; Humans; Infant; Influenza Vaccines; Influenza, Human; Male; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Seasons; Time Factors; Treatment Outcome; Zanamivir | 2008 |
[Antiviral treatment of influenza in humans].
Topics: Amantadine; Animals; Antiviral Agents; Clinical Trials as Topic; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Rimantadine; Virus Replication; Virus Shedding; Zanamivir | 2007 |
Modifying clinical practices to manage influenza in children effectively.
Topics: Adolescent; Animals; Antiviral Agents; Chemoprevention; Child; Child, Preschool; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H2N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2008 |
[Neuraminidase inhibitors in prophylaxis and treatment of influenza].
Topics: Antiviral Agents; Disease Outbreaks; Drug Administration Schedule; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2008 |
Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.
Topics: Amantadine; Antiviral Agents; Cost-Benefit Analysis; Humans; Influenza, Human; Models, Economic; Oseltamivir; Practice Guidelines as Topic; Premedication; Randomized Controlled Trials as Topic; Seasons; Treatment Outcome; Zanamivir | 2009 |
Influenza.
Topics: Acute Disease; Administration, Inhalation; Humans; Incidence; Influenza Vaccines; Influenza, Human; Oseltamivir; Rimantadine; Zanamivir | 2009 |
Antivirals for the treatment and prevention of epidemic and pandemic influenza.
Topics: Amantadine; Antiviral Agents; Chemoprevention; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza, Human; Oseltamivir; Rimantadine; Zanamivir | 2007 |
Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women.
Topics: Breast Feeding; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lactation; Neuraminidase; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Treatment Outcome; Viral Vaccines; Zanamivir | 2009 |
Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2009 |
Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza.
Topics: Antiviral Agents; Disease Outbreaks; Drug Administration Schedule; Humans; Influenza A virus; Influenza, Human; Nausea; Neuraminidase; Oseltamivir; Risk Factors; Vomiting; Zanamivir | 2009 |
Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis.
Topics: Adult; Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Treatment Outcome; United Kingdom; Zanamivir | 2009 |
Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials.
Topics: Anti-Bacterial Agents; Antiviral Agents; Asthma; Bias; Child; Child, Preschool; Enzyme Inhibitors; Humans; Infant; Influenza, Human; Neuraminidase; Oseltamivir; Otitis Media; Randomized Controlled Trials as Topic; Risk Factors; Zanamivir | 2009 |
[Pandemic influenza A H1N1 2009 flu during pregnancy: Epidemiology, diagnosis and management].
Topics: Antiviral Agents; Disease Outbreaks; Female; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Nasopharynx; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Zanamivir | 2009 |
The use of antiviral agents for the management of severe influenza.
Topics: Age Factors; Antiviral Agents; Drug Therapy, Combination; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interferons; Length of Stay; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Ribavirin; Risk Factors; Viral Load; Zanamivir | 2010 |
Antiviral treatment and prophylaxis of influenza virus in children.
Topics: Amantadine; Antiviral Agents; Chemoprevention; Child; Child, Preschool; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Post-Exposure Prophylaxis; Zanamivir | 2009 |
[Research progress of neuraminidase inhibitors for anti-influenza].
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2009 |
Neuraminidase inhibitors for preventing and treating influenza in healthy adults.
Topics: Adult; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Post-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Zanamivir | 2010 |
[Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
Topics: Adult; Antiviral Agents; Child; Clinical Trials as Topic; Disease Outbreaks; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Influenza A virus; Influenza, Human; Male; Models, Molecular; Molecular Structure; Mutation, Missense; Neuraminidase; Oseltamivir; Point Mutation; Pregnancy; Pregnancy Complications, Infectious; Protein Conformation; Viral Proteins; Zanamivir | 2010 |
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Biological; Oseltamivir; Recombinant Fusion Proteins; Zanamivir | 2010 |
[Influenza A, pregnancy and neuraminidase inhibitors].
Topics: Animals; Antiviral Agents; Australia; Centers for Disease Control and Prevention, U.S.; Drug Evaluation, Preclinical; Drug Utilization; Europe; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; New Zealand; Oseltamivir; Pandemics; Practice Guidelines as Topic; Pregnancy; Pregnancy Outcome; Risk Assessment; United States; Viral Proteins; World Health Organization; Zanamivir | 2011 |
Influenza in the tropics.
Topics: Animals; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Genetic Variation; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Oseltamivir; Prevalence; Tropical Climate; Zanamivir | 2010 |
Swine flu.
Topics: Antiviral Agents; Contact Tracing; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Travel; Zanamivir | 2009 |
[Change of strategies for novel and seasonal flu during pregnancy].
Topics: Antiviral Agents; Disease Outbreaks; Female; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Zanamivir | 2010 |
[Current anti-influenza virus chemotherapy].
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Drug Utilization; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Japan; Oseltamivir; Pandemics; Zanamivir | 2010 |
[Present and future in development of new anti-influenza drugs].
Topics: Amantadine; Antiviral Agents; DNA-Directed RNA Polymerases; Drug Design; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
[Influenza A/H1N1v 2009 during pregnancy and breastfeeding: which antiviral to choose?].
Topics: Adult; Antiviral Agents; Breast Feeding; Female; Fetus; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Zanamivir | 2010 |
Treatment options for H5N1: lessons learned from the H1N1 pandemic.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Pneumonia, Viral; Pyrans; Severity of Illness Index; Sialic Acids; Zanamivir | 2010 |
Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review.
Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Post-Exposure Prophylaxis; Treatment Outcome; Viral Matrix Proteins; Zanamivir | 2011 |
Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Administration Routes; Drug Administration Schedule; Guanidines; Humans; Influenza, Human; Mice; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pandemics; Prodrugs; Pyrans; Rats; Sialic Acids; Zanamivir | 2010 |
[Research progress of anti-influenza virus agents].
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Guanidines; Humans; Indoles; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrrolidines; Rimantadine; Structure-Activity Relationship; Viral Matrix Proteins; Zanamivir | 2010 |
Influenza vaccination, diagnosis, and treatment in children.
Topics: Antiviral Agents; Child; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Real-Time Polymerase Chain Reaction; Vaccination; Zanamivir | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir | 2011 |
Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Topics: Administration, Inhalation; Adult; Animals; Antiviral Agents; Birds; Caprylates; Child; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza in Birds; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Viral Proteins; Virus Replication; Zanamivir | 2011 |
Antiviral drugs for influenza.
Topics: Adult; Amantadine; Antiviral Agents; Child; Female; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pregnancy; Rimantadine; Zanamivir | 2012 |
Neuraminidase inhibitors for preventing and treating influenza in children.
Topics: Acetamides; Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2012 |
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
Topics: Adult; Antiviral Agents; Child; Drug Evaluation; Enzyme Inhibitors; Europe; Health Status; Humans; Influenza, Human; Japan; Legislation, Drug; Neuraminidase; Oseltamivir; Publication Bias; Randomized Controlled Trials as Topic; United Kingdom; United States; Zanamivir | 2012 |
Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies.
Topics: Administration, Inhalation; Administration, Oral; Amantadine; Antiviral Agents; Confounding Factors, Epidemiologic; Hospitalization; Humans; Influenza, Human; Oseltamivir; Rimantadine; Treatment Outcome; Zanamivir | 2012 |
Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).
Topics: Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2012 |
Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Benzoic Acid; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Models, Molecular; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2012 |
[Drug resistance of influenza viruses].
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Matrix Proteins; Zanamivir | 2012 |
Antiviral drugs for influenza 2012-2013.
Topics: Animals; Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2012 |
Management of influenza in pregnancy.
Topics: Antiviral Agents; Female; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Patient Isolation; Pregnancy; Pregnancy Complications, Infectious; Zanamivir | 2013 |
European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN.
Topics: Acetamides; Antiviral Agents; Hematopoietic Stem Cell Transplantation; Humans; Influenza, Human; Leukemia; Oseltamivir; Practice Guidelines as Topic; Zanamivir | 2013 |
Influenza virus resistance to neuraminidase inhibitors.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2013 |
Executive summary. Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiolo
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Child; Cross Infection; Disease Management; Drug Resistance, Viral; Humans; Influenza Vaccines; Influenza, Human; Organ Transplantation; Oseltamivir; Postoperative Complications; Superinfection; Zanamivir | 2013 |
Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Child; Cross Infection; Diagnosis, Differential; Disease Management; Drug Resistance, Viral; HN Protein; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Inpatients; Kidney Diseases; Organ Transplantation; Oseltamivir; Outpatients; Pneumonia; Postoperative Complications; Superinfection; Zanamivir | 2013 |
The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews.
Topics: Antibiotic Prophylaxis; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir | 2013 |
Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.
Topics: Adult; Antibiotic Prophylaxis; Antiviral Agents; Child; Dose-Response Relationship, Drug; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Pandemics; Viral Proteins; Zanamivir | 2013 |
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2013 |
Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies.
Topics: Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Influenza, Human; Oseltamivir; Survival Analysis; Treatment Outcome; Zanamivir | 2013 |
Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: summary of an ecological study.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Survival Analysis; Treatment Outcome; Viral Proteins; Zanamivir | 2013 |
Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.
Topics: Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2013 |
Antiviral drugs for influenza 2013-2014.
Topics: Animals; Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Zanamivir | 2014 |
Neuraminidase inhibitors for preventing and treating influenza in adults and children.
Topics: Adult; Antiviral Agents; Child; Drug Evaluation; Enzyme Inhibitors; Europe; Health Status; Humans; Influenza, Human; Japan; Legislation, Drug; Neuraminidase; Oseltamivir; Pneumonia; Publication Bias; Randomized Controlled Trials as Topic; United Kingdom; United States; Zanamivir | 2014 |
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
Topics: Adolescent; Adult; Antiviral Agents; Child; Enzyme Inhibitors; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pandemics; Proportional Hazards Models; Treatment Outcome; Young Adult; Zanamivir | 2014 |
[Multisystem failure: the story of antinfluenza drugs].
Topics: Antiviral Agents; Clinical Trials as Topic; Evidence-Based Medicine; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Italy; Neuraminidase; Oseltamivir; Pandemics; Publication Bias; Randomized Controlled Trials as Topic; Risk Factors; Zanamivir | 2014 |
Antivirals--current trends in fighting influenza.
Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Rimantadine; Viral Matrix Proteins; Zanamivir | 2014 |
Influenza viruses resistant to neuraminidase inhibitors.
Topics: Adult; Aged; Antiviral Agents; Child; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2014 |
Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy.
Topics: Animals; Antiviral Agents; Birds; Enzyme Inhibitors; Humans; Immunologic Factors; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Population Surveillance; Public Health; Randomized Controlled Trials as Topic; Zanamivir | 2014 |
Antiviral drugs for seasonal influenza 2014-2015.
Topics: Administration, Inhalation; Administration, Oral; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Seasons; Zanamivir | 2014 |
Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Investigational New Drug Application; Male; Middle Aged; Oseltamivir; Pregnancy; Retrospective Studies; United States; Young Adult; Zanamivir | 2015 |
Optimizing antiviral therapy for influenza: understanding the evidence.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; RNA-Dependent RNA Polymerase; Sialic Acids; Viral Matrix Proteins; Viral Proteins; Zanamivir | 2015 |
Inhibitors targeting the influenza virus hemagglutinin.
Topics: Amantadine; Antiviral Agents; Enzyme Inhibitors; Hemagglutinin Glycoproteins, Influenza Virus; Neuraminidase; Orthomyxoviridae; Oseltamivir; Rimantadine; Zanamivir | 2015 |
Antiviral medications for influenza.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir | 2015 |
Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.
Topics: Acids, Carbocyclic; Amides; Antiviral Agents; Clinical Trials as Topic; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pyrans; Pyrazines; Republic of Korea; Sialic Acids; Zanamivir | 2015 |
Treatment and prophylaxis of influenza and the problem of resistance to neuraminidase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Young Adult; Zanamivir | 2015 |
Influenza and its treatment during pregnancy: A review.
Topics: Animals; Antiviral Agents; Female; Humans; Influenza Vaccines; Influenza, Human; Membrane Transport Proteins; Oseltamivir; Post-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Vaccination; Zanamivir | 2015 |
Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.
Topics: Adult; Antiviral Agents; Asthma; Child; Dose-Response Relationship, Drug; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Zanamivir | 2016 |
Antiviral therapy for respiratory viral infections in immunocompromised patients.
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Coronavirus Infections; Cyclopentanes; Guanidines; Humans; Immunocompromised Host; Influenza, Human; Oseltamivir; Palivizumab; Paramyxoviridae Infections; Picornaviridae Infections; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Ribavirin; Zanamivir | 2017 |
Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Disease Outbreaks; Enzyme Inhibitors; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Middle Aged; Neuraminidase; Observational Studies as Topic; Oseltamivir; Pandemics; Pneumonia; Young Adult; Zanamivir | 2017 |
Clinical Mimics: An Emergency Medicine-Focused Review of Influenza Mimics.
Topics: Acids, Carbocyclic; Aged; Aged, 80 and over; Antiviral Agents; Child, Preschool; Cyclopentanes; Emergency Medicine; Guanidines; Humans; Infant; Influenza, Human; Middle Aged; Oseltamivir; Risk Factors; United States; Zanamivir | 2017 |
Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses.
Topics: Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pneumonia; Zanamivir | 2017 |
Prevalence of human influenza virus in Iran: Evidence from a systematic review and meta-analysis.
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Iran; Male; Oseltamivir; Prevalence; Zanamivir | 2018 |
Treatment of influenza with neuraminidase inhibitors.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2018 |
Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Half-Life; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2019 |
Influenza management with new therapies.
Topics: Adrenal Cortex Hormones; Amides; Antiviral Agents; Critical Care; Critical Illness; Dibenzothiepins; Enzyme Inhibitors; Humans; Influenza, Human; Morpholines; Neuraminidase; Oseltamivir; Pyrazines; Pyridines; Pyridones; Pyrimidines; Pyrroles; Respiration, Artificial; Triazines; Zanamivir | 2020 |
Antivirals Targeting the Neuraminidase.
Topics: Antibodies, Monoclonal; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Neuraminidase inhibitors are effective and safe in reducing influenza complications: meta-analysis of randomized controlled trials.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Zanamivir | 2021 |
Antiviral use in healthcare workers-A systematic review.
Topics: Antiviral Agents; Enzyme Inhibitors; Health Personnel; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
Topics: Animals; Antiviral Agents; Dibenzothiepins; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Knowledge; Morpholines; Neuraminidase; Oseltamivir; Pyridones; SARS-CoV-2; Triazines; Virus Replication; Zanamivir | 2021 |
Comparative effectiveness of neuraminidase inhibitors in patients with influenza: A systematic review and network meta-analysis.
Topics: Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Network Meta-Analysis; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Antiviral Treatments for Influenza.
Topics: Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2021 |
The current strategies of optimization of oseltamivir against mutant neuraminidases of influenza A：A review.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Glycoside Hydrolases; Guanidines; Humans; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Antiviral therapies for influenza.
Topics: Antiviral Agents; COVID-19; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2023 |
Conformationally locked sugar derivatives and analogues as potential neuraminidase inhibitors.
Topics: Antiviral Agents; Cyclohexenes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Zanamivir | 2023 |
23 trial(s) available for oseltamivir and zanamivir
| Article | Year |
|---|---|
[Flu and antiviral agents....].
Topics: Acetamides; Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Placebos; Pyrans; Risk Factors; Sialic Acids; Zanamivir | 2000 |
Neuraminidase inhibitors in the management of influenza--experience of an outpatient practice.
Topics: Acetamides; Aged; Ambulatory Care; Antiviral Agents; Child; Enzyme Inhibitors; Fibrinogen; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2002 |
Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors.
Topics: Acetamides; Animals; Antiviral Agents; Cell Line; Child; Child, Preschool; Chlorocebus aethiops; Guanidines; Humans; Infant; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Vero Cells; Virus Shedding; Zanamivir | 2005 |
A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Female; Fever; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Japan; Male; Oseltamivir; Treatment Outcome; Zanamivir | 2008 |
Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
Topics: Administration, Inhalation; Administration, Oral; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Virus Shedding; Zanamivir | 2010 |
Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Viral Load; Zanamivir | 2010 |
Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Treatment Outcome; Zanamivir | 2010 |
An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.
Topics: Adult; Antiviral Agents; Asian People; Cross-Over Studies; Female; Humans; Male; Middle Aged; Oseltamivir; Young Adult; Zanamivir | 2011 |
A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza.
Topics: Adult; Antiviral Agents; Cytokines; Drugs, Chinese Herbal; Enzyme Inhibitors; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Statistics, Nonparametric; Treatment Outcome; Zanamivir | 2012 |
Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Disease Outbreaks; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir | 2012 |
A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases.
Topics: Adult; Aged; Antiviral Agents; Asthma; Chronic Disease; Double-Blind Method; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2013 |
Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Nasal Mucosa; Oseltamivir; Treatment Outcome; Virus Shedding; Young Adult; Zanamivir | 2012 |
Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cough; Drug Therapy, Combination; Enzyme Inhibitors; Family Characteristics; Female; Fever; Follow-Up Studies; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Multivariate Analysis; Neuraminidase; Oseltamivir; Time Factors; Young Adult; Zanamivir | 2012 |
Utility of Maoto in an influenza season where reduced effectiveness of oseltamivir was observed - a clinical, non-randomized study in children.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Age Factors; Alphainfluenzavirus; Antiviral Agents; Betainfluenzavirus; Child; Child, Preschool; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Infant; Influenza, Human; Male; Oseltamivir; Seasons; Treatment Outcome; Zanamivir | 2012 |
Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks.
Topics: Administration, Inhalation; Adult; Antiviral Agents; Chemoprevention; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Health Personnel; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Placebos; Thailand; Young Adult; Zanamivir | 2013 |
Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013.
Topics: Acids, Carbocyclic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Outpatients; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Young Adult; Zanamivir | 2013 |
Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Female; Guanidines; Humans; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2017 |
Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Double-Blind Method; Female; Hospitalization; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Treatment Outcome; Young Adult; Zanamivir | 2017 |
Factors associated with non-persistence to oral and inhaled antiviral therapies for seasonal influenza: a secondary analysis of a double-blind, multicentre, randomised clinical trial.
Topics: Administration, Inhalation; Administration, Oral; Antiviral Agents; Double-Blind Method; Female; France; Humans; Influenza, Human; Kaplan-Meier Estimate; Lost to Follow-Up; Male; Medication Adherence; Multivariate Analysis; Oseltamivir; Proportional Hazards Models; Treatment Outcome; Zanamivir | 2017 |
Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir | 2018 |
Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Double-Blind Method; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitro Compounds; Oseltamivir; Severe Acute Respiratory Syndrome; Thiazoles; Treatment Outcome; Young Adult; Zanamivir | 2019 |
Efficacy of oseltamivir compared with zanamivir in COPD patients with seasonal influenza virus infection: a randomized controlled trial.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pulmonary Disease, Chronic Obstructive; Zanamivir | 2020 |
Lessons from resistance analysis in clinical trials of IV zanamivir.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2023 |
461 other study(ies) available for oseltamivir and zanamivir
| Article | Year |
|---|---|
Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
Topics: Acids, Carbocyclic; Antiviral Agents; Binding Sites; Crystallography, X-Ray; Cyclopentanes; Enzyme Inhibitors; Guanidines; Influenza A virus; Models, Molecular; Neuraminidase; Protein Binding; Stereoisomerism; Structure-Activity Relationship | 2001 |
Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
Topics: Amides; Animals; Antiviral Agents; Cells, Cultured; Cytopathogenic Effect, Viral; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Lung; Mice; Mice, Inbred BALB C; Oseltamivir; Oxygen; Pyrazines; Survival Analysis; Virus Replication | 2007 |
Synthesis of potent pyrrolidine influenza neuraminidase inhibitors.
Topics: Antiviral Agents; Influenza A virus; Influenza B virus; Molecular Structure; Neuraminidase; Pyrrolidines; Structure-Activity Relationship | 2008 |
QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network.
Topics: Enzyme Inhibitors; Linear Models; Models, Biological; Neuraminidase; Quantitative Structure-Activity Relationship | 2008 |
Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
Topics: Antiviral Agents; Cell Line; Enzyme Inhibitors; Humans; In Vitro Techniques; Kinetics; Neuraminidase; Orthomyxoviridae; Oseltamivir; Recombinant Proteins; RNA, Messenger; Zanamivir | 2008 |
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; HeLa Cells; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Mice; Neuraminidase; Prodrugs; Zanamivir | 2009 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
Topics: Animals; Antiviral Agents; Brain; Drug Resistance, Viral; Female; Influenza A Virus, H5N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Oseltamivir; Virus Replication | 2009 |
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Influenza A Virus, H5N1 Subtype; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Orthomyxoviridae Infections; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
QSAR study of flavonoids and biflavonoids as influenza H1N1 virus neuraminidase inhibitors.
Topics: Drug Design; Enzyme Inhibitors; Flavonoids; Influenza A Virus, H1N1 Subtype; Molecular Structure; Neuraminidase; Quantitative Structure-Activity Relationship; Stereoisomerism; Structure-Activity Relationship | 2010 |
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
Topics: Antiviral Agents; Cells, Cultured; Child, Preschool; Drug Resistance, Viral; Genetic Testing; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Molecular Sequence Data; Neuraminidase; Oseltamivir; Point Mutation; Sequence Analysis, DNA | 2010 |
Complexity in influenza virus targeted drug design: interaction with human sialidases.
Topics: Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Models, Molecular; Molecular Conformation; Neuraminidase; Orthomyxoviridae | 2010 |
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
Topics: Acids, Carbocyclic; Animals; Cell Line; Cyclopentanes; Dogs; Enzyme Assays; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
Topics: Acids, Carbocyclic; Antiviral Agents; Crystallography, X-Ray; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hydrogen Bonding; Influenza B virus; Models, Molecular; Molecular Structure; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Zanamivir | 2010 |
Inhibition of human neuraminidase 3 (NEU3) by C9-triazole derivatives of 2,3-didehydro-N-acetyl-neuraminic acid.
Topics: Alkynes; Azides; Binding Sites; Catalysis; Computer Simulation; Copper; Humans; N-Acetylneuraminic Acid; Neuraminidase; Structure-Activity Relationship; Triazoles | 2010 |
Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
Topics: Administration, Oral; Antiviral Agents; Carbon Dioxide; Cell Line; Drug Evaluation, Preclinical; Enzyme Inhibitors; Esters; Guanidine; Humans; Hydrophobic and Hydrophilic Interactions; Influenza A virus; Influenza, Human; Ions; Molecular Structure; Naphthols; Neuraminidase; Oseltamivir; Prodrugs; Zanamivir | 2011 |
The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
Topics: Acids, Carbocyclic; Antiviral Agents; Crystallography, X-Ray; Cyclopentanes; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Neuraminidase; Protein Binding; Recombinant Proteins; Zanamivir | 2011 |
Development of oseltamivir phosphonate congeners as anti-influenza agents.
Topics: Acetamides; Administration, Oral; Alphainfluenzavirus; Animals; Antiviral Agents; Betainfluenzavirus; Biological Availability; Blood Proteins; Cyclohexenes; Cytopathogenic Effect, Viral; Dogs; Drug Resistance, Viral; Drug Stability; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Madin Darby Canine Kidney Cells; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Phosphorous Acids; Protein Binding; Rats; Structure-Activity Relationship | 2012 |
Bifunctional thiosialosides inhibit influenza virus.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; N-Acetylneuraminic Acid | 2014 |
Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
Topics: Administration, Oral; Amidines; Animals; Antiviral Agents; Biological Availability; Dogs; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Mutation; Neuraminidase; Oseltamivir; Prodrugs; Protein Binding; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Swine | 2014 |
Tamiphosphor monoesters as effective anti-influenza agents.
Topics: Animals; Antiviral Agents; Biological Availability; Caco-2 Cells; Cell Line; Chickens; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esters; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Microbial Sensitivity Tests; Models, Molecular; Molecular Conformation; Neuraminidase; Orthomyxoviridae; Oseltamivir; Phosphorous Acids; Structure-Activity Relationship | 2014 |
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
Topics: | 2012 |
Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay.
Topics: Administration, Oral; Animals; Biological Availability; Enzyme Inhibitors; Half-Life; Mice; Neuraminidase; Prodrugs; Sialic Acids; Viral Proteins | 2015 |
Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives.
Topics: Alkaloids; Animals; Antiviral Agents; Boronic Acids; Cell Line; Female; Humans; Indoles; Influenza A virus; Influenza, Human; Mice; NF-kappa B; Orthomyxoviridae Infections; Quinolines; Signal Transduction | 2017 |
Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
Topics: Administration, Oral; Antiviral Agents; Dose-Response Relationship, Drug; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Orthomyxoviridae; Oseltamivir; Prodrugs; Structure-Activity Relationship; Zanamivir | 2018 |
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
Topics: Amino Acid Sequence; Antiviral Agents; Binding Sites; Catalytic Domain; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Isoenzymes; Kinetics; Molecular Dynamics Simulation; Neuraminidase; Sequence Alignment; Viral Proteins; Zanamivir | 2018 |
Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Influenza A Virus, H3N2 Subtype; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Neuraminidase; Structure-Activity Relationship; Thiazoles | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.
Topics: Acetamides; Adsorption; Animals; Binding Sites; Birds; Cell Line; Conserved Sequence; Dogs; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Heating; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Kinetics; Molecular Structure; Mutation; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Phenotype; Pyrans; Sialic Acids; Substrate Specificity; Viral Plaque Assay; Virus Replication; Zanamivir | 1998 |
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Topics: Acetamides; Administration, Oral; Amines; Animals; Antiviral Agents; Disease Models, Animal; Female; Ferrets; Guanidines; Influenza A virus; Influenza B virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Pyrans; Rats; Rats, Sprague-Dawley; Sialic Acids; Virus Replication; Zanamivir | 1998 |
Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Topics: Acetamides; Administration, Intranasal; Administration, Oral; Amines; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Dogs; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Lung Diseases; Mice; Mice, Inbred BALB C; Molecular Structure; Neuraminidase; Oseltamivir; Pyrans; Ribavirin; Sialic Acids; Zanamivir | 1998 |
New ways to tackle influenza highlighted at ICAAC. Interscience Conference on Antimicrobial Agents and Chemotherapy.
Topics: Adolescent; Amines; Child; Child, Preschool; Clinical Trials as Topic; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1998 |
Progress treating, preventing influenza.
Topics: Amines; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1998 |
Disarming flu viruses.
Topics: Amines; Animals; Antiviral Agents; Disease Outbreaks; Drug Design; Enzyme Inhibitors; Guanidines; Hemagglutinins; Humans; Influenza Vaccines; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Virus Diseases; Virus Replication; Zanamivir | 1999 |
Two neuraminidase inhibitors for treatment of influenza.
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Amantadine; Amines; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Zanamivir | 1999 |
[Neuraminidase inhibitors against influenza].
Topics: Amines; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1999 |
Influenza--a new problem?
Topics: Amines; Antiviral Agents; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1999 |
Do the new flu drugs measure up?
Topics: Acetamides; Antiviral Agents; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1999 |
Neuraminidase inhibitors for treatment of influenza A and B infections.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Drug Interactions; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 1999 |
Neuraminidase inhibitors and relief of influenza symptoms.
Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2000 |
[New flu therapy. Progress or burden for the budget?].
Topics: Acetamides; Antiviral Agents; Cost-Benefit Analysis; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2000 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Acetamides; Acyclovir; Aged; Amantadine; Animals; Anti-HIV Agents; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Enzyme Inhibitors; Famciclovir; Ganciclovir; Guanidines; Guanine; Herpes Simplex; Herpes Zoster; History, 18th Century; HIV Infections; Humans; Injections, Intravenous; Interferon-alpha; Lamivudine; Neuraminidase; Oseltamivir; Pyrans; Rats; Ribavirin; Sialic Acids; Teratogens; Valacyclovir; Valine; Zanamivir | 1999 |
New influenza drugs zanamivir (Relenza) and oseltamivir (Tamiflu): unexpected serious reactions.
Topics: Acetamides; Acute Kidney Injury; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antiviral Agents; Canada; Child; Enzyme Inhibitors; Female; Guanidines; Humans; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Respiratory Tract Diseases; Sialic Acids; United States; United States Food and Drug Administration; Zanamivir | 2000 |
Antiviral agents for influenza.
Topics: Acetamides; Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Child; Child, Preschool; Guanidines; Guidelines as Topic; Humans; Infant; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Treatment Outcome; Zanamivir | 2000 |
Synthesis of 6-acetamido-5-amino- and -5-guanidino-3, 4-dehydro-N-(2-ethylbutyryl)- 3-piperidinecarboxylic acids related to zanamivir and oseltamivir, inhibitors of influenza virus neuraminidases.
Topics: Acetamides; Antiviral Agents; Clostridium perfringens; Enzyme Inhibitors; Guanidines; Neuraminidase; Orthomyxoviridae; Oseltamivir; Piperidines; Pyrans; Sialic Acids; Zanamivir | 2000 |
Flu-fighting options: decisions, decisions....
Topics: Acetamides; Amantadine; Antiviral Agents; Guanidines; Humans; Influenza, Human; Oseltamivir; Pneumonia; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2000 |
Flu drugs. Have I got news for flu.
Topics: Acetamides; Drug Approval; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; United Kingdom; Zanamivir | 2000 |
Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Topics: Acetamides; Acids, Carbocyclic; Administration, Intranasal; Administration, Oral; Animals; Antiviral Agents; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Species Specificity; Survival Analysis; Time Factors; Zanamivir | 2001 |
Advances in pharmacology. New treatments for influenza: neuraminidase inhibitors.
Topics: Acetamides; Antiviral Agents; Drug Approval; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sensitivity and Specificity; Sialic Acids; United States; Zanamivir | 2001 |
Unprepared for an influenza pandemic.
Topics: Acetamides; Amantadine; Antiviral Agents; Disease Outbreaks; Drug Resistance, Microbial; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2001 |
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Body Weight; Brain; Cyclopentanes; Disease Models, Animal; Dogs; Female; Guanidines; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H9N2 Subtype; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Virus Replication; Zanamivir | 2001 |
ACIP releases guidelines on the prevention and control of influenza. Advisory Committee on Immunization Practices.
Topics: Acetamides; Age Factors; Amantadine; Antiviral Agents; Drug Administration Schedule; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Patient Selection; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2001 |
Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Resistance, Viral; Edetic Acid; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2002 |
Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Topics: Acetamides; Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Influenza A virus; Influenza B virus; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Substrate Specificity; Zanamivir | 2001 |
Are we ready for the next flu pandemic?
Topics: Acetamides; Adult; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Global Health; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2001 |
[Pneumonia diagnosis in the practice on the test-bench: how much diagnosis is necessary?].
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Diagnosis, Differential; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pneumonia; Pyrans; Research; Sialic Acids; Time Factors; Zanamivir | 2002 |
Evidence-based emergency medicine/systematic review abstract. Use of the neuraminidase inhibitor class of antiviral drugs for treatment of healthy adults with an acute influenza-like illness.
Topics: Acetamides; Adolescent; Adult; Age Factors; Antiviral Agents; Confidence Intervals; Emergency Medicine; Enzyme Inhibitors; Evidence-Based Medicine; Guanidines; Humans; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Systematic Reviews as Topic; Time Factors; Treatment Outcome; Zanamivir | 2002 |
In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
Topics: Acetamides; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Genetic Variation; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Mutagenesis; Neuraminidase; Oseltamivir; Phenotype; Pyrans; Pyrrolidines; Sialic Acids; Zanamivir | 2002 |
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Topics: Acetamides; Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Child; Child, Preschool; Cost-Benefit Analysis; Guanidines; Humans; Infant; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Rimantadine; Risk Factors; Sialic Acids; United States; Vaccination; Zanamivir | 2002 |
Structural studies of the resistance of influenza virus neuramindase to inhibitors.
Topics: Acetamides; Acids, Carbocyclic; Alphainfluenzavirus; Antiviral Agents; Crystallography, X-Ray; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Pyrans; Sialic Acids; Zanamivir | 2002 |
Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Topics: Acetamides; Acids, Carbocyclic; Canada; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Fluorometry; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Luminescent Measurements; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2002 |
Economic analysis of influenza vaccination and antiviral treatment for healthy working adults.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Decision Trees; Drug Costs; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Rimantadine; Sensitivity and Specificity; Sialic Acids; Vaccination; Zanamivir | 2002 |
Summaries for patients. Influenza vaccination or antiviral treatment for healthy working adults: an economic analysis.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Vaccination; Zanamivir | 2002 |
Current strategies for management of influenza in the elderly population.
Topics: Acetamides; Aged; Aged, 80 and over; Chemoprevention; Complementary Therapies; Cost-Benefit Analysis; Disease Management; Guanidines; Health Services for the Aged; Humans; Influenza, Human; Institutionalization; Oseltamivir; Patient Compliance; Population Surveillance; Prevalence; Pyrans; Rimantadine; Sialic Acids; Vaccination; Zanamivir | 2002 |
Influenza prevention 2002-2003.
Topics: Acetamides; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guanidines; Headache; Humans; Infant; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pregnancy; Pyrans; Sialic Acids; Zanamivir | 2002 |
Cost-effectiveness of newer treatment strategies for influenza.
Topics: Acetamides; Adult; Age Distribution; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Diagnostic Tests, Routine; Drug Costs; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Monte Carlo Method; Neuraminidase; Oseltamivir; Pennsylvania; Pyrans; Quality-Adjusted Life Years; Sialic Acids; Zanamivir | 2002 |
Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.
Topics: Acetamides; Antiviral Agents; Guanidines; Influenza A virus; Mutation; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Structure-Activity Relationship; Zanamivir | 2002 |
[Neuraminidase inhibitor permitted. The first pill against influenza].
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Aged; Antiviral Agents; Child; Child, Preschool; Guanidines; Humans; Infant; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir | 2002 |
[New diagnostic possibilities and medications. Fit for influenza?].
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Aged; Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir | 2002 |
Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Family Practice; Guanidines; Humans; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Patient Acceptance of Health Care; Pyrans; Sialic Acids; State Medicine; United Kingdom; Zanamivir | 2003 |
[Oral neuraminidase inhibitor and an early warning system. New weapons against influenza].
Topics: Acetamides; Adult; Aged; Antiviral Agents; Female; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sentinel Surveillance; Sialic Acids; Zanamivir | 2003 |
We need to determine who benefits most from flu treatments.
Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2003 |
Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.
Topics: Acetamides; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Fluorescence; Guanidines; Humans; Luminescent Measurements; Neuraminidase; Orthomyxoviridae; Oseltamivir; Protein Structure, Tertiary; Pyrans; Sialic Acids; Zanamivir | 2003 |
Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model.
Topics: Acetamides; Animals; Antiviral Agents; Disease Models, Animal; Drug Therapy, Combination; Glucocorticoids; Guanidines; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Rats; Sialic Acids; Sigmodontinae; Triamcinolone Acetonide; Zanamivir | 2003 |
Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.
Topics: Acetamides; Aged; Amantadine; Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Quality-Adjusted Life Years; Rimantadine; Sensitivity and Specificity; Sialic Acids; Zanamivir | 2003 |
Summaries for patients. Cost-effective management of flu in adults older than 65 years of age.
Topics: Acetamides; Aged; Amantadine; Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Guanidines; Humans; Influenza, Human; Oseltamivir; Pyrans; Quality-Adjusted Life Years; Rimantadine; Sensitivity and Specificity; Sialic Acids; Zanamivir | 2003 |
Neuraminidase inhibitors slightly beneficial for shortening flu symptoms.
Topics: Acetamides; Adolescent; Adult; Aged; Antiviral Agents; Child; Double-Blind Method; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir | 2003 |
Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
Topics: Acetamides; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Flow Cytometry; Guanidines; Humans; In Vitro Techniques; Influenza A virus; Influenza B virus; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Phenotype; Pyrans; Sialic Acids; Virus Replication; Zanamivir | 2004 |
[English meta-analysis on zanamivir and oseltamivir. Knowledge of effects of influenza agents still not sufficient].
Topics: Acetamides; Antiviral Agents; Guanidines; Humans; Influenza, Human; Meta-Analysis as Topic; Oseltamivir; Practice Guidelines as Topic; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2003 |
Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Topics: Acetamides; Antiviral Agents; Asia, Southeastern; Australasia; Drug Resistance, Viral; Fluorescence; Guanidines; Humans; Hymecromone; Influenza A virus; Influenza B virus; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2004 |
[Strategies in the diagnosis and treatment of patients with avian influenza].
Topics: Acetamides; Animals; Antiviral Agents; Birds; Guanidines; Humans; Influenza A virus; Influenza in Birds; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2004 |
A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
Topics: Acetamides; Antiviral Agents; Fluorescence; Guanidines; Humans; Influenza A virus; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Virology; Zanamivir | 2004 |
Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Topics: Acetamides; Antiviral Agents; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Luminescent Measurements; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Population Surveillance; Pyrans; Sialic Acids; Zanamivir | 2004 |
Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
Topics: Acetamides; Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza B virus; Luminescent Measurements; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2004 |
Influenza outbreaks in aged-care facilities: staff vaccination and the emerging use of antiviral therapy.
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Disease Outbreaks; Female; Guanidines; Homes for the Aged; Humans; Infection Control; Infectious Disease Transmission, Patient-to-Professional; Influenza A virus; Influenza, Human; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Vaccination; Victoria; Zanamivir | 2004 |
Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.
Topics: Acetamides; Amantadine; Antiviral Agents; Drug Resistance, Viral; Germany; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Primary Health Care; Pyrans; Sialic Acids; Zanamivir | 2004 |
Avian influenza should be ruffling our feathers.
Topics: Acetamides; Amantadine; Animals; Antiviral Agents; Asia, Eastern; Asia, Southeastern; Birds; Disease Outbreaks; Guanidines; Humans; Influenza in Birds; Influenza Vaccines; Influenza, Human; International Cooperation; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; World Health Organization; Zanamivir | 2004 |
A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
Topics: Acetamides; Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Inhibitory Concentration 50; Mutation; Neuraminidase; Oseltamivir; Pyrans; Recombination, Genetic; Sialic Acids; Zanamivir | 2004 |
Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
Topics: Acetamides; Antiviral Agents; Australia; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Population Surveillance; Pyrans; Sialic Acids; Zanamivir | 2003 |
Prevention of influenza in the general population: recommendation statement from the Canadian Task Force on Preventive Health Care.
Topics: Acetamides; Aged; Canada; Guanidines; Health Policy; Humans; Infant; Influenza Vaccines; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Preventive Medicine; Public Health; Pyrans; Risk Factors; Sialic Acids; Zanamivir | 2004 |
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
Topics: Acetamides; Animals; Antiviral Agents; Cell Line; Cell Survival; Dogs; Drug Synergism; Enzyme Inhibitors; Guanidines; Influenza A virus; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Viral Plaque Assay; Virus Replication; Zanamivir | 2004 |
A side effect of neuraminidase inhibitor in a patient with liver cirrhosis.
Topics: Acetamides; Aged; Diagnosis, Differential; Drug Eruptions; Enzyme Inhibitors; Female; Guanidines; Humans; Liver Cirrhosis; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2005 |
Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom.
Topics: Acetamides; Adolescent; Adult; Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; United Kingdom; Zanamivir | 2005 |
Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo.
Topics: Acetamides; Acids, Carbocyclic; Administration, Intranasal; Administration, Oral; Animals; Antiviral Agents; Cyclopentanes; Dose-Response Relationship, Drug; Guanidines; Mice; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Structure-Activity Relationship; Survival Rate; Treatment Outcome; Zanamivir | 2005 |
Avian flu special: what's in the medicine cabinet?
Topics: Acetamides; Animals; Antiviral Agents; Guanidines; Humans; Influenza, Human; Internationality; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; World Health Organization; Zanamivir | 2005 |
Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.
Topics: Acetamides; Animals; Antiviral Agents; Brain; Cell Line; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guanidines; Influenza A virus; Inhibitory Concentration 50; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Virulence; Virus Replication; Zanamivir | 2005 |
Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors.
Topics: Acetamides; Amantadine; Animals; Antiviral Agents; Chick Embryo; Chickens; Enzyme Inhibitors; Guanidines; Influenza A virus; Influenza in Birds; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Rimantadine; Sialic Acids; Zanamivir | 2006 |
Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Topics: Acetamides; Enzyme Inhibitors; France; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2005 |
Threat of pandemic brings flu drug back to life.
Topics: Acetamides; Animals; Antiviral Agents; Birds; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Influenza in Birds; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2005 |
Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors.
Topics: Acetamides; Agglutination; Animals; Antiviral Agents; Cell Line; Dogs; Enzyme Inhibitors; Erythrocytes; Glycosylation; Guanidines; Hemagglutinins; Models, Molecular; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2005 |
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.
Topics: Acetamides; Amino Acid Substitution; Animals; Cell Line; Coculture Techniques; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Viral; Drug Tolerance; Enzyme Inhibitors; Enzyme Stability; Female; Ferrets; Genetic Variation; Guanidines; Kinetics; Mutagenesis, Site-Directed; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Recombination, Genetic; Sialic Acids; Temperature; Virus Replication; Zanamivir | 2005 |
Avian flu: isolation of drug-resistant H5N1 virus.
Topics: Acetamides; Adolescent; Adult; DNA Mutational Analysis; Drug Resistance, Viral; Female; Ferrets; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Mutation; Neuraminidase; Oseltamivir; Polymerase Chain Reaction; Pyrans; Sialic Acids; Zanamivir | 2005 |
Use of antiviral agents and other measures in an influenza pandemic.
Topics: Acetamides; Antiviral Agents; Disease Outbreaks; Guanidines; Humans; Influenza A virus; Influenza, Human; Netherlands; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Pyrans; Risk; Sialic Acids; Zanamivir | 2005 |
Consideration of use of neuraminidase inhibitors such as oseltamivir and zanamivir in IgA nephropathy.
Topics: Acetamides; Animals; Enzyme Inhibitors; Glomerulonephritis, IGA; Guanidines; Humans; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2005 |
[Influenza prevention in your practice (interview by Waldtraud Paukstadt)].
Topics: Acetamides; Adult; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Infant; Influenza Vaccines; Influenza, Human; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2005 |
Star role for bacteria in controlling flu pandemic?
Topics: Acetamides; Animals; Antiviral Agents; Birds; Chemistry, Pharmaceutical; Disease Outbreaks; Drugs, Generic; Escherichia coli; Genetic Engineering; Global Health; Guanidines; Humans; Illicium; Influenza in Birds; Influenza, Human; Oseltamivir; Pyrans; Shikimic Acid; Sialic Acids; Technology, Pharmaceutical; Zanamivir | 2005 |
Oseltamivir resistance--disabling our influenza defenses.
Topics: Acetamides; Binding Sites; Child; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Pyrans; Self Administration; Sialic Acids; Zanamivir | 2005 |
Review says oseltamivir and zanamivir should be kept for epidemics of flu.
Topics: Acetamides; Antiviral Agents; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2006 |
[What do your patients want to know now? The most frequent questions about avian influenza].
Topics: Acetamides; Animals; Antiviral Agents; Birds; Chickens; Child; Child, Preschool; Ducks; Enzyme Inhibitors; Geese; Guanidines; History, 16th Century; Humans; Infant; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza Vaccines; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2006 |
Oseltamivir resistance in influenza A (H5N1) infection.
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2006 |
Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.
Topics: Acetamides; Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Baculoviridae; Base Sequence; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Sequence Data; Neuraminidase; Oseltamivir; Pyrans; Recombinant Proteins; Sialic Acids; Zanamivir | 2006 |
Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.
Topics: Acetamides; Binding Sites; Computer Simulation; Enzyme Activation; Guanidines; Influenza A Virus, H5N1 Subtype; Models, Chemical; Models, Molecular; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Protein Binding; Protein Conformation; Pyrans; Sequence Analysis, Protein; Sialic Acids; Structure-Activity Relationship; Zanamivir | 2006 |
In vitro efficacies of oseltamivir carboxylate and zanamivir against equine influenza A viruses.
Topics: Acetamides; Animals; Antiviral Agents; Guanidines; Horses; Influenza A virus; Inhibitory Concentration 50; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2006 |
Roles of neuraminidase in the initial stage of influenza virus infection.
Topics: Acetamides; Animals; Cell Line; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Membrane Fusion; Neuraminidase; Oseltamivir; Pyrans; Reassortant Viruses; Sialic Acids; Zanamivir | 2006 |
Non-voluntary licensing of antivirals under patent: options the Australian Government should consider in light of a potential bird flu pandemic.
Topics: Acetamides; Animals; Antiviral Agents; Australia; Birds; Drugs, Generic; Guanidines; Health Services Needs and Demand; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Legislation, Drug; Oseltamivir; Patents as Topic; Public Health; Pyrans; Sialic Acids; Zanamivir | 2006 |
Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Evolution, Molecular; France; Influenza A Virus, H3N2 Subtype; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Zanamivir | 2006 |
Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Kidney Failure, Chronic; Oseltamivir; Zanamivir | 2006 |
Symptomatic predictors of influenza virus positivity in children during the influenza season.
Topics: Acetamides; Aging; Antiviral Agents; Child; Child, Preschool; Cough; Fever; Guanidines; Headache; Humans; Infant; Influenza, Human; Logistic Models; Muscular Diseases; Odds Ratio; Oseltamivir; Pyrans; Risk Factors; Seasons; Sialic Acids; Zanamivir | 2006 |
Possible case scenarios and logistic issues in H5N1 pandemic.
Topics: Antiviral Agents; Disease Outbreaks; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Severe Acute Respiratory Syndrome; Zanamivir | 2006 |
Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.
Topics: Adamantane; Antiviral Agents; Australia; Drug Resistance, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A virus; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Rimantadine; Zanamivir | 2007 |
[Avian influenza pandemic prevention - current research].
Topics: Acetamides; Animals; Antiviral Agents; Disease Outbreaks; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Models, Animal; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2006 |
Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Cyclopentanes; Drug Resistance, Multiple; Drug Resistance, Viral; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Mutation; Oseltamivir; Zanamivir | 2006 |
Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Topics: Acids, Carbocyclic; Amantadine; Animals; Antiviral Agents; Base Sequence; Birds; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Influenza A Virus, H1N1 Subtype; Mutation; Mutation, Missense; Neuraminidase; Oseltamivir; Selection, Genetic; Sequence Deletion; Viral Proteins; Zanamivir | 2007 |
Antiviral management of seasonal and pandemic influenza.
Topics: Amantadine; Animals; Antiviral Agents; Clinical Trials as Topic; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Mice; Neuraminidase; Oseltamivir; Rimantadine; Seasons; Zanamivir | 2006 |
Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents.
Topics: Adolescent; Adult; Aged; Animals; Child; Child, Preschool; Clinical Trials as Topic; Disease Outbreaks; Enzyme Inhibitors; Female; Homes for the Aged; Humans; Immunocompromised Host; Infant; Influenza Vaccines; Influenza, Human; Leukemia; Middle Aged; Nursing Homes; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Rats; Risk; United States; Vaccination; Zanamivir | 2006 |
Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.
Topics: Animals; Antiviral Agents; Binding Sites; Chickens; Drug Resistance, Viral; Enzyme Inhibitors; Hydrophobic and Hydrophilic Interactions; Influenza A Virus, H5N1 Subtype; Models, Chemical; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Sequence Analysis, Protein; Structure-Activity Relationship; Zanamivir | 2007 |
[Significance of virological diagnostics for the effective treatment of hospitalized patients infected with influenza virus].
Topics: Adult; Amantadine; Antiviral Agents; Diagnosis, Differential; Fluorescent Antibody Technique; Hospitalization; Humans; Influenza A virus; Influenza, Human; Middle Aged; Oseltamivir; Respiratory Tract Diseases; Reverse Transcriptase Polymerase Chain Reaction; Rimantadine; Treatment Outcome; Zanamivir | 2006 |
Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Drug Resistance, Multiple, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Male; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2006 |
Oseltamivir: new indication. Prevention of influenza in at-risk children: vaccination is best.
Topics: Amantadine; Antiviral Agents; Child; Drug Approval; Drug Resistance; Europe; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Vaccination; Zanamivir | 2007 |
Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999.
Topics: Amantadine; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Enzyme Inhibitors; Germany; Hemagglutination, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Influenza A Virus, H3N2 Subtype; Neuraminidase; Oseltamivir; Swine; Zanamivir | 2007 |
Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Japan; Neuraminidase; Orthomyxoviridae; Oseltamivir; Zanamivir | 2007 |
John F. Enders lecture 2006: antivirals for influenza.
Topics: Antiviral Agents; Drug Design; Drug Resistance, Viral; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
Topics: Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Enzyme Inhibitors; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Mutation; Neuraminidase; Oseltamivir; Sialic Acids; Viral Plaque Assay; Virus Replication; Zanamivir | 2007 |
General practitioners' management of influenza with or without neuraminidase inhibitors.
Topics: Adolescent; Adult; Antiviral Agents; Cohort Studies; Enzyme Inhibitors; Female; France; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Physicians, Family; Practice Patterns, Physicians'; Prospective Studies; Time Factors; Zanamivir | 2007 |
Hydrophobic polycationic coatings inactivate wild-type and zanamivir- and/or oseltamivir-resistant human and avian influenza viruses.
Topics: Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A virus; Oseltamivir; Polyethyleneimine; Zanamivir | 2008 |
Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; France; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Sequence Analysis, DNA; Viral Proteins; Zanamivir | 2008 |
Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.
Topics: Acids, Carbocyclic; Algorithms; Antiviral Agents; Binding Sites; Catalysis; Computer Simulation; Cyclopentanes; Databases, Protein; Guanidines; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Influenza A Virus, H5N1 Subtype; Inhibitory Concentration 50; Ligands; Models, Molecular; Molecular Conformation; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Pressure; Protein Binding; Protein Structure, Secondary; Static Electricity; Temperature; Thermodynamics; Time Factors; Water; Zanamivir | 2008 |
Reduced sensitivity of influenza A (H5N1) to oseltamivir.
Topics: Antiviral Agents; Drug Resistance, Viral; Influenza A Virus, H5N1 Subtype; Oseltamivir; Sialic Acids; Zanamivir | 2007 |
Influenza A virus neuraminidase limits viral superinfection.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Hemagglutinins; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Neuraminidase; Oseltamivir; Viral Interference; Viral Matrix Proteins; Viral Proteins; Zanamivir | 2008 |
Influenza.
Topics: Amantadine; Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Mass Vaccination; Oseltamivir; Rimantadine; Zanamivir | 2008 |
Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Area Under Curve; Body Temperature; Clopidogrel; Diclofenac; Dose-Response Relationship, Drug; Hypothermia; Male; Mice; Oseltamivir; Platelet Aggregation Inhibitors; Ticlopidine; Zanamivir | 2008 |
[Influenza in children: what should be considered in prevention and treatment?].
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Female; Germany; Humans; Infant; Infectious Disease Transmission, Professional-to-Patient; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Seasons; Zanamivir | 2008 |
Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Receptors, Virus; Recombination, Genetic; Respiratory Mucosa; Species Specificity; Viral Proteins; Virus Replication; Zanamivir | 2008 |
In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses.
Topics: Animals; Antiviral Agents; Cell Line; Chick Embryo; Drug Evaluation, Preclinical; Enzyme Inhibitors; Genes, Reporter; Genetic Engineering; Hemagglutinins, Viral; Humans; Influenza, Human; Leukemia Virus, Murine; Neuraminidase; Orthomyxoviridae; Oseltamivir; Virus Shedding; Zanamivir | 2008 |
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.
Topics: Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Kinetics; Models, Molecular; Molecular Conformation; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Zanamivir | 2008 |
Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Fever; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Oseltamivir; Retrospective Studies; Treatment Outcome; Zanamivir | 2008 |
Editorial commentary: viral susceptibility and the choice of influenza antivirals.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Practice Patterns, Physicians'; Zanamivir | 2008 |
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Oseltamivir; Pregnancy; Seasons; United States; Zanamivir | 2008 |
Statement on influenza vaccination for the 2008-2009 season. An Advisory Committee Statement (ACS).
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Canada; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Zanamivir | 2008 |
Antivirals and influenza: frequency of resistance.
Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Rimantadine; Zanamivir | 2008 |
Antiinfluenza medication kits need work, FDA advisers conclude.
Topics: Antiviral Agents; Disease Outbreaks; First Aid; Humans; Influenza, Human; Oseltamivir; United States; United States Food and Drug Administration; Zanamivir | 2008 |
Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method.
Topics: Amantadine; Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Genetic Markers; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Rimantadine; RNA, Viral; Sensitivity and Specificity; Sequence Analysis, RNA; Zanamivir | 2009 |
Neuropsychiatric concerns related to influenza treatment.
Topics: Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Mental Disorders; Nervous System Diseases; Oseltamivir; Zanamivir | 2009 |
Comparison of the effectiveness of Zanamivir and Oseltamivir against influenza A/H1N1, A/H3N2, and B.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Middle Aged; Oseltamivir; Treatment Outcome; Young Adult; Zanamivir | 2009 |
Update: infections with a swine-origin influenza A (H1N1) virus--United States and other countries, April 28, 2009.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Disease Outbreaks; Female; Humans; Infection Control; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mexico; Middle Aged; Oseltamivir; Travel; United States; Zanamivir | 2009 |
Swine flu outbreak. What role for antiviral drugs?
Topics: Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Zanamivir | 2009 |
How severe will the flu outbreak be?
Topics: Animals; Antiviral Agents; Disease Outbreaks; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Time Factors; Zanamivir | 2009 |
Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
Topics: Animals; Cell Line; Dogs; Enzyme Inhibitors; Germany; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Viral Proteins; Zanamivir | 2009 |
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Asia, Southeastern; Cluster Analysis; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oceania; Oseltamivir; Phylogeny; RNA, Viral; Sequence Analysis, DNA; Sequence Homology; South Africa; Viral Proteins; Zanamivir | 2009 |
Basic rules of influenza: how to combat the H1N1 influenza (swine flu) virus.
Topics: Antiviral Agents; Disease Outbreaks; Health Planning; Humans; Infectious Disease Incubation Period; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Oseltamivir; United States; Vaccination; Zanamivir | 2009 |
Telephone triage of patients with influenza.
Topics: Antiviral Agents; Clinical Protocols; Disease Outbreaks; Family Practice; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mass Screening; Nursing Care; Oseltamivir; Telephone; Triage; Zanamivir | 2009 |
FDA notifications. EUA issued for treating novel 2009 H1N1 flu.
Topics: Antiviral Agents; Child; Child, Preschool; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; United States; United States Food and Drug Administration; Zanamivir | 2009 |
Apropos "vaccines in a hurry".
Topics: Antiviral Agents; Disease Outbreaks; Drug Industry; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Microbial Sensitivity Tests; Oseltamivir; Zanamivir | 2009 |
Swine influenza: nephrologist's perspective.
Topics: Antiviral Agents; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Nephrology; Oseltamivir; Renal Insufficiency, Chronic; Zanamivir | 2009 |
Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.
Topics: Animals; Antiviral Agents; Asia, Southeastern; Australasia; Cell Line; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2009 |
Clinical features of cases of influenza A (H1N1)v in Osaka prefecture, Japan, May 2009.
Topics: Adolescent; Adult; Antigens, Viral; Antiviral Agents; Child; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Reagent Kits, Diagnostic; Reverse Transcriptase Polymerase Chain Reaction; Schools; Sensitivity and Specificity; Treatment Outcome; Young Adult; Zanamivir | 2009 |
Summary of the Australasian Society for Infectious Diseases and the Thoracic Society of Australia and New Zealand guidelines: treatment and prevention of H1N1 influenza 09 (human swine influenza) with antiviral agents.
Topics: Adult; Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2009 |
Q&A: What have we found out about the influenza A (H1N1) 2009 pandemic virus?
Topics: Animals; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Humans; Immunity, Active; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Time Factors; Virulence; Zanamivir | 2009 |
Why are oseltamivir and zanamivir effective against the newly emerged influenza A virus (A/H1N1)?
Topics: Antiviral Agents; Base Sequence; Binding Sites; Computer Simulation; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Molecular Sequence Data; Oseltamivir; Zanamivir | 2009 |
Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Influenza A Virus, H5N1 Subtype; Molecular Conformation; Molecular Dynamics Simulation; Neuraminidase; Organophosphonates; Oseltamivir; Time Factors; Zanamivir | 2009 |
[Inquired of the President of the.Robert Koch Institute. How dangerous is Mexican influenza?].
Topics: Animals; Antiviral Agents; Disease Outbreaks; Enzyme Inhibitors; Germany; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mexico; Orthomyxoviridae Infections; Oseltamivir; Swine; World Health Organization; Zanamivir | 2009 |
[New influenza A (H1N1): advised indication and prescription of antiviral drugs].
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Utilization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Netherlands; Oseltamivir; Zanamivir | 2009 |
Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing.
Topics: Amino Acid Substitution; Antiviral Agents; DNA Primers; Drug Resistance, Viral; Genotype; Humans; Influenza B virus; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Phylogeny; Polymorphism, Genetic; RNA, Viral; Sequence Analysis, DNA; Victoria; Viral Proteins; Zanamivir | 2010 |
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.
Topics: Animals; Antiviral Agents; Binding Sites; Caco-2 Cells; Cell Proliferation; Dogs; Humans; Influenza, Human; Mutation; N-Acetylneuraminic Acid; Neuraminidase; Orthomyxoviridae; Oseltamivir; Recombinant Fusion Proteins; Zanamivir | 2009 |
Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Time Factors; Zanamivir | 2009 |
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Zanamivir | 2010 |
Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.
Topics: Cross Infection; Drug Resistance, Viral; Global Health; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Population Surveillance; Rimantadine; Zanamivir | 2009 |
H1N1 influenza in pregnancy: cause for concern.
Topics: Antiviral Agents; Compassionate Use Trials; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Zanamivir | 2010 |
Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza.
Topics: Antiviral Agents; Child; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Investigational New Drug Application; Oseltamivir; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Zanamivir | 2010 |
Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase.
Topics: Amino Acid Sequence; Binding Sites; Disaccharides; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Dynamics Simulation; Molecular Sequence Data; Neuraminidase; Oseltamivir; Plant Extracts; Sequence Alignment; Triterpenes; Zanamivir | 2010 |
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Treatment Outcome; Zanamivir | 2010 |
Clinical presentation and response to treatment of novel influenza A H1N1 in a university-based summer camp population.
Topics: Adolescent; Antiviral Agents; Disease Outbreaks; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Time Factors; Treatment Outcome; United States; Zanamivir | 2010 |
The truth about Tamiflu? Zanamivir should be inhaled, not nebulised.
Topics: Administration, Inhalation; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Nebulizers and Vaporizers; Off-Label Use; Oseltamivir; Zanamivir | 2010 |
Administration of neuraminidase inhibitors for the treatment of Japanese patients infected with the novel influenza A (H1N1).
Topics: Adolescent; Adult; Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Young Adult; Zanamivir | 2010 |
H1N1 influenza in pregnancy: risks, vaccines, and antivirals.
Topics: Antiviral Agents; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Zanamivir | 2009 |
Influenza A/H1N1 (2009) infection in pregnancy--an Asian perspective.
Topics: Administration, Oral; Adolescent; Adult; Antiviral Agents; Cohort Studies; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Prospective Studies; Singapore; Time Factors; Young Adult; Zanamivir | 2010 |
Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Topics: Animals; Antiviral Agents; Female; Guanidines; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Zanamivir | 2010 |
A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.
Topics: Adolescent; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Child, Preschool; Dogs; Drug Resistance, Viral; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Molecular Epidemiology; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Phylogeny; Sequence Analysis, DNA; Treatment Outcome; Viral Proteins; Virulence; Zanamivir | 2010 |
[Controversies about neuraminidase inhibitor. Is the influenza drug less effective than assumed?].
Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Infant; Influenza A virus; Influenza, Human; Male; Meta-Analysis as Topic; Middle Aged; Neuraminidase; Oseltamivir; Pregnancy; Risk Factors; Seasons; Zanamivir | 2010 |
Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection.
Topics: Antiviral Agents; Child; Cystic Fibrosis; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Oseltamivir; Pseudomonas aeruginosa; Pseudomonas Infections; Zanamivir | 2010 |
Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.
Topics: Antiviral Agents; Compassionate Use Trials; Critical Illness; Drug Resistance, Viral; Female; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Injections, Intravenous; Oseltamivir; Treatment Outcome; Viral Load; Zanamivir | 2010 |
In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
Topics: Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation.
Topics: Adolescent; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Fever; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Microbial Sensitivity Tests; Mutation, Missense; Nasopharynx; Neuraminidase; Oseltamivir; Treatment Outcome; Viral Proteins; Zanamivir | 2010 |
[Fatal pneumonitis due to oseltamivir-resistant new influenza A(H1N1) in the case of an intensive care patient].
Topics: Antiviral Agents; Drug Resistance, Viral; Fatal Outcome; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pneumonia; Zanamivir | 2010 |
Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan.
Topics: Amantadine; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Phylogeny; Seasons; Sequence Analysis, Protein; Time Factors; Viral Matrix Proteins; Zanamivir | 2010 |
Antiviral drug susceptibilities of seasonal human influenza viruses in Lebanon, 2008-09 season.
Topics: Amantadine; Animals; Antiviral Agents; Cell Line; Child, Preschool; Dogs; Drug Resistance, Viral; Environmental Monitoring; Epidemiological Monitoring; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Lebanon; Male; Microbial Sensitivity Tests; Oseltamivir; Phylogeny; Seasons; Zanamivir | 2010 |
Influenza A(H1N1) outbreak in a long-term care facility for severely handicapped residents, Slovenia, March-April 2009.
Topics: Adolescent; Adult; Antiviral Agents; Disabled Persons; Disease Outbreaks; Drug Resistance; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Residential Facilities; Severity of Illness Index; Slovenia; Young Adult; Zanamivir | 2010 |
Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
Topics: Animals; Antiviral Agents; Cell Line; Crystallography; Disease Models, Animal; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Ferrets; Humans; Influenza A Virus, H5N1 Subtype; Kidney; Male; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Structure, Tertiary; Recombinant Proteins; Zanamivir | 2010 |
Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir.
Topics: Animals; Antiviral Agents; Caco-2 Cells; Chromatography, High Pressure Liquid; Humans; In Vitro Techniques; Intestinal Absorption; Jejunum; Magnetic Resonance Spectroscopy; Male; Oseltamivir; Rats; Rats, Wistar; Zanamivir | 2010 |
An unusual cause of fever in a neonate: influenza A (H1N1) virus pneumonia.
Topics: Antiviral Agents; Fever; Gentamicins; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Zanamivir | 2010 |
Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Disease Models, Animal; DNA Mutational Analysis; Drug Resistance, Viral; Female; Ferrets; Humans; Influenza A Virus, H5N1 Subtype; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Viral Proteins; Zanamivir | 2010 |
In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza B virus; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Serial Passage; Zanamivir | 2011 |
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Birds; Catalytic Domain; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza in Birds; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Conformation; Species Specificity; Swine; Swine Diseases; Viral Proteins; Zanamivir | 2010 |
Neuraminidase inhibitors for influenza treatment and prevention in healthy adults.
Topics: Adult; Antiviral Agents; Disease Transmission, Infectious; Enzyme Inhibitors; Family; Female; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Primary Prevention; Zanamivir | 2010 |
[Naturally occurring oseltamivir resistance in influenza A].
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
Foreword: this issue of the Seton Hall Law Review presents contributions to Preparing for Pharmaceutical Response to Pandemic Influenza, a two-day Symposium held at Seton hall University School of Law in the fall of 2008.
Topics: Animals; Antiviral Agents; Birds; Disease Outbreaks; Global Health; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza Vaccines; Influenza, Human; Oseltamivir; United States; Zanamivir | 2009 |
[Influenza A H1N1v treated with extracorporeal membrane oxygenation].
Topics: Adult; Antiviral Agents; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pneumonia, Viral; Zanamivir | 2010 |
Influenza antiviral prescribing practices during the 2007-08 and 2008-09 influenza seasons in the setting of increased resistance to oseltamivir among circulating influenza viruses.
Topics: Adamantane; Antiviral Agents; Disease Outbreaks; Drug Resistance, Viral; Drug Utilization; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Rimantadine; Seasons; Surveys and Questionnaires; Zanamivir | 2010 |
Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models.
Topics: Animals; Disease Models, Animal; Drug Resistance, Viral; Ferrets; Guinea Pigs; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2010 |
Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Excipients; Humans; Influenza A virus; Neuraminidase; Oseltamivir; Peptides; Polymers; Viral Plaque Assay; Zanamivir | 2011 |
Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus.
Topics: Amino Acid Substitution; Antiviral Agents; Child, Preschool; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Fatal Outcome; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Neuraminidase; Oseltamivir; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Viral Load; Zanamivir | 2010 |
[Impact of avian influenza virus H5N1 neuraminidase mutations on the activity of neuraminidase and the sensibility to neuraminidase inhibitors].
Topics: Animals; Antiviral Agents; Cells, Cultured; Chick Embryo; Dogs; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
Feasibility of diagnosing influenza within 24 hours of symptom onset in children 1-3 years of age.
Topics: Antigens, Viral; Antiviral Agents; Child, Preschool; Early Diagnosis; Feasibility Studies; Fluoroimmunoassay; Humans; Infant; Influenza A virus; Influenza B virus; Influenza, Human; Oseltamivir; Point-of-Care Systems; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Sensitivity and Specificity; Zanamivir | 2011 |
Oseltamivir-resistant pandemic (H1N1) 2009 treated with nebulized zanamivir.
Topics: Child, Preschool; Dosage Forms; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation; Nebulizers and Vaporizers; Oseltamivir; Pandemics; Zanamivir | 2010 |
Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Germany; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Matrix Proteins; Viral Proteins; Young Adult; Zanamivir | 2011 |
Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Virulence; Zanamivir | 2011 |
Peri-operative novel 2009 H1N1 influenza virus infection successfully treated with oseltamivir and zanamivir in a lung transplant recipient.
Topics: Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung Transplantation; Oseltamivir; Perioperative Care; Treatment Outcome; Young Adult; Zanamivir | 2011 |
Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons.
Topics: Adolescent; Adult; Antiviral Agents; Enzyme Inhibitors; Female; Fever; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Seasons; Young Adult; Zanamivir | 2011 |
Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrrolidines; Recombination, Genetic; Viral Plaque Assay; Viral Proteins; Virus Replication; Zanamivir | 2011 |
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Topics: Acids, Carbocyclic; Adamantane; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrans; Pyrrolidines; Sialic Acids; Viral Plaque Assay; Zanamivir | 2010 |
Antivirals in treatment of H1N1 infection: are they really effective?
Topics: Antiviral Agents; Child; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Treatment Outcome; Zanamivir | 2011 |
Antiviral treatment of influenza A (H1N1-09) guided by molecular resistance testing in aplasia after allo-SCT.
Topics: Antiviral Agents; Drug Resistance, Viral; Female; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Zanamivir | 2011 |
Resistance to neuraminidase inhibitors.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Virus Shedding; Zanamivir | 2011 |
Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Humans; Influenza, Human; Male; Microbial Sensitivity Tests; Nasal Mucosa; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pharynx; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Virus Shedding; Zanamivir | 2011 |
Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds.
Topics: Animals; Antiviral Agents; Computational Biology; Databases, Nucleic Acid; Drug Resistance, Viral; Ducks; Influenza A virus; Influenza in Birds; Mutation, Missense; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; Swine; Zanamivir | 2011 |
Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Guanidines; Influenza A Virus, H1N1 Subtype; Oseltamivir; Zanamivir | 2011 |
Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico.
Topics: Adamantane; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mexico; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pandemics; Point Mutation; Reverse Transcriptase Polymerase Chain Reaction; Zanamivir | 2011 |
Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antiviral Agents; Child; Critical Illness; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Respiration, Artificial; Time Factors; Treatment Failure; Virus Shedding; Zanamivir | 2011 |
Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System.
Topics: Adverse Drug Reaction Reporting Systems; Antiviral Agents; Case-Control Studies; Congenital Abnormalities; Female; Humans; Immunization; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Prospective Studies; Risk Assessment; Societies, Medical; United States; Zanamivir | 2011 |
Extracorporeal membrane oxygenation for severe refractory respiratory failure secondary to 2009 H1N1 influenza A.
Topics: Adolescent; Adult; Antiviral Agents; Child; Critical Illness; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units, Pediatric; Male; Oseltamivir; Respiratory Insufficiency; Retrospective Studies; Young Adult; Zanamivir | 2011 |
Comparison of the efficacies of amantadine treatment of swine-origin influenza virus A H1N1 and seasonal influenza H1N1 and H3N2 in Japan (2008-2009).
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Amantadine; Amino Acid Sequence; Analysis of Variance; Antiviral Agents; Body Temperature; Child; Child, Preschool; Disease Outbreaks; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Middle Aged; Molecular Sequence Data; Mutation; Oseltamivir; Seasons; Sequence Alignment; Treatment Outcome; Viral Matrix Proteins; Zanamivir | 2011 |
Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance.
Topics: Amino Acid Substitution; Antibodies, Viral; Antigenic Variation; Antiviral Agents; Drug Resistance, Viral; Hemagglutinins; Humans; Immune Evasion; Influenza A virus; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Zanamivir | 2011 |
Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Asparagine; Disease Models, Animal; Drug Resistance, Viral; Female; Ferrets; Influenza A Virus, H5N1 Subtype; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Point Mutation; Rodent Diseases; Serine; Survival Analysis; Treatment Outcome; Viral Proteins; Virulence; Virulence Factors; Virus Replication; Zanamivir | 2011 |
Real-time estimation and prediction for pandemic A/H1N1(2009) in Japan.
Topics: Antiviral Agents; Databases, Factual; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Models, Statistical; Oseltamivir; Pandemics; Population Surveillance; Predictive Value of Tests; Zanamivir | 2011 |
Structural basis for Streptococcus pneumoniae NanA inhibition by influenza antivirals zanamivir and oseltamivir carboxylate.
Topics: Animals; Antiviral Agents; Carboxylic Acids; Humans; Isoenzymes; Mice; Molecular Sequence Data; Molecular Structure; Neuraminidase; Oseltamivir; Protein Conformation; Streptococcus pneumoniae; Zanamivir | 2011 |
Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H2N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2011 |
Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Genetic Testing; Genotype; Hemagglutination Inhibition Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Molecular Typing; Mutation, Missense; Neuraminidase; Oseltamivir; Pandemics; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Zanamivir | 2011 |
Online monitoring of flu in Belgium.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Belgium; Child; Child, Preschool; Disease Notification; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Online Systems; Oseltamivir; Pandemics; Population Surveillance; Young Adult; Zanamivir | 2011 |
Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation.
Topics: Antiviral Agents; Australia; Drug Resistance; Genetic Predisposition to Disease; Genetic Variation; Humans; Incidence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Polymorphism, Single Nucleotide; Population Surveillance; Risk Assessment; Risk Factors; Singapore; Zanamivir | 2011 |
Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
Topics: Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Enzyme Inhibitors; Germany; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H1N2 Subtype; Influenza A Virus, H3N2 Subtype; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Swine; Swine Diseases; Zanamivir | 2012 |
Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis.
Topics: Antiviral Agents; Base Sequence; DNA Probes; Drug Resistance, Viral; Enzyme Inhibitors; Epithelial Cells; Genotype; High-Throughput Screening Assays; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Neuraminidase; Oseltamivir; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA; Viral Proteins; Zanamivir | 2011 |
Severe H1N1-infection during pregnancy.
Topics: Abortion, Spontaneous; Antiviral Agents; Extracorporeal Membrane Oxygenation; Fatal Outcome; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Respiration, Artificial; Severity of Illness Index; Young Adult; Zanamivir | 2011 |
Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies.
Topics: Adult; Age Distribution; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Population Surveillance; Seasons; Zanamivir | 2011 |
Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy.
Topics: Adult; Antiviral Agents; Cohort Studies; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Humans; Infant, Low Birth Weight; Infant, Newborn; Influenza, Human; Male; Maternal Age; Maternal-Fetal Exchange; Neuraminidase; Oseltamivir; Parity; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Risk Factors; Young Adult; Zanamivir | 2011 |
[Etiotropic therapy of influenza: lessons from the last pandemic].
Topics: Antiviral Agents; Communicable Diseases, Emerging; Drug Resistance, Viral; Early Diagnosis; Hemagglutination, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pandemics; Pneumonia, Viral; Prognosis; Severity of Illness Index; Viral Interference; Viral Tropism; Zanamivir | 2011 |
[Clinical features and contagiousness of influenza A(H1N1) in health care workers and hospitalized patients in a Mexico City hospital].
Topics: Adult; Aged; Antiviral Agents; Comorbidity; Contact Tracing; Cross Infection; Disease Outbreaks; Female; Hospital Mortality; Hospitals, Urban; Humans; Immunocompromised Host; Infectious Disease Transmission, Patient-to-Professional; Infectious Disease Transmission, Professional-to-Patient; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inpatients; Male; Mexico; Middle Aged; Neoplasms; Occupational Diseases; Oseltamivir; Personnel, Hospital; Virulence; Zanamivir | 2011 |
Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child.
Topics: Adolescent; Antiviral Agents; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Female; Humans; Immunocompetence; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2011 |
Intravenous zanamivir in critically ill patients due to pandemic 2009 (H1N1) influenza A virus.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Intensive Care Units; Male; Middle Aged; Oseltamivir; Pneumonia, Viral; Singapore; Survival Analysis; Zanamivir | 2011 |
Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection.
Topics: Adolescent; Adult; Child, Preschool; Critical Illness; Drug Therapy, Combination; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Middle Aged; Netherlands; Oseltamivir; Retrospective Studies; Time Factors; Treatment Outcome; Viral Load; Zanamivir | 2011 |
Novel antiviral activity of neuraminidase inhibitors against an avian influenza a virus.
Topics: Animals; Antiviral Agents; Cell Line; Chickens; Dogs; Humans; Influenza A virus; Influenza in Birds; Influenza, Human; Microscopy, Electron, Scanning; Neuraminidase; Oseltamivir; Virion; Virus Assembly; Zanamivir | 2011 |
Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.
Topics: Acids, Carbocyclic; Binding, Competitive; Cyclopentanes; Enzyme Assays; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Inhibitory Concentration 50; Kinetics; Mutation; N-Acetylneuraminic Acid; Neuraminidase; Orthomyxoviridae; Oseltamivir; Protein Binding; Substrate Specificity; Time Factors; Viral Proteins; Zanamivir | 2011 |
High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals.
Topics: Administration, Intranasal; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Female; Guanidines; Influenza A virus; Inhibitory Concentration 50; Lung; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Viral Load; Zanamivir | 2012 |
Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Guideline Adherence; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Odds Ratio; Oseltamivir; Pandemics; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pregnancy; Pregnancy Complications, Infectious; Rimantadine; United States; Young Adult; Zanamivir | 2011 |
Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.
Topics: Antiviral Agents; Caprylates; Catalytic Domain; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Zanamivir | 2011 |
Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza.
Topics: Adolescent; Adult; Age Distribution; Aged; Antiviral Agents; Child; Child, Preschool; Death, Sudden; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Middle Aged; Oseltamivir; Young Adult; Zanamivir | 2011 |
Drugs: Lines of defence.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2011 |
Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Ferrets; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pandemics; Reverse Genetics; Viral Proteins; Virus Replication; Zanamivir | 2012 |
Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Bacterial Agents; Antiviral Agents; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Severity of Illness Index; Treatment Outcome; Viral Load; Young Adult; Zanamivir | 2013 |
Computational study on new natural polycyclic compounds of H1N1 influenza virus neuraminidase.
Topics: Antiviral Agents; Catalytic Domain; Computer Simulation; Hydrogen Bonding; Influenza A Virus, H1N1 Subtype; Models, Molecular; Molecular Structure; Neuraminidase; Oseltamivir; Polycyclic Compounds; Protein Binding; Protein Structure, Secondary; Structural Homology, Protein; Thermodynamics; Zanamivir | 2012 |
Virological surveillance and antiviral resistance of human influenza virus in Argentina, 2005-2008.
Topics: Amantadine; Animals; Antiviral Agents; Argentina; Cell Line; Dogs; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Morbidity; Mutation, Missense; Neuraminidase; Oseltamivir; Point Mutation; Population Surveillance; Seasons; Virus Cultivation; Zanamivir | 2011 |
In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Neuraminidase; Oseltamivir; Zanamivir | 2012 |
[Clinical trials and intensive therapy of the swine flu (H1N1)].
Topics: Administration, Inhalation; Adult; Aged; Bilirubin; Disease Outbreaks; Female; Georgia (Republic); Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Male; Middle Aged; Oseltamivir; Zanamivir | 2012 |
The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
Topics: Antiviral Agents; Biological Assay; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kinetics; Luminescence; Luminescent Measurements; Neuraminidase; Oseltamivir; Sequence Analysis, RNA; Software; Viral Proteins; Zanamivir | 2012 |
The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
Topics: Antiviral Agents; Biological Assay; Drug Resistance, Viral; Enzyme Inhibitors; Fluorescence; Humans; Influenza, Human; Kinetics; Neuraminidase; Orthomyxoviridae; Oseltamivir; Sequence Analysis, RNA; Software; Spectrometry, Fluorescence; Viral Proteins; Zanamivir | 2012 |
Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Catalytic Domain; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza B virus; Influenza, Human; Male; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Point Mutation; RNA, Viral; Sequence Analysis, DNA; Zanamivir | 2012 |
In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.
Topics: Acids, Carbocyclic; Animals; Cells, Cultured; Cyclopentanes; Dogs; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Serial Passage; Zanamivir | 2012 |
Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
Topics: Amino Acid Substitution; Antiviral Agents; Computer Graphics; Computer Simulation; Crystallography, X-Ray; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; History, 21st Century; Humans; Hydrogen Bonding; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Molecular; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Pandemics; Point Mutation; Protein Conformation; Protein Structure, Secondary; Static Electricity; Zanamivir | 2012 |
Postexposure prophylaxis for influenza in pediatric wards oseltamivir or zanamivir after rapid antigen detection.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Antigens, Viral; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Health Personnel; Humans; Infant; Influenza, Human; Inpatients; Orthomyxoviridae; Oseltamivir; Young Adult; Zanamivir | 2012 |
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Prescriptions; Drug Utilization; Female; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; United States; Young Adult; Zanamivir | 2012 |
Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Female; Fever; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Middle Aged; Neuraminidase; Oseltamivir; Seasons; Severity of Illness Index; Treatment Outcome; Young Adult; Zanamivir | 2013 |
I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y.
Topics: Antiviral Agents; Drug Resistance, Viral; Influenza A virus; Mutation; Neuraminidase; Oseltamivir; Zanamivir | 2012 |
Quantitative predictions of binding free energy changes in drug-resistant influenza neuraminidase.
Topics: Antiviral Agents; Drug Resistance, Viral; Models, Molecular; Molecular Dynamics Simulation; Neuraminidase; Orthomyxoviridae; Oseltamivir; Thermodynamics; Zanamivir | 2012 |
Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission.
Topics: Adolescent; Antiviral Agents; Child, Preschool; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Zanamivir | 2012 |
Molecular basis of drug resistance in A/H1N1 virus.
Topics: Amino Acid Substitution; Antiviral Agents; Computer Simulation; Drug Resistance, Viral; Humans; Hydrogen Bonding; Influenza A Virus, H1N1 Subtype; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Static Electricity; Thermodynamics; Viral Proteins; Zanamivir | 2012 |
Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: an ecological study.
Topics: Antiviral Agents; Enzyme Inhibitors; Geography; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Poisson Distribution; Regression Analysis; Socioeconomic Factors; World Health Organization; Zanamivir | 2012 |
H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis.
Topics: Adamantane; Amino Acid Substitution; Antiviral Agents; Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Hydrophobic and Hydrophilic Interactions; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Pandemics; Protein Conformation; Zanamivir | 2012 |
[Neuraminidase inhibitors: effects still unclear].
Topics: Administration, Inhalation; Antiviral Agents; Bias; Conflict of Interest; Double-Blind Method; Drug Industry; Humans; Influenza, Human; Length of Stay; Neuraminidase; Oseltamivir; Publication Bias; Randomized Controlled Trials as Topic; Research Design; Zanamivir | 2012 |
The ongoing battle against influenza: Drug-resistant influenza viruses: why fitness matters.
Topics: Antiviral Agents; Drug Resistance, Viral; Genetic Fitness; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Zanamivir | 2012 |
Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.
Topics: Antiviral Agents; Catalytic Domain; Enzyme Inhibitors; Guanidines; Humans; Hydrogen Bonding; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Molecular Docking Simulation; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Protein Interaction Domains and Motifs; Pyrans; Sialic Acids; Static Electricity; Viral Proteins; Zanamivir | 2012 |
Synchronous dynamics of observed and predicted values of anti-influenza drugs in environmental waters during a seasonal influenza outbreak.
Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Environmental Monitoring; Humans; Influenza, Human; Japan; Oseltamivir; Rivers; Sewage; Water Pollutants, Chemical; Zanamivir | 2012 |
A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Catalytic Domain; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; HEK293 Cells; Humans; Influenza B virus; Madin Darby Canine Kidney Cells; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Conformation; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2012 |
[Establishment of drug screening assay and pharmacodynamic evaluation method targeting influenza RNA polymerase].
Topics: Alphainfluenzavirus; Amantadine; Antiviral Agents; Drug Evaluation, Preclinical; Genes, Reporter; HEK293 Cells; Humans; Luciferases; Oseltamivir; Plasmids; Reproducibility of Results; Ribavirin; RNA-Dependent RNA Polymerase; Sensitivity and Specificity; Transfection; Zanamivir | 2012 |
Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
Topics: Antiviral Agents; China; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Zanamivir | 2013 |
Reduction in sympathetic nerve activity as a possible mechanism for the hypothermic effect of oseltamivir, an anti-influenza virus drug, in normal mice.
Topics: Animals; Antiviral Agents; Body Temperature; Hexamethonium; Hypothermia; Injections, Intraperitoneal; Injections, Intraventricular; Male; Mecamylamine; Mice; Neuraminidase; Nicotine; Oseltamivir; Zanamivir | 2013 |
Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors.
Topics: Animals; Antiviral Agents; Biocatalysis; Conserved Sequence; Crystallography, X-Ray; Drug Resistance, Viral; Enzyme Inhibitors; Fluorescence; Humans; Kinetics; Madin Darby Canine Kidney Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Mutant Proteins; N-Acetylneuraminic Acid; Neuraminidase; Orthomyxoviridae; Oseltamivir; Tyrosine; Virus Replication; Zanamivir | 2013 |
Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity.
Topics: Animals; Antiviral Agents; Crystallography, X-Ray; Dogs; Enzyme Inhibitors; Humans; Madin Darby Canine Kidney Cells; Neuraminidase; Orthomyxoviridae; Oseltamivir; Protein Conformation; Sialic Acids; Structure-Activity Relationship; Zanamivir | 2013 |
Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
Topics: Animals; Antiviral Agents; Catalytic Domain; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza B virus; Influenza, Human; Japan; Madin Darby Canine Kidney Cells; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2013 |
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Topics: Acids, Carbocyclic; Africa; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oceania; Oseltamivir; Pyrans; Seasons; Sentinel Surveillance; Sialic Acids; South America; Zanamivir | 2013 |
Outcomes of infants exposed to oseltamivir or zanamivir in utero during pandemic (H1N1) 2009.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antiviral Agents; Female; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prospective Studies; Time Factors; Zanamivir | 2013 |
Value of pharmacy-based influenza surveillance - Ontario, Canada, 2009.
Topics: Adolescent; Adult; Antiviral Agents; Drug Prescriptions; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Ontario; Oseltamivir; Population Surveillance; Reproducibility of Results; Retrospective Studies; Time Factors; Young Adult; Zanamivir | 2013 |
Early therapy with neuraminidase inhibitors for influenza A (H1N1) pdm 2009 infection.
Topics: Child; Early Medical Intervention; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Zanamivir | 2013 |
Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; DNA Mutational Analysis; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2013 |
Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; China; Coinfection; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Plaque Assay; Viral Proteins; Zanamivir | 2013 |
Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Assays; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Kinetics; Luminescent Measurements; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Protein Binding; Viral Proteins; Zanamivir | 2013 |
Should neuraminidase inhibitors be prescribed for patients with influenza?
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2014 |
Resistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivir.
Topics: Animals; Anseriformes; Antiviral Agents; Chick Embryo; Computational Biology; Drug Resistance, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Influenza A virus; Influenza in Birds; Male; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Water; Zanamivir | 2013 |
Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Influenza A Virus, H1N1 Subtype; Molecular Dynamics Simulation; Mutant Proteins; Neuraminidase; Oseltamivir; Protein Binding; Protein Conformation; Static Electricity; Thermodynamics; Viral Proteins; Zanamivir | 2013 |
Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Culture Techniques; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Gene Expression; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Load; Viral Proteins; Virus Replication; Zanamivir | 2013 |
Therapy of H7N9 pneumonia: current perspectives.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pulmonary Ventilation; Zanamivir | 2013 |
The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
Topics: Animals; Antiviral Agents; Dogs; Drug Resistance, Viral; Fluorometry; Humans; Influenza A Virus, H3N2 Subtype; Inhibitory Concentration 50; Luminescent Measurements; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Mutant Proteins; Mutation, Missense; Neuraminidase; Oseltamivir; Selection, Genetic; Virus Cultivation; Zanamivir | 2014 |
Neuraminidase inhibitors for critically ill children with influenza.
Topics: Acids, Carbocyclic; Adolescent; Betainfluenzavirus; California; Child; Child, Preschool; Critical Care; Critical Illness; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Logistic Models; Multivariate Analysis; Neuraminidase; Odds Ratio; Oseltamivir; Pandemics; Population Surveillance; Treatment Outcome; Zanamivir | 2013 |
Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.
Topics: Antiviral Agents; Drug Resistance, Viral; Epidemiological Monitoring; Humans; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae; Oseltamivir; United States; Viral Proteins; Zanamivir | 2014 |
Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; British Columbia; Child; Child, Preschool; Cohort Studies; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Retrospective Studies; Treatment Outcome; Young Adult; Zanamivir | 2014 |
Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity.
Topics: Acids, Carbocyclic; Antiviral Agents; Computational Biology; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Molecular Dynamics Simulation; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Zanamivir | 2013 |
Sequential influenza B viral load and susceptibility in children treated with oseltamivir and zanamivir.
Topics: Antiviral Agents; Child; Child, Preschool; Female; Humans; Infant; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Nasal Cavity; Oseltamivir; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Viral Load; Zanamivir | 2014 |
Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Dogs; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Oseltamivir; Pyrans; Sialic Acids; United States; Virus Replication; Zanamivir | 2014 |
Critics attack chief medical officer's advice to use antivirals for flu.
Topics: Antiviral Agents; Evidence-Based Medicine; Humans; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; State Medicine; United Kingdom; Zanamivir | 2014 |
Department of Health's misguided alert recommending neuraminidase inhibitors for flu.
Topics: England; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Practice Guidelines as Topic; Zanamivir | 2014 |
Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden.
Topics: Amino Acid Sequence; Analysis of Variance; Animals; Colorimetry; Drug Resistance, Viral; Ducks; Genotype; Influenza A virus; Inhibitory Concentration 50; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Sequence Alignment; Sweden; Zanamivir | 2014 |
Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Influenza A Virus, H7N9 Subtype; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2013 |
Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses.
Topics: Animals; Antiviral Agents; Body Weight; Disease Models, Animal; Drug Therapy, Combination; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Lung; Mice, Inbred C57BL; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Treatment Outcome; Viral Load; Zanamivir | 2014 |
Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study.
Topics: Adolescent; Adult; Antiviral Agents; Epidemiological Monitoring; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prospective Studies; United Kingdom; Young Adult; Zanamivir | 2014 |
Study claiming Tamiflu saved lives was based on "flawed" analysis.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Cochrane review questions effectiveness of neuraminidase inhibitors.
Topics: Antiviral Agents; Humans; Influenza, Human; Oseltamivir; Zanamivir | 2014 |
Multisystem failure: the story of anti-influenza drugs.
Topics: Antiviral Agents; Drug and Narcotic Control; Evidence-Based Medicine; History, 20th Century; History, 21st Century; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Policy Making; Zanamivir | 2014 |
Tamiflu report comes under fire.
Topics: Antiviral Agents; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Observational Studies as Topic; Oseltamivir; Randomized Controlled Trials as Topic; Strategic Stockpile; Zanamivir | 2014 |
A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.
Topics: Animals; Antiviral Agents; Dogs; Drug Combinations; Drug Resistance, Viral; Enzyme Inhibitors; Female; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2014 |
Editor in chief's reply to Nguyen-Van-Tam.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Principal author of PRIDE study responds to news story in The BMJ claiming that the study was based on "flawed" analysis.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Authors' reply to Mark Jones's second critique of the study by Muthuri and colleagues reported in The BMJ.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Authors' reply to Mark Jones's critique of the study by Muthuri and colleagues reported in The BMJ.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Mark Jones's reply to Myles and Leonardi-Bee's response to his critique of their paper reported in The BMJ.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Tug of war for antiviral drugs data.
Topics: Antiviral Agents; Clinical Trials as Topic; Dissent and Disputes; Drug Industry; Humans; Influenza, Human; Information Dissemination; Oseltamivir; Research Design; Zanamivir | 2014 |
Neuraminidase inhibitors for influenza.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Risk Assessment; Zanamivir | 2014 |
Effectiveness of neuraminidase inhibitors for severe influenza.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Fever; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pyrans; Severity of Illness Index; Sialic Acids; Time Factors; Treatment Outcome; Viral Proteins; Virus Shedding; Zanamivir | 2015 |
Antivirals for influenza: where now for clinical practice and pandemic preparedness?
Topics: Antiviral Agents; Child; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal.
Topics: Acids, Carbocyclic; Cyclopentanes; Enzyme Inhibitors; Guanidines; Kinetics; Mutant Proteins; Neuraminidase; Orthomyxoviridae; Oseltamivir; Protein Binding; Viral Proteins; Zanamivir | 2014 |
Anti-influenza viral effects of honey in vitro: potent high activity of manuka honey.
Topics: Animals; Antiviral Agents; Dogs; Drug Synergism; Honey; Influenza A Virus, H1N1 Subtype; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Oseltamivir; Viral Plaque Assay; Virus Replication; Zanamivir | 2014 |
Anti-viral drugs in flu: not that good?
Topics: Adult; Antiviral Agents; Child, Preschool; Humans; Influenza, Human; Oseltamivir; Treatment Outcome; Zanamivir | 2014 |
Predictors of fatality in pandemic influenza A (H1N1) virus infection among adults.
Topics: Adult; Antiviral Agents; Cross Infection; Disease Outbreaks; Female; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Multivariate Analysis; Neuraminidase; Odds Ratio; Oseltamivir; Pregnancy; Turkey; Zanamivir | 2014 |
Primarily oseltamivir-resistant influenza A (H1N1pdm09) virus evolving into a multidrug-resistant virus carrying H275Y and I223R neuraminidase substitutions.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Middle Aged; Mutation; Myelodysplastic Syndromes; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2015 |
Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Topics: Antiviral Agents; Enzyme Inhibitors; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pandemics; Zanamivir | 2014 |
Oseltamivir and zanamivir have limited effect on symptoms and do not reduce hospitalisation or serious complications of influenza.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2014 |
Glycan based detection and drug susceptibility of influenza virus.
Topics: Antiviral Agents; Biosensing Techniques; Drug Resistance, Viral; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Limit of Detection; Microarray Analysis; Microbial Sensitivity Tests; Oseltamivir; Polysaccharides; Zanamivir | 2014 |
Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Female; Humans; Immunoenzyme Techniques; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pandemics; Phenotype; RNA, Viral; Seasons; Sequence Analysis, DNA; Spain; Viral Proteins; Zanamivir | 2014 |
Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Portugal; Viral Proteins; Zanamivir | 2015 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2014 |
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2014 |
Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico.
Topics: Algorithms; Binding Sites; Computational Biology; Drug Design; Humans; Influenza, Human; Inhibitory Concentration 50; Least-Squares Analysis; Models, Molecular; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Quantitative Structure-Activity Relationship; Software; Technology, Pharmaceutical; Zanamivir | 2014 |
Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Fatal Outcome; Female; Guanidines; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Influenza A Virus, H3N2 Subtype; Influenza, Human; Leukemia, B-Cell; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Transplantation, Homologous; Viral Proteins; Zanamivir | 2014 |
[Drug susceptibility of wild-type and mutant H7N9 neuraminidase to zanamivir and oseltamivir].
Topics: Antiviral Agents; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2014 |
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Madin Darby Canine Kidney Cells; Middle Aged; Neuraminidase; Oseltamivir; Young Adult; Zanamivir | 2015 |
Characterization of human Influenza Viruses in Lebanon during 2010-2011 and 2011-2012 post-pandemic seasons.
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Lebanon; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Pyrans; Sialic Acids; Zanamivir | 2014 |
Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Genomic Instability; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Kinetics; Mice; Mutant Proteins; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Virulence; Virus Replication; Zanamivir | 2015 |
Review: Neuraminidase inhibitors reduce symptomatic influenza; oseltamivir does not reduce hospitalizations.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2014 |
Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro.
Topics: Antiviral Agents; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H7N1 Subtype; Neuraminidase; Nitro Compounds; Oseltamivir; Thiazoles; Zanamivir | 2015 |
Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.
Topics: Animals; Antiviral Agents; Dogs; Drug Resistance, Viral; Guanidines; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Mutation; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2015 |
Do we need a replacement medication for influenza with good efficacy?
Topics: Antiviral Agents; Drug Combinations; Drug Synergism; Humans; Indoles; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Plant Extracts; Treatment Outcome; Zanamivir | 2014 |
Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients.
Topics: Acids, Carbocyclic; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Beijing; Cohort Studies; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Hong Kong; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza, Human; Male; Middle Aged; Multivariate Analysis; Neuraminidase; Oseltamivir; Pneumonia, Bacterial; Proportional Hazards Models; Prospective Studies; Protective Factors; Respiratory Insufficiency; Retrospective Studies; Risk Factors; Singapore; Superinfection; Young Adult; Zanamivir | 2015 |
Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium.
Topics: Analysis of Variance; Animals; Area Under Curve; DNA Primers; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Genetic Fitness; High-Throughput Nucleotide Sequencing; Humans; Influenza B virus; Kinetics; Madin Darby Canine Kidney Cells; Mutation, Missense; Neuraminidase; Oseltamivir; Respiratory Mucosa; Reverse Genetics; Reverse Transcriptase Polymerase Chain Reaction; Zanamivir | 2015 |
Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Topics: Acids, Carbocyclic; Adamantane; Amino Acid Substitution; Animals; Antiviral Agents; Base Sequence; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Genotype; Guanidines; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H1N2 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Phenotype; Phylogeny; Swine; Swine Diseases; Time Factors; United States; Viral Proteins; Zanamivir | 2015 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; China; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Europe; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Inhibitory Concentration 50; Japan; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Phylogeny; Pyrans; Sialic Acids; Time Factors; United States; World Health Organization; Zanamivir | 2015 |
A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir.
Topics: Animals; Antiviral Agents; Cell Line; Enzyme Inhibitors; Humans; Influenza, Human; Inhibitory Concentration 50; Insecta; Mutation; Neuraminidase; Oseltamivir; Surface Plasmon Resonance; Zanamivir | 2015 |
Electrochemical assay to detect influenza viruses and measure drug susceptibility.
Topics: Antiviral Agents; Drug Resistance, Viral; Electrochemical Techniques; Glucose; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Oseltamivir; Zanamivir | 2015 |
Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2015 |
Quantitative analysis of influenza A (H3N2) E119V and R292K variants in clinical specimens by real-time reverse transcription polymerase chain reaction.
Topics: Amino Acid Substitution; Antiviral Agents; Bodily Secretions; Child; Child, Preschool; Drug Resistance, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Mutant Proteins; Mutation, Missense; Nasal Cavity; Oseltamivir; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Zanamivir | 2015 |
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Young Adult; Zanamivir | 2015 |
Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Cities; Cyclopentanes; Drug Residues; Environmental Monitoring; Guanidines; Japan; Limit of Detection; Oseltamivir; Ozone; Pyrans; Risk Assessment; Rivers; Sewage; Sialic Acids; Water Pollutants, Chemical; Water Purification; Zanamivir | 2015 |
Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking.
Topics: Acids, Carbocyclic; Binding Sites; Cyclopentanes; Databases, Chemical; Glycoside Hydrolase Inhibitors; Guanidines; Influenza A Virus, H5N1 Subtype; Ligands; Molecular Docking Simulation; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Structure-Activity Relationship; Viral Proteins; Zanamivir | 2016 |
Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Humans; Infant; Influenza B virus; Influenza, Human; Middle Aged; Neuraminidase; Oseltamivir; Young Adult; Zanamivir | 2016 |
Computational Study of Drug Binding Affinity to Influenza A Neuraminidase Using Smooth Reaction Path Generation (SRPG) Method.
Topics: Catalytic Domain; Computer Simulation; Drug Delivery Systems; Drug Resistance; Forecasting; Humans; Influenza A Virus, H5N1 Subtype; Ligands; Models, Biological; Neuraminidase; Oseltamivir; Protein Binding; Thermodynamics; Zanamivir | 2015 |
WHO Global Influenza Surveillance and Response System working group on surveillance of influenza antiviral susceptibility.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Humans; Influenza A Virus, H10N7 Subtype; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Polymorphism, Single Nucleotide; Population Surveillance; Practice Guidelines as Topic; World Health Organization; Zanamivir | 2015 |
[Susceptibility of human influenza A (H3N2) viruses to neuraminidase inhibitors isolated during 2011-2012 in China].
Topics: Antiviral Agents; China; Drug Resistance, Viral; Enzyme Inhibitors; Epidemiological Monitoring; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2015 |
Knowledge gaps about Tamiflu and Relenza for pandemic flu are blamed on research failure.
Topics: Antiviral Agents; Biomedical Research; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pandemics; Zanamivir | 2015 |
[Haut Conseil de la Santé Publique (HCSP). Guidance on the prioritization of antiviral drugs in case of seasonal influenza epidemics (March 3, 2015)].
Topics: Adult; Age Factors; Aged; Antiviral Agents; Child; Comorbidity; Disease Management; Disease Susceptibility; Drug Utilization; Epidemics; Female; France; Humans; Influenza Vaccines; Influenza, Human; Male; Meta-Analysis as Topic; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Seasons; Vulnerable Populations; Zanamivir | 2015 |
The accuracy and timeliness of neuraminidase inhibitor dispensing data for predicting laboratory-confirmed influenza.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Utilization; Epidemiological Monitoring; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Middle Aged; Oseltamivir; Quebec; Young Adult; Zanamivir | 2016 |
NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots.
Topics: Antiviral Agents; Computer Graphics; Enzyme Assays; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Internet; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Zanamivir | 2016 |
H274Y's Effect on Oseltamivir Resistance: What Happens Before the Drug Enters the Binding Site.
Topics: Antiviral Agents; Binding Sites; Drug Resistance, Viral; Histidine; Hydrogen Bonding; Influenza A Virus, H5N1 Subtype; Molecular Dynamics Simulation; Mutation; Neuraminidase; Oseltamivir; Protein Conformation; Zanamivir | 2016 |
[Evidence under scrutiny. Neuraminidase inhibitors in severe influenza: yes or no?].
Topics: Ambulatory Care; Antiviral Agents; Cause of Death; Evidence-Based Medicine; Germany; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Survival Analysis; Zanamivir | 2015 |
Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2014.
Topics: Animals; Antigens, Viral; Antiviral Agents; Australia; Chickens; Drug Resistance, Viral; Epidemiological Monitoring; Hemagglutinins, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; International Cooperation; Oseltamivir; Phylogeny; Retrospective Studies; Zanamivir; Zygote | 2015 |
Design, synthesis, and in vitro biological evaluation of novel 6-methyl-7-substituted-7-deaza purine nucleoside analogs as anti-influenza A agents.
Topics: Antiviral Agents; Drug Discovery; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Inhibitory Concentration 50; Microbial Sensitivity Tests; Oseltamivir; Purine Nucleosides; Ribavirin; Zanamivir | 2016 |
Within-Host Models of High and Low Pathogenic Influenza Virus Infections: The Role of Macrophages.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Viral; Antiviral Agents; B-Lymphocytes; Cell Death; Epithelial Cells; Host-Pathogen Interactions; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C; Models, Immunological; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Viral Load; Virulence; Zanamivir | 2016 |
[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].
Topics: Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Japan; Medication Adherence; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir | 2015 |
Susceptibility of influenza viruses circulating in Western Saudi Arabia to neuraminidase inhibitors.
Topics: Alphainfluenzavirus; Antiviral Agents; Betainfluenzavirus; Humans; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Prospective Studies; Respiratory System; Saudi Arabia; Zanamivir | 2016 |
The neuraminidase inhibitors evidence of harms - in context.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Neuraminidase; Oseltamivir; Zanamivir | 2016 |
ECDC public consultation on the use of neuraminidase inhibitors.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2016 |
Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.
Topics: Alberta; Antiviral Agents; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Nasopharynx; Neuraminidase; Oseltamivir; Seasons; Viral Load; Zanamivir | 2016 |
Recommendations for Prevention and Control of Influenza in Children, 2016-2017.
Topics: Antiviral Agents; Child; Drug Storage; Egg Hypersensitivity; Health Personnel; Hospitalization; Humans; Immunization Schedule; Infectious Disease Transmission, Patient-to-Professional; Infectious Disease Transmission, Professional-to-Patient; Influenza Vaccines; Influenza, Human; Oseltamivir; United States; Zanamivir | 2016 |
Droplet digital PCR to investigate quasi-species at codons 119 and 275 of the A(H1N1)pdm09 neuraminidase during zanamivir and oseltamivir therapies.
Topics: Antiviral Agents; Codon; Drug Resistance, Viral; Genetic Variation; Genotyping Techniques; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Polymerase Chain Reaction; Sensitivity and Specificity; Zanamivir | 2017 |
Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Humans; Influenza A virus; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2016 |
Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background.
Topics: Amino Acid Substitution; Animals; Dogs; Drug Design; Drug Discovery; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Kinetics; Madin Darby Canine Kidney Cells; Mutation; Mutation, Missense; Neuraminidase; Oseltamivir; Reverse Genetics; Viral Proteins; Zanamivir | 2016 |
Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Greece; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2017 |
Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.
Topics: Antiviral Agents; Binding Sites; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Hydrogen Bonding; Influenza A virus; Influenza, Human; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Neuraminidase; Oseltamivir; Protein Binding; Protein Structure, Quaternary; Static Electricity; Substrate Specificity; Thermodynamics; Zanamivir | 2016 |
Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014.
Topics: Antiviral Agents; Denmark; Drug Resistance, Viral; Genotype; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Zanamivir | 2017 |
Stockpile, use during outbreaks, restock, repeat.
Topics: Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Oseltamivir; Post-Exposure Prophylaxis; Strategic Stockpile; Zanamivir | 2017 |
In silico prediction of drug resistance due to S247R mutation of Influenza H1N1 neuraminidase protein.
Topics: Catalytic Domain; Computer Simulation; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Ligands; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Viral Proteins; Zanamivir | 2018 |
Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Fluorescence; Hymecromone; Inhibitory Concentration 50; Microbial Sensitivity Tests; Neuraminidase; Orthomyxoviridae; Oseltamivir; Zanamivir | 2017 |
Adverse events of prophylactic anti-influenza agents in medical staffs.
Topics: Adult; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Influenza, Human; Medical Staff; Middle Aged; Oseltamivir; Post-Exposure Prophylaxis; Retrospective Studies; Zanamivir | 2017 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Epidemiological Monitoring; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Seasons; Sialic Acids; World Health Organization; Zanamivir | 2017 |
Multiscale Simulation of Receptor-Drug Association Kinetics: Application to Neuraminidase Inhibitors.
Topics: Antiviral Agents; Enzyme Inhibitors; Influenza A Virus, H1N1 Subtype; Kinetics; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Receptors, Drug; Zanamivir | 2017 |
Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2015.
Topics: Africa; Annual Reports as Topic; Antigens, Viral; Antiviral Agents; Asia; Australia; Drug Resistance, Viral; Genotype; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Phylogeny; World Health Organization; Zanamivir | 2017 |
Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Databases, Genetic; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Protein Conformation; Pyrans; Recombinant Proteins; Sialic Acids; Viral Proteins; Zanamivir | 2017 |
Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection.
Topics: Animals; Antiviral Agents; Chemokine CXCL10; Chick Embryo; Dogs; Female; Gene Expression Regulation; Host-Pathogen Interactions; Immunologic Factors; IMP Dehydrogenase; Influenza A Virus, H5N1 Subtype; Interferon-beta; Interleukin-1beta; Interleukin-6; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Mycophenolic Acid; Orthomyxoviridae Infections; Oseltamivir; RNA, Viral; Survival Analysis; Virus Replication; Zanamivir | 2017 |
Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Birds; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza in Birds; Influenza, Human; Madin Darby Canine Kidney Cells; Mutagenesis; Neuraminidase; Orthomyxoviridae; Oseltamivir; Reverse Genetics; Zanamivir | 2018 |
Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Drug Therapy, Combination; Humans; Influenza A Virus, H1N1 Subtype; Oseltamivir; Virus Cultivation; Zanamivir | 2018 |
Different Inhibitory Potencies of Oseltamivir Carboxylate, Zanamivir, and Several Tannins on Bacterial and Viral Neuraminidases as Assessed in a Cell-Free Fluorescence-Based Enzyme Inhibition Assay.
Topics: Anti-Bacterial Agents; Antiviral Agents; Drug Synergism; Enzyme Assays; Hydrolyzable Tannins; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Tannins; Vibrio cholerae; Viral Proteins; Zanamivir | 2017 |
The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; Clarithromycin; Cohort Studies; Comorbidity; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Phosphorous Acids; Pneumonia; Prospective Studies; Treatment Outcome; Zanamivir | 2017 |
Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.
Topics: Amides; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Mice, Nude; Neuraminidase; Nucleic Acid Synthesis Inhibitors; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Pyrazines; Sialic Acids; Zanamivir | 2018 |
Oseltamivir Treatment of Influenza in Children.
Topics: Child; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Zanamivir | 2018 |
Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2.
Topics: Animals; Antiviral Agents; Defective Viruses; Denmark; Dogs; Drug Resistance, Viral; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Respiratory System; RNA-Dependent RNA Polymerase; RNA, Viral; Sequence Deletion; Treatment Outcome; Viral Proteins; Zanamivir | 2018 |
Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
Topics: Acids, Carbocyclic; Adolescent; Betainfluenzavirus; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Seasons; Sialic Acids; Treatment Outcome; Zanamivir | 2018 |
Trends of neuraminidase inhibitors use in children with influenza related respiratory infections.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Drug Utilization; Enzyme Inhibitors; Female; Guanidines; Hospitalization; Humans; Infant; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2018 |
Clinicians' attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza.
Topics: Adult; Antiviral Agents; Attitude of Health Personnel; Glycoside Hydrolase Inhibitors; Hospitalization; Humans; Influenza, Human; Medical Staff, Hospital; Neuraminidase; Oseltamivir; Randomized Controlled Trials as Topic; Research Personnel; Surveys and Questionnaires; United Kingdom; Zanamivir | 2018 |
Humoral immunity to influenza in an at-risk population and severe influenza cases in Russia in 2016-2017.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Birds; Epidemics; Humans; Immunity, Herd; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H5N8 Subtype; Influenza B virus; Influenza in Birds; Influenza, Human; Oseltamivir; Poultry; Poultry Diseases; Russia; Zanamivir | 2018 |
Antigenic and genetic characterization of influenza viruses isolated in Mozambique during the 2015 season.
Topics: Animals; Antiviral Agents; Child; Child, Preschool; Dogs; Female; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Madin Darby Canine Kidney Cells; Male; Mozambique; Neuraminidase; Oseltamivir; Phylogeny; Viral Proteins; Zanamivir | 2018 |
Outpatient influenza antivirals in a distributed data network for influenza surveillance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Drug Utilization; Epidemiological Monitoring; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Male; Middle Aged; Oseltamivir; Outpatients; Prescriptions; Young Adult; Zanamivir | 2018 |
A Small-Molecule Compound Has Anti-influenza A Virus Activity by Acting as a ''PB2 Inhibitor".
Topics: A549 Cells; Animals; Antiviral Agents; Blotting, Western; Cell Line; Dogs; Drug Synergism; HEK293 Cells; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Microscopy, Fluorescence; Molecular Docking Simulation; Oseltamivir; Real-Time Polymerase Chain Reaction; RNA-Dependent RNA Polymerase; Surface Plasmon Resonance; Viral Proteins; Virus Replication; Zanamivir | 2018 |
Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Enzyme Inhibitors; India; Influenza A Virus, H5N1 Subtype; Mutagenesis; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2018 |
A tetravalent sialic acid-coated tetraphenylethene luminogen with aggregation-induced emission characteristics: design, synthesis and application for sialidase activity assay, high-throughput screening of sialidase inhibitors and diagnosis of bacterial va
Topics: Adult; Clostridium perfringens; Enzyme Inhibitors; Female; Fluorescence; Fluorescent Dyes; Fluorometry; High-Throughput Screening Assays; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Limit of Detection; Middle Aged; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Sialic Acids; Stilbenes; Vaginosis, Bacterial; Vibrio cholerae; Young Adult; Zanamivir | 2018 |
Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodeficiency.
Topics: Antiviral Agents; Child; Cord Blood Stem Cell Transplantation; Drug Resistance, Viral; Genetic Variation; Humans; Immunoglobulins, Intravenous; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation, Missense; Neuraminidase; Oseltamivir; Real-Time Polymerase Chain Reaction; Severe Combined Immunodeficiency; Viral Load; Viral Proteins; Zanamivir | 2018 |
Intravenous zanamivir for influenza myocarditis and enteral malabsorption.
Topics: Administration, Intravenous; Adult; Antiviral Agents; Catecholamines; Female; Humans; Influenza, Human; Malabsorption Syndromes; Middle Aged; Myocarditis; Oseltamivir; Zanamivir | 2018 |
Comparison of the Clinical Courses of Patients with Influenza after Neuraminidase Inhibitors Treatment: A Postcard Survey of the 2013-2014 Influenza Season in Osaka.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Disease Outbreaks; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Surveys and Questionnaires; Treatment Outcome; Zanamivir | 2016 |
Association of severe abnormal behavior and acetaminophen with/without neuraminidase inhibitors.
Topics: Acetaminophen; Adolescent; Age Factors; Antiviral Agents; Behavioral Symptoms; Child; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Humans; Incidence; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Risk Factors; Sialic Acids; Zanamivir | 2019 |
Selection of avian influenza A (H9N2) virus with reduced susceptibility to neuraminidase inhibitors oseltamivir and zanamivir.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Chick Embryo; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H9N2 Subtype; Molecular Dynamics Simulation; Mutation; Neuraminidase; Oseltamivir; Zanamivir | 2019 |
Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Enzyme Inhibitors; Female; Guanidines; Inflammation; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2019 |
Antiviral treatment and virological monitoring of oseltamivir-resistant influenza virus A(H1N1)pdm09 in a patient with chronic B lymphocytic leukemia.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Oseltamivir; Pneumonia, Viral; Treatment Outcome; Virus Shedding; Zanamivir | 2019 |
Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; HEK293 Cells; Humans; Influenza A Virus, H7N9 Subtype; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Pyrans; Serial Passage; Sialic Acids; Species Specificity; Viral Proteins; Zanamivir | 2019 |
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2017
Topics: Animals; Antigens, Viral; Antiviral Agents; Australia; Chickens; Dogs; Drug Resistance, Viral; Eggs; Female; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Phylogeny; World Health Organization; Zanamivir | 2019 |
Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Chickens; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Virus Replication; Zanamivir | 2019 |
A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Chickens; Drug Resistance, Viral; India; Influenza A Virus, H5N1 Subtype; Inhibitory Concentration 50; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir; Zygote | 2019 |
Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies.
Topics: Acids, Carbocyclic; Antiviral Agents; Cell Line; Crystallography, X-Ray; Cyclopentanes; Drug Resistance, Viral; Epithelial Cells; Epitopes; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Mutant Proteins; Mutation, Missense; Neuraminidase; Oseltamivir; Protein Conformation; Selection, Genetic; Viral Proteins; Virus Replication; Zanamivir | 2019 |
Influenza A/H4N2 mallard infection experiments further indicate zanamivir as less prone to induce environmental resistance development than oseltamivir.
Topics: Animals; Anseriformes; Antiviral Agents; Drug Resistance, Viral; Ducks; Influenza A virus; Influenza in Birds; Mutation; Oseltamivir; Zanamivir | 2020 |
[The model of prediction of the inhibition of neuraminidases of influenza A and B based on a reduced set of energy terms].
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Enzyme Inhibitors; Guanidines; Influenza A virus; Influenza B virus; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2019 |
Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.
Topics: Aged; Antiviral Agents; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Transplant Recipients; Zanamivir | 2019 |
Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews.
Topics: Acids, Carbocyclic; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza, Human; Internet; Male; Middle Aged; Neuraminidase; Odds Ratio; Oseltamivir; Patient Participation; Pyrans; Risk Factors; Sialic Acids; United States; United States Food and Drug Administration; Young Adult; Zanamivir | 2020 |
Association of moderately abnormal behavior and administered neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Adolescent; Antiviral Agents; Child; Cyclopentanes; Enzyme Inhibitors; Guanidines; Humans; Illness Behavior; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Young Adult; Zanamivir | 2020 |
Interactive molecular dynamics in virtual reality for accurate flexible protein-ligand docking.
Topics: Benzamidines; Binding Sites; Carbamates; Furans; HIV Protease; Ligands; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Protein Binding; Sulfonamides; Trypsin; Virtual Reality; Zanamivir | 2020 |
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2018.
Topics: Animals; Antigens, Viral; Antiviral Agents; Australia; Chickens; Drug Resistance, Viral; Humans; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Phylogeny; World Health Organization; Zanamivir | 2020 |
Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2020 |
[Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia].
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza, Human; Oseltamivir; Russia; Zanamivir | 2019 |
Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea.
Topics: Acids, Carbocyclic; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mutation; Neuraminidase; Oropharynx; Oseltamivir; Phylogeny; Republic of Korea; Sequence Analysis, DNA; Zanamivir | 2020 |
Probing antiviral drugs against SARS-CoV-2 through virus-drug association prediction based on the KATZ method.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Drug Evaluation, Preclinical; Host-Pathogen Interactions; Humans; Molecular Docking Simulation; Oseltamivir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Zanamivir | 2020 |
Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019.
Topics: Amino Acid Substitution; Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Enzyme Inhibitors; Gene Expression; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Microbial Sensitivity Tests; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Conformation; Reassortant Viruses; Viral Proteins; Zanamivir | 2020 |
Intravenous Zanamivir: A Viable Option for Critically Ill Patients With Influenza.
Topics: Antiviral Agents; Critical Illness; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2021 |
In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Cell Line; Dibenzothiepins; Dogs; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Guanidines; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Morpholines; Neuraminidase; Nucleic Acid Synthesis Inhibitors; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Pyridones; Ribavirin; Triazines; Viral Proteins; Virus Replication; Zanamivir | 2020 |
Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients.
Topics: Alphainfluenzavirus; Antiviral Agents; Dibenzothiepins; Drug Resistance, Viral; Humans; Immunocompromised Host; Influenza, Human; Morpholines; Neuraminidase; Oseltamivir; Pyridones; Triazines; Zanamivir | 2021 |
Low rate of oseltamivir prescription among adults and children with confirmed influenza illness in France during the 2018-19 influenza season.
Topics: Adult; Antiviral Agents; Child; Enzyme Inhibitors; Female; France; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pregnancy; Prescriptions; Prospective Studies; Seasons; Zanamivir | 2021 |
Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance.
Topics: Child; Drug-Related Side Effects and Adverse Reactions; Humans; Oseltamivir; Pharmacovigilance; Retrospective Studies; Zanamivir | 2022 |
Two phytocompounds from Schinopsis brasiliensis show promising antiviral activity with multiples targets in Influenza A virus.
Topics: Antiviral Agents; Drug Resistance, Viral; Humans; Influenza A virus; Molecular Docking Simulation; Oseltamivir; Zanamivir | 2021 |
Comparison of the incidence of bleeding between baloxavir marboxil and other anti-influenza drugs among outpatients with influenza virus infection: A retrospective cohort study using an employment-based health insurance claims database in Japan.
Topics: Antiviral Agents; Communicable Diseases; Dibenzothiepins; Employment; Humans; Incidence; Influenza, Human; Insurance, Health; Japan; Morpholines; Oseltamivir; Outpatients; Pyridones; Retrospective Studies; Triazines; Zanamivir | 2022 |
Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009-2019.
Topics: Antiviral Agents; Compassionate Use Trials; Enzyme Inhibitors; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Genetic and biological properties of H10N3 avian influenza viruses: A potential pandemic candidate?
Topics: Animals; Chick Embryo; Chickens; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza in Birds; Influenza, Human; Mammals; Mice; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Poultry; Rodent Diseases; Zanamivir | 2022 |
Inhaled Zanamivir vs Oral Oseltamivir to Prevent Influenza-related Hospitalization or Death: A Nationwide Population-based Quasi-experimental Study.
Topics: Antiviral Agents; Cohort Studies; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Humans; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Is Inhaled Zanamivir Non-inferior to Oral Oseltamivir in the Treatment of Outpatients With Influenza?
Topics: Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Outpatients; Zanamivir | 2022 |
Response to "Inhaled Zanamivir versus Oral Oseltamivir to Prevent Influenza-related Hospitalization or Death: A Nationwide Population-based Quasi-experimental Study".
Topics: Antiviral Agents; Hospitalization; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
In Silico Studies Reveal Peramivir and Zanamivir as an Optimal Drug Treatment Even If H7N9 Avian Type Influenza Virus Acquires Further Resistance.
Topics: Acids, Carbocyclic; Antiviral Agents; Arginine; Benserazide; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Molecular Docking Simulation; Mutation; Neuraminidase; Oseltamivir; Zanamivir | 2022 |
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2020-2021.
Topics: Antiviral Agents; Australia; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Neuraminidase; Oseltamivir; World Health Organization; Zanamivir | 2022 |
Neuraminidase is a host-directed approach to regulate neutrophil responses in sepsis and COVID-19.
Topics: Animals; COVID-19; Humans; Lipopolysaccharides; Matrix Metalloproteinase 9; Mice; Neuraminidase; Neutrophils; Oseltamivir; Reactive Oxygen Species; Sepsis; Zanamivir | 2023 |
Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.
Topics: Aged; Antiviral Agents; Enzyme Inhibitors; Guanidines; Hospital Mortality; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir | 2023 |
Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014-2019/2020 seasons in Japan: an o
Topics: Adult; Antiviral Agents; Child; Enzyme Inhibitors; Humans; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Outpatients; RNA, Viral; Seasons; Zanamivir | 2023 |
An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections.
Topics: Animals; Humans; Immunoglobulin Light Chains; Influenza, Human; Mice; Mice, Inbred BALB C; Neuraminidase; Oseltamivir; Zanamivir | 2023 |
Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Guanidine; Guanidines; Herpesvirus 1, Cercopithecine; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2023 |
Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2022.
Topics: Animals; Antiviral Agents; Australia; Chickens; Drug Resistance, Viral; Female; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; World Health Organization; Zanamivir | 2023 |
Antiviral drugs for influenza for 2023-2024.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2023 |
Comparison chart: Antiviral drugs for influenza for 2023-2024.
Topics: Antiviral Agents; Enzyme Inhibitors; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2023 |